[
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "",
    "text": "Brought you by Taiwan Medical Mission (TMM) in the Republic of Somaliland\n2024 Multidisciplinary Specialty Conference (#2024MSC)\nDate: Saturday, 11 May, 2024\nTime: 08:30 AM - 12:40 PM\nVenue: Conference Hall (1F), Carro Edeg Hotel, Hargeisa, Somaliland\nThis year, we have 3 topics:\n\nTaiwan Cares: Somaliland Dengue Control Project\nEsophageal cancer, Hepatoma, Breast cancer, and Digital pathology in Somaliland\nOrthopedic training in HGH and Taipei Municipal Wanfang Hospital"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About Us",
    "section": "",
    "text": "Taiwan Medical Mission (TMM) has been working in the Republic of Somaliland since 2022 July, providing essential healthcare services and capacity building support to improve the health and well-being of the Somaliland people.\nIn collaboration with local partners, such as the Ministry of Health Development and Hargeisa Group Hospital, TMM has implemented various projects focusing on medical education, training, and healthcare delivery. These initiatives include the military trauma kit, co-training of orthopedic residents, spine surgery, the introduction cervical cancer screening, laparoscopic simulation training, consultant of infection prevention program, and the organization of multi-specialty conferences to facilitate knowledge exchange between Taiwanese and Somaliland medical professionals.\nTMM’s dedicated team of doctors, nurses, and volunteers work tirelessly to strengthen the healthcare system in Somaliland, addressing critical health challenges and promoting sustainable development. Through their efforts, TMM aims to foster long-term cooperation and friendship between Taiwan and Somaliland, while making a meaningful impact on the lives of those they serve.\n(Website Powered by Rstudio Server and Github Pages 2022-2024)"
  },
  {
    "objectID": "agenda.html",
    "href": "agenda.html",
    "title": "Conference Agenda",
    "section": "",
    "text": "Download current agenda"
  },
  {
    "objectID": "h2023MSC.html",
    "href": "h2023MSC.html",
    "title": "2023 Multidisciplinary Specialty Conference",
    "section": "",
    "text": "2023MSC review: 2023MSC"
  },
  {
    "objectID": "index.html#collaborating-for-public-health-sharing-knowledge-saving-lives",
    "href": "index.html#collaborating-for-public-health-sharing-knowledge-saving-lives",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Collaborating for Public Health: Sharing Knowledge, Saving Lives",
    "text": "Collaborating for Public Health: Sharing Knowledge, Saving Lives\nBrought you by Taiwan Medical Mission (TMM) in the Republic of Somaliland\n2024 Multidisciplinary Specialty Conference (#2024MSC)\nDate: Saturday, 11 May, 2024\nTime: 08:30 AM - 12:40 PM\nVenue: Conference Hall (1F), Carro Edeg Hotel, Hargeisa, Somaliland\nThis year, we have 3 topics:\n\nTaiwan Cares: Somaliland Dengue Control Project\nEsophageal cancer, Hepatoma, Breast cancer, and Digital pathology in Somaliland\nOrthopedic training in HGH and Taipei Municipal Wanfang Hospital\n512 International Nurse Day, on 12th May 2024"
  },
  {
    "objectID": "index.html#esteemed-colleagues-healthcare-professionals-and-distinguished-guests",
    "href": "index.html#esteemed-colleagues-healthcare-professionals-and-distinguished-guests",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Esteemed colleagues, healthcare professionals, and distinguished guests",
    "text": "Esteemed colleagues, healthcare professionals, and distinguished guests\nIt is our great pleasure to invite you to the 2024 Multi-Specialty Conference (2024MSC), a groundbreaking event that will bring together brilliant minds from Taipei Municipal Wanfang Hospital (TMWH) and Hargeisa Group Hospital (HGH). This extraordinary collaboration aims to foster knowledge exchange, forge new partnerships, and ultimately improve public health outcomes in both Taiwan and Somaliland.\nJoin us on Saturday, 11 May, 2024, at the stunning Conference Hall of Carro Edeg Hotel in Hargeisa, where we will deliver critical topics that shape the future of healthcare. From the pressing issue of dengue fever prevention and control to the latest advancements in managing breast cancer, esophageal cancer and hepatoma, our expert speakers will share their invaluable insights and experiences.\nPrepare to be amazed as we will unveil a groundbreaking milestone in Somaliland’s healthcare history! In 2024, the specialists of general surgery from Taiwan Medical Mission (TMM) and Hargeisa Group Hospital (HGH) are joining forces to introduce the first-ever laparoscopic surgery in a public hospital in Somaliland in the near future. This revolutionary technique, also known as minimally invasive surgery, promises to transform the surgical landscape, offering patients faster recovery times, less pain, and reduced scarring. With the expertise of TMM’s renowned surgeon and the dedication of HGH’s skilled medical team, we are poised to usher in a new era of surgical excellence. Witness history in the making as we push the boundaries of what’s possible, bringing cutting-edge technology and innovative techniques to the forefront of patient care. Get ready to be inspired by this extraordinary collaboration that will redefine surgical standards and elevate healthcare to new heights in Somaliland!\nBut that’s not all! We will also explore the exciting world of orthopedic training, as we showcase the incredible programs at HGH partnered with University of Hargeisa and TMWH. This is a unique opportunity to learn from the best and forge lasting connections with fellow professionals who share your passion for excellence.\nDon’t miss this chance to be a part of a truly transformative event that will inspire, educate, and empower you to make a real difference in the lives of your patients and communities.\nRegister now and secure your spot at the 2024MSC, where together, we will collaborate for public health, share knowledge, and save lives.\nWe look forward to seeing you there!"
  },
  {
    "objectID": "2024delegation_schedule.html",
    "href": "2024delegation_schedule.html",
    "title": "2024 TMWH Delegation Schedule",
    "section": "",
    "text": "The schedule for the TMWH delegation visit to the Republic of Somaliland:\nDelegation Members:\n\nSpecialists: Superintendent Dr. Tsan-Hon Liou, Deputy Superintendent Dr. Chen-Yuan Chiang; HQ of TMM, Director Dr. Chen Chin-I, Deputy Director Dr. Chen Yu-Pin, and Cancer Center Dr. Chiou Tzeon-Jye.\nAdministrative Staff: Wu Hua-Lun, Tseng Yu-Ping\n\n\nThursday, May 9, 2024\n14:30 | Flight from Bole International Airport (ADD), Ethiopia, arrive Hargeisa International Airport (HGA), Somaliland\n(Mr. Chris Lee, accompanied by the Deputy Ambassador, will be present at the airport to welcome and receive the delegation team from Taipei Municipal Wanfang Hospital, TMWH)\n16:00 - 17:00 | Visit to Taiwan Representative Office in Somaliland (TRO), Amb. Lou, and Mr. Chris Lee\n\nPublic Health projects by TMM (e.g., Dengue Fever prevention and control)\nCollaborative Synergy: The Power of TMM and HGH’s Partnership\n\n18:00 - 20:00 | Dinner with TMM at Damal Hotel Restaurant; Hargeisa Group Hospital, Director, Dr. Abdirahman, and Deputy Director, Dr. Adnan, and orthopedic Dr. Hassan.\n\nAccommodation at Carro Edeg Hotel\n\n\nFriday, May 10, 2024 | Day off |\n09:00 - 11:00 | Morning meeting (Carro Edeg Hotel)\n11:00 - 12:00 | Visit to Taiwan Medical Mission (TMM) in Somaliland\n13:00 | Lunch break\n14:00 - 15:00 | Dr. Hassan introducing OT, arthroscopic set, POP, ward, emergency to orthopedic Dr. Chen, in Hargeisa Group Hospital\naccompanied with orthopedic residents, and OT director Mr. Ahmed\n16:00 - 18:00 | Caano geel farm (Garas) 現擠駱駝鮮奶\n18:00 | Dinner: Delegation, TMM, and HGH orthopedic team\n\n\nSaturday, May 11, 2024\n08:30 - 13:00 | 2024 Multidisciplinary Specialty Conference (2024MSC) at Carro Edeg Hotel (https://texchi2.github.io/2024MSC/agenda.html)\nLunch break included\n17:55 | Departure from Hargeisa International Airport (HGA)"
  },
  {
    "objectID": "registration.html",
    "href": "registration.html",
    "title": "2024MSC Registration",
    "section": "",
    "text": "Please fill out the form below to register for the 2024 Multi-Specialty Conference:\n\nName: \nEmail: \nCategory:  Select your category Doctor Pharmacist Nurse Other \nSpecialty (if applicable):  Select your specialty Pharmacy Internal Medicine General Surgery OBGYN Pediatrics Orthopedics Neurology Neurosurgery Cardiology ENT OMS Eye Rehabilitation Pathology Nephrology Radiology Urology Other \n\nRegister"
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html",
    "href": "project_HGH_laparoscopicCentre.html",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "",
    "text": "The Taiwan Medical Mission (TMM) in the Republic of Somaliland, in collaboration with the Hargeisa Group Hospital (HGH), proposes the establishment of a Laparoscopic Training Center to enhance surgical care and improve patient outcomes in the region. This initiative aims to introduce and develop laparoscopic surgery techniques among the general surgery department at HGH, under the guidance of Dr. Yen-Hsiang Wang, a visiting surgeon from Taipei Municipa Wanfang Hospital (TMWH), Taiwan.\n\n\nDr. Yen-Hsiang Wang, a general surgeon from TMWH, has been working with the TMM in Somaliland for nearly four weeks. During this time, he has collaborated with the local general surgery team, participating in outpatient clinics, surgeries, and ward rounds. The initial assessment has revealed a significant opportunity to fulfill the shared aspirations of the TMM and the local general surgeons: the development of laparoscopic surgery in Somaliland. Currently, at least six attending physicians at HGH have had exposure to laparoscopic surgery during their specialist training in neighboring Ethiopia. However, due to the lack of necessary equipment at HGH, they have been unable to perform laparoscopic procedures. The attending physicians and residents in the general surgery department at HGH have expressed a strong interest in learning laparoscopic surgery under the guidance of Dr. Wang. Their proficiency in a wide range of open surgical techniques makes laparoscopy an area where Taiwanese surgeons can showcase their expertise."
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html#project-overview",
    "href": "project_HGH_laparoscopicCentre.html#project-overview",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "",
    "text": "The Taiwan Medical Mission (TMM) in the Republic of Somaliland, in collaboration with the Hargeisa Group Hospital (HGH), proposes the establishment of a Laparoscopic Training Center to enhance surgical care and improve patient outcomes in the region. This initiative aims to introduce and develop laparoscopic surgery techniques among the general surgery department at HGH, under the guidance of Dr. Yen-Hsiang Wang, a visiting surgeon from Taipei Municipa Wanfang Hospital (TMWH), Taiwan.\n\n\nDr. Yen-Hsiang Wang, a general surgeon from TMWH, has been working with the TMM in Somaliland for nearly four weeks. During this time, he has collaborated with the local general surgery team, participating in outpatient clinics, surgeries, and ward rounds. The initial assessment has revealed a significant opportunity to fulfill the shared aspirations of the TMM and the local general surgeons: the development of laparoscopic surgery in Somaliland. Currently, at least six attending physicians at HGH have had exposure to laparoscopic surgery during their specialist training in neighboring Ethiopia. However, due to the lack of necessary equipment at HGH, they have been unable to perform laparoscopic procedures. The attending physicians and residents in the general surgery department at HGH have expressed a strong interest in learning laparoscopic surgery under the guidance of Dr. Wang. Their proficiency in a wide range of open surgical techniques makes laparoscopy an area where Taiwanese surgeons can showcase their expertise."
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html#project-objectives",
    "href": "project_HGH_laparoscopicCentre.html#project-objectives",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Project Objectives",
    "text": "Project Objectives\n\nEstablish a Laparoscopic Training Center at Hargeisa Group Hospital.\nTrain attending physicians and residents in laparoscopic surgical techniques.\nImprove patient care by introducing minimally invasive surgical options.\nFoster collaboration and knowledge exchange between Taiwanese and Somaliland surgeons."
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html#implementation-plan",
    "href": "project_HGH_laparoscopicCentre.html#implementation-plan",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Implementation Plan",
    "text": "Implementation Plan\n\nDr. Wang will develop a comprehensive laparoscopic surgery training curriculum, tailored to the needs and resources of HGH.\nThe TMM kindly requests the Teaching Department of TMWH to lend a laparoscopic simulator for a period of four months. Dr. Wang will return the simulator upon his return to Taiwan.\nDr. Wang will conduct hands-on training sessions, demonstrations, and supervised laparoscopic procedures during his remaining four months in Somaliland.\nThe TMM will explore the possibility of procuring laparoscopic equipment for HGH, with the aim of providing long-term benefits to the people of Somaliland.\n\n\nLaparoscopic Simulator:\nBrand: 3D Systems (formerly Simbionix)\nModel: LAP Mentor III\nFeatures:\n\nRealistic 3D graphics and tactile feedback\nAdjustable difficulty levels for various training scenarios\nComprehensive curriculum with guided tasks and performance metrics\nCompatibility with a wide range of laparoscopic instruments\nReference https://surgicalscience.com/medical-specialities/general-surgery/\n\n\n\nLaparoscopic Instrument Set:\n\n5mm Maryland dissector (x2)\n5mm curved scissors (x2)\n5mm atraumatic grasper (x2)\n5mm Babcock forceps (x2)\n5mm Hasson trocar (x2)\n5mm-11mm reducer (x2)\n10mm-11mm trocar (x2)\n10mm-0° laparoscope (x1)\n10mm-30° laparoscope (x1)\nLight cable (x2)\nVeress needle (x2)\nSuction-irrigation device (x1)\nNeedle holder (x2)\nClip applicator (x1)\nMonopolar hook electrode (x2)\nBipolar forceps (x1)\nGrasping forceps (x2)\nKnot pusher (x1)"
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html#future-prospects",
    "href": "project_HGH_laparoscopicCentre.html#future-prospects",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Future Prospects",
    "text": "Future Prospects\nIn 2025, Dr. Mrr Kuan, a general surgeon from Tong General Hospital (Taiwan), is expected to join the TMM in Somaliland. The establishment of the Laparoscopic Training Centre will lay the foundation for continued training and development in minimally invasive surgery.\nThe TMM will work towards securing funds for the procurement of laparoscopic equipment, ensuring the sustainability and long-term impact of the project."
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html#budget-planning-for-laparoscopic-equipment-made-in-india",
    "href": "project_HGH_laparoscopicCentre.html#budget-planning-for-laparoscopic-equipment-made-in-india",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Budget Planning for Laparoscopic Equipment (Made in India)",
    "text": "Budget Planning for Laparoscopic Equipment (Made in India)\n\n\n\n\n\n\n\n\n\nItem\nQuantity\nUnit Price (USD)\nTotal (USD)\n\n\n\n\nLaparoscopic Trolley\n1\n$1,500\n$1,500\n\n\nLaparoscopic Camera System\n1\n$6,000\n$6,000\n\n\nLaparoscopic Light Source\n1\n$1,200\n$1,200\n\n\nLaparoscopic Insufflator\n1\n$1,500\n$1,500\n\n\nLaparoscopic Monitor\n2\n$800\n$1,600\n\n\nLaparoscopic Instrument Set\n2\n$3,000\n$6,000\n\n\nLaparoscopic Suction-Irrigation\n1\n$500\n$500\n\n\nLaparoscopic Electrodes\n2 sets\n$300\n$600\n\n\nLaparoscopic Trocars\n2 sets\n$400\n$800\n\n\nLaparoscopic Needle Holders\n2\n$200\n$400\n\n\nLaparoscopic Clip Applicators\n2\n$250\n$500\n\n\nLaparoscopic Veress Needles\n2\n$50\n$100\n\n\nLaparoscopic Graspers\n2 sets\n$400\n$800\n\n\nLaparoscopic Scissors\n2 sets\n$300\n$600\n\n\nLaparoscopic Knot Pushers\n2\n$100\n$200\n\n\nTotal Budget\n\n\nUSD22,300\n\n\n\nNote: Prices are estimated based on average costs of laparoscopic equipment made in India. Actual prices may vary depending on the specific manufacturer, model, and negotiated discounts.\nThis budget plan covers the essential equipment required to establish a functional laparoscopic surgery unit at Hargeisa Group Hospital. The procurement of high-quality, cost-effective equipment from Indian manufacturers will ensure the sustainability and long-term success of the Laparoscopic Training Centre initiative."
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html#conclusion",
    "href": "project_HGH_laparoscopicCentre.html#conclusion",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Conclusion",
    "text": "Conclusion\nThe establishment of a Laparoscopic Training Centre at Hargeisa Group Hospital represents a significant step towards improving surgical care and patient outcomes in Somaliland. Through collaboration, training, and knowledge exchange, this initiative will empower local surgeons, transform lives, and contribute to the overall development of the healthcare system in the region."
  },
  {
    "objectID": "registration_form.html",
    "href": "registration_form.html",
    "title": "2024MSC Registration Form",
    "section": "",
    "text": "Closed; Mahasanid"
  },
  {
    "objectID": "2024MSC_registration.html",
    "href": "2024MSC_registration.html",
    "title": "2024MSC Registration",
    "section": "",
    "text": "Please fill out the form below to register for the 2024 Multi-Specialty Conference:\n\n&lt;p&gt;Loading…&lt;/p&gt;"
  },
  {
    "objectID": "x_registration.html",
    "href": "x_registration.html",
    "title": "2024MSC Registration",
    "section": "",
    "text": "Please fill out the form below to register for the 2024 Multi-Specialty Conference:\n\nName: \nEmail: \nCategory:  Select your category Doctor Pharmacist Nurse Other \nSpecialty (if applicable):  Select your specialty Pharmacy Internal Medicine General Surgery OBGYN Pediatrics Orthopedics Neurology Neurosurgery Cardiology ENT OMS Eye Rehabilitation Pathology Nephrology Radiology Urology Other \n\nRegister"
  },
  {
    "objectID": "x_2024MSC_registration.html",
    "href": "x_2024MSC_registration.html",
    "title": "2024MSC Registration",
    "section": "",
    "text": "Please fill out the form below to register for the 2024 Multi-Specialty Conference:\n\n&lt;p&gt;Loading…&lt;/p&gt;"
  },
  {
    "objectID": "project_HGH_laparoscopicCentre.html#budget-planning-for-laparoscopic-equipment-estimated-if-made-in-india",
    "href": "project_HGH_laparoscopicCentre.html#budget-planning-for-laparoscopic-equipment-estimated-if-made-in-india",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Budget Planning for Laparoscopic Equipment (estimated, if Made in India)",
    "text": "Budget Planning for Laparoscopic Equipment (estimated, if Made in India)\n\n\n\n\n\n\n\n\n\nItem\nQuantity\nUnit Price (USD)\nTotal (USD)\n\n\n\n\nLaparoscopic Trolley\n1\n$1,500\n$1,500\n\n\nLaparoscopic Camera System\n1\n$6,000\n$6,000\n\n\nLaparoscopic Light Source\n1\n$1,200\n$1,200\n\n\nLaparoscopic Insufflator\n1\n$1,500\n$1,500\n\n\nLaparoscopic Monitor\n2\n$800\n$1,600\n\n\nLaparoscopic Instrument Set\n2\n$3,000\n$6,000\n\n\nLaparoscopic Suction-Irrigation\n1\n$500\n$500\n\n\nLaparoscopic Electrodes\n2 sets\n$300\n$600\n\n\nLaparoscopic Trocars\n2 sets\n$400\n$800\n\n\nLaparoscopic Needle Holders\n2\n$200\n$400\n\n\nLaparoscopic Clip Applicators\n2\n$250\n$500\n\n\nLaparoscopic Veress Needles\n2\n$50\n$100\n\n\nLaparoscopic Graspers\n2 sets\n$400\n$800\n\n\nLaparoscopic Scissors\n2 sets\n$300\n$600\n\n\nLaparoscopic Knot Pushers\n2\n$100\n$200\n\n\nTotal Budget\n\n\nUSD22,300\n\n\n\nNote: Prices are estimated based on average costs of laparoscopic equipment made in India. Actual prices may vary depending on the specific manufacturer, model, and negotiated discounts.\nThis budget plan covers the essential equipment required to establish a functional laparoscopic surgery unit at Hargeisa Group Hospital. The procurement of high-quality, cost-effective equipment from Indian manufacturers will ensure the sustainability and long-term success of the Laparoscopic Training Centre initiative."
  },
  {
    "objectID": "abstract_uploads.html",
    "href": "abstract_uploads.html",
    "title": "Abstract and Keynote",
    "section": "",
    "text": "Please fill out the form below to submit your CV, abstract, and keynote slides:\n\nName: \nEmail: \nCV: \nAbstract:\n\nKeynote Slides: \n\nSubmit\n\n\n\nPlease upload your CV and keynote files to the following URL: https://rb.gy/47a3kw\n\n\nPassword: 1aIh"
  },
  {
    "objectID": "abstract_uploads.html#speaker-submission",
    "href": "abstract_uploads.html#speaker-submission",
    "title": "Abstract and Keynote",
    "section": "Speaker Submission",
    "text": "Speaker Submission\n\n\nPlease fill out the form below to submit your abstract:\n\nName:  Abstract:\n\n\nSubmit\n\n\nPlease also upload your CV and keynote files to”\n\nuploading\n\n\n(choose “Upload File”)\n\n\n(Access Password: kB3U)"
  },
  {
    "objectID": "abstract_uploads.html#invited-speakers",
    "href": "abstract_uploads.html#invited-speakers",
    "title": "Abstract and Keynote",
    "section": "Invited Speakers",
    "text": "Invited Speakers\n\n\n\n\nhttps://share.multcloud.link/share/90e256e5-95e4-4db5-aa8d-7c66510c3ac7 pw= 1aIh"
  },
  {
    "objectID": "index.html#online-registration",
    "href": "index.html#online-registration",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Online registration",
    "text": "Online registration\nPlease\n\nCLICK\n\n(deadline on 10 May 2024; Lunch will be provided for registered participants only following the conference.)"
  },
  {
    "objectID": "index.html#statistics-of-participants",
    "href": "index.html#statistics-of-participants",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Statistics of Participants",
    "text": "Statistics of Participants"
  },
  {
    "objectID": "abstract_uploads.html#video",
    "href": "abstract_uploads.html#video",
    "title": "Abstract and Keynote",
    "section": "Video",
    "text": "Video\nDr. Ming-Shun Wu’s talk:\n\nmp4\n\nOnline Q&A with Dr. Ming-Shun Wu:\n\ngoogle meet"
  },
  {
    "objectID": "index.html#acknowledgement",
    "href": "index.html#acknowledgement",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Acknowledgement",
    "text": "Acknowledgement\nWe would like to express our sincere gratitude to Dr. Deq Said Jama, Director of the WHO Office in Hargeisa, for his invaluable contribution to the 2024 Multi-Specialty Conference. Although Dr. Deq is unable to attend the conference in person due to prior commitments, his support and dedication to the improvement of public health in Somaliland have been truly remarkable.\nDr. Deq has graciously provided the conference organizers with the WHO-prepared Dengue slides, which will be presented by Dr. Jamal Tex Li-Hsing Chi, Chief of the Taiwan Medical Mission, and Dr. Ahmed Abdi Hersi, internal medicine specialist in Hargeisa Group Hospital. These slides contain crucial information on the WHO Dengue Fever Recommendations and Strategies, which will undoubtedly benefit the conference attendees and contribute to the overall success of the event.\nWe are deeply appreciative of Dr. Deq’s efforts in sharing this valuable resource with us, despite his inability to attend the conference. His commitment to advancing medical knowledge and promoting best practices in the management of dengue fever is commendable.\nOn behalf of the organizing committee, speakers, and attendees of the 2024 Multi-Specialty Conference, we extend our heartfelt thanks to WHO’s support and collaboration. We look forward to future opportunities to work together in the fight against dengue fever and other public health challenges facing Somaliland."
  },
  {
    "objectID": "thanks.html",
    "href": "thanks.html",
    "title": "Acknowledgements",
    "section": "",
    "text": "The organizing committee of the 2024 Multi-Specialty Conference (2024MSC) would like to express our sincere gratitude to all those who have contributed to the success of this event. We deeply appreciate the support, dedication, and expertise of everyone involved."
  },
  {
    "objectID": "thanks.html#speakers",
    "href": "thanks.html#speakers",
    "title": "Acknowledgements",
    "section": "Speakers",
    "text": "Speakers\nWe extend our heartfelt thanks to our esteemed speakers for sharing their knowledge and insights. Your valuable contributions have enriched the conference and inspired attendees.\n\nDr. Tsan-Hon Liou\nDr. Jamal Tex Li-Hsing Chi\nDr. Ahmed Abdi Hersi\nDr. Chin-I Chen\nDr. Omar Marshal\nDr. Fadumo Ahmed Liban\nDr. Abdillahi Abdi Ali\nDr. Vincent, Ming-Shun Wu\nDr. Yen-Hsiang Wang\nDr. Ahmed Saed Ali\nDr. Yu-Pin Chen\nDr. Abdirashid Ismail\nDr. Abdirahman Mohamed Osman"
  },
  {
    "objectID": "thanks.html#conference-master",
    "href": "thanks.html#conference-master",
    "title": "Acknowledgements",
    "section": "Conference Master",
    "text": "Conference Master\nWe would like to express our gratitude to Dr. Hassan Mohamoud Nour for his exceptional role as the Conference Master. Your leadership and guidance have been instrumental in making this conference a resounding success."
  },
  {
    "objectID": "thanks.html#panel-discussion-participants",
    "href": "thanks.html#panel-discussion-participants",
    "title": "Acknowledgements",
    "section": "Panel Discussion Participants",
    "text": "Panel Discussion Participants\nWe extend our appreciation to the panel discussion participants for each session. Your engaging discussions and expert opinions have greatly enhanced the conference experience.\n\nSession 1: Dr. Adnan, Dr. Ahmed, Dr. Jamal, Dr. Chen, and Dr. Chen-Yuan Chiang\nSession 2: Dr. Omar, Dr. Wang, Dr. Afnan, Dr. Fadumo, Dr. Abdillahi, Dr. Wu (online), and Dr. Tzeon-Jye Chiou\nSession 3: Dr. Ahmed, Dr. Abdirashid, and Dr. Chen"
  },
  {
    "objectID": "thanks.html#special-thanks",
    "href": "thanks.html#special-thanks",
    "title": "Acknowledgements",
    "section": "Special Thanks",
    "text": "Special Thanks\nWe would like to express our special thanks to Dr. Deq Said Jama, Director of the WHO Office in Hargeisa, for his invaluable contribution. Although Dr. Deq could not attend the conference in person, he generously provided the WHO-prepared Dengue slides, which were presented by Dr. Tex Li-Hsing Chi and Dr. Ahmed Abdi Hersi. We are grateful for his support and commitment to advancing public health in Somaliland."
  },
  {
    "objectID": "thanks.html#organizing-committee---taiwan-medical-mission",
    "href": "thanks.html#organizing-committee---taiwan-medical-mission",
    "title": "Acknowledgements",
    "section": "Organizing Committee - Taiwan Medical Mission",
    "text": "Organizing Committee - Taiwan Medical Mission\nWe would like to acknowledge the tireless efforts of the 2024MSC organizing committee. Your dedication, hard work, and attention to detail have made this conference a truly memorable and successful event."
  },
  {
    "objectID": "thanks.html#sponsors-and-partners---taiwan-ministry-of-foreign-affairs-and-taiwan-representative-office-in-somaliland",
    "href": "thanks.html#sponsors-and-partners---taiwan-ministry-of-foreign-affairs-and-taiwan-representative-office-in-somaliland",
    "title": "Acknowledgements",
    "section": "Sponsors and Partners - Taiwan Ministry of Foreign Affairs and Taiwan Representative Office in Somaliland",
    "text": "Sponsors and Partners - Taiwan Ministry of Foreign Affairs and Taiwan Representative Office in Somaliland\nWe extend our gratitude to our sponsors and partners for their generous support and collaboration. Your contributions have been essential in bringing this conference to fruition."
  },
  {
    "objectID": "thanks.html#attendees",
    "href": "thanks.html#attendees",
    "title": "Acknowledgements",
    "section": "Attendees",
    "text": "Attendees\nFinally, we would like to thank all the attendees for their participation and engagement throughout the conference. Your presence and active involvement have made this event a platform for meaningful exchange and learning.\nOnce again, thank you to everyone who has contributed to the success of the 2024 Multi-Specialty Conference. We look forward to continued collaboration and future opportunities to advance healthcare and medical knowledge together.\nSincerely,\nThe 2024MSC Organizing Committee - Taiwan Medical Mission\n14 May 2024"
  },
  {
    "objectID": "2024TMM_relief_list.html",
    "href": "2024TMM_relief_list.html",
    "title": "2024 TMM project priority for HGH",
    "section": "",
    "text": "Dear Dr. Abdirahman,\nI hope this letter finds you well. On behalf of the Taiwan Medical Mission (TMM), I would like to express our continued commitment to supporting healthcare services at Hargeisa Group Hospital (HGH) and across Somaliland. As we plan our collaboration for 2024, we kindly suggest you to share HGH’s updated projects list, prioritizing items that align with our upcoming 2024 projects in public health and medical services.\nIn particular, we would like to highlight the following initiatives and equipment needs, arranged by priority:\n\nLaparoscopic Surgery for General Surgery Department:\n\nProject: Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative\nLed by TMM staff Dr. Andrew Wang, and HGH Dr. Afnan\nRequired equipment: Laparoscopic surgical instruments and training models\n\nBreast Cancer and Cervical Cancer Screening:\n\nProject: Comprehensive Women’s Cancer Screening Program\nLed by HGH Dr. Fatima, TMM staff Dr. Andrew Wang (General Surgeon) and Dr. Huang (OBGYN)\nRequired equipment: Ultrasound machine and probes\n\nDengue Fever Management and ICU Support:\n\nProject: Strengthening Dengue Patient Care and Outcomes\nRequired supplies: Arterial Blood Gas (ABG) reagent materials for severe dengue cases in ICU\n\nVisiting Scholarships for Training in Taiwan:\n\nProject: Capacity Building for Somaliland Medical Personnel\nCollaborators: Taipei Municipal Wanfang Hospital (TMWH), Taiwan Medical Mission (TMM), and Hargeisa Group Hospital (HGH)\nInitiatives:\n\nProvide “Visiting Scholar Scholarships” for 15 Somaliland medical personnel to receive training in Taiwan for up to three months\nConduct selection process jointly by Taiwan Medical Mission and HGH Director’s Office\nInvite selected personnel to participate in TMM’s 2024 public health programs\n\nRequired support:\n\nTMM: Scholarship funding for 13 to 15 medical personnel (3 batches of 5)\nCoordination with TMWH for training arrangements\nCollaboration with HGH for personnel selection and public health program participation\nMoU between HGH and TMWH\n13 scholarship candidates:\n\n\nBatch 1\n\nDr. Abdirahman Hohamed Osman (Hospital Director)\nDr. Khadar Good Nur (IPC Director)\nDr. Mohamed Hassan Nur (Resident, Orthopedic)\nDr. Hassan Mohamed Nur (Resident, Orthopedic)\n\nBatch 2\n\nDr. Saed Mohamed Osman (Resident, Orthopedic)\nDr. Abdulrahman Adoosh Abdulaahi (Resident, Orthopedic)\nDr. Adnan Sayid Abdo (General Surgery) =&gt; laparoscopic training\nDr. Mustafe Ahmed Yusuf (Neurosurgery) =&gt; spine surgery\nDr. Idris Hassan Dahir (Cardiologist)\n\nBatch 3\n\nDr. Abdihamid Mohamed Ali (Neurosurgery) =&gt; cranial surgery\nMr. Mustafe (Technician, Pathology)\nMr. Ahmed (Nurse, OT director)\nDr. Omer Mohamed Bihi (Pathology)\n\n\n\nLiver Cancer Prevention and Control:\n\nProject: Comprehensive Hepatitis B Virus (HBV) Screening and Vaccination Program\nCollaborators: WHO Somaliland Office, Dr. Deq Jama\nInitiatives:\n\nFocus on adult HBV prevention and control\nConduct HBV, HCV, liver function, and tumor marker screening for high-risk populations\nPerform abdominal ultrasound examinations for early detection of liver abnormalities\nImplement HBV vaccination program for healthcare workers at HGH, expanding to University of Hargeisa medical and nursing students\nEstablish regular follow-up of HBV carriers’ liver health at internal medicine outpatient clinic\n\nRequired equipment and supplies:\n\nHBV and HCV laboratory tests\nLiver function test reagents\nTumor marker (AFP, Ca19-9, CEA) assay kits\nHBV vaccines and vaccination supplies\n\n\nArthroscopic Instruments for Orthopedic Department:\n\nStryker shaver (2023) was provided by TMM, and two endoscope sets (2022) were donated by ADFA\nAdditional requirement: Arthroscopic instruments to complement existing equipment\n\nCraniotomy Drill Set:\n\nRequested by Neurosurgery and Maxillofacial Department\nRequired equipment: Complete craniotomy drill set\n\nDoppler Ultrasound for Vascular Access:\n\nRequested by Hemodialysis Centre (Dr. Ahmed Wali)\nRequired equipment: Doppler ultrasound machine\n\nCystoscope:\n\nRequested by Senior Urologist Dr. Ahmed\nRequired equipment: Cystoscope\n\n\nWe greatly value your input and partnership in determining the most pressing needs at HGH. Your prioritized relief list will guide our procurement and planning efforts to ensure maximum impact.\nThank you for your tireless dedication to improving healthcare for the people of Somaliland. We look forward to our continued partnership in 2024 and beyond.\nBest regards,\nDr. Jamal Tex Li-Hsing Chi, DDS., Ph.D.\nChief, Taiwan Medical Mission\n7 May 2024"
  },
  {
    "objectID": "2024Projects_TMM.html",
    "href": "2024Projects_TMM.html",
    "title": "2024 TMM Project",
    "section": "",
    "text": "[1] \"zh_TW.UTF-8/zh_TW.UTF-8/zh_TW.UTF-8/C/zh_TW.UTF-8/en_US.UTF-8\""
  },
  {
    "objectID": "2024Projects_TMM.html#public-health-and-medical-services-common-diseases-with-double-burden",
    "href": "2024Projects_TMM.html#public-health-and-medical-services-common-diseases-with-double-burden",
    "title": "2024 TMM Project",
    "section": "Public health and medical services (common diseases with double burden)",
    "text": "Public health and medical services (common diseases with double burden)\n\nThe Laparoscopic Training Initiative for General Surgery Department\n\n\nProject: Empowering Surgeons, Transforming Lives:\nLed by TMM staff Dr. Andrew Wang, and HGH Dr. Afnan\nBackground: Hargeisa Group Hospital的一般外科醫師皆有豐富的開刀經驗，然受限於醫療資源的缺乏，Somaliland只有在私立醫院才有腹腔鏡手術，公立醫院則無。腹腔鏡手術已經是外科開刀的基本技能，舉凡任何的外科手術，如外傷手術、良性疾病的手術、惡性癌症的手術皆可以應用。HGH的醫師都有在外國接受過腹腔鏡手術的訓練，數位醫師甚至在私立醫院執行腹腔鏡手術。公立醫院若能配備腹腔鏡設備，手術的費用較廉宜，一般民眾也能付擔，有助於顯著提升一般外科的醫療水準。\nRequired equipment: Laparoscopic surgical instruments and training models; 借用萬芳醫院的腹腔鏡模擬器械，在王醫師任期內，可以讓每位HGH一般外科醫師均熟悉腹腔鏡的操作。進一步若能編列預算，2024年採購完成腹腔鏡器械，則這項醫療服務將能在HGH生根壯大。\n\n\nDengue Fever Management and ICU Support:\n\n\nProject: Strengthening Dengue Patient Care and Outcomes\nRequired supplies: Arterial Blood Gas (ABG) reagent materials for severe dengue cases in ICU\n\n\nOsteoporosis\n\n\n骨質健康-「TOM 骨質疏鬆」篩檢與預防保健計劃\nTOM: Taiwan Osteoporosis Master (from femural x-ray to T-score)\n\n\n三大癌症防治計劃(肝癌、子宮頸癌、乳癌)\nNon-communicable diseases (NCD) 防治計劃"
  },
  {
    "objectID": "2024Projects_TMM.html#outreach",
    "href": "2024Projects_TMM.html#outreach",
    "title": "2024 TMM Project",
    "section": "Outreach",
    "text": "Outreach\n篩檢同步舉辦NCD義診活動(四次)，免費提供醫療服務藥物與諮詢\n\nBreast Cancer and Cervical Cancer Screening (子宮頸及乳癌篩檢):\n\n\nProject: Comprehensive Women’s Cancer Screening Program\nLed by HGH Dr. Fatima, TMM staff Dr. Andrew Wang (General Surgeon) and Dr. Huang (OBGYN)\nCCCP: comprehensive cancer control plans\n\nHPV DNA test\nPap stain and pathology training: Dr. Chen and Dr. Omar\nHPV vaccination for school girls (age 9-13)\n\nRequired equipment: Ultrasound machine and probes, HPV vaccine\n\n\nOsteoporosis\n\n\nHGH orthopedic and Burco General Hospital (BGH)\n\n\nHBV screening and vaccination for HGH staff\n\n\n與WHO合作\n哈格爾薩總醫院 (HGH) HBV clinic (since 2024/05)\n\nHGH 約500-700名醫護人員: HBV篩檢和疫苗接種（每人三劑），建立示範效應。隨後逐步擴大至哈格爾薩大學 (University of Hargeisa) 的醫學生和護理系學生\n定期追蹤HBV帶原者的肝臟健康\n衛生教育：製作索馬利蘭語的宣傳手冊 (Booklet)，向民眾宣導健康飲食、不吸菸、不嚼食khat葉與菸草等，有效預防肝臟發炎\nRequired equipment: HBV vaccine\n\n\nOutbound outreach\n\n\nat Naasahablood site B (難民村)\ntriage: 分流(婦兒,男)\nconsultation, medicine, T-score screening\nhealth education"
  },
  {
    "objectID": "2024Projects_TMM.html#visiting-scholarships-for-training-in-taiwan",
    "href": "2024Projects_TMM.html#visiting-scholarships-for-training-in-taiwan",
    "title": "2024 TMM Project",
    "section": "Visiting Scholarships for Training in Taiwan",
    "text": "Visiting Scholarships for Training in Taiwan\n\nProject: Capacity Building for Somaliland Medical Personnel\nCollaborators: Taipei Municipal Wanfang Hospital (TMWH), Taiwan Medical Mission (TMM), and Hargeisa Group Hospital (HGH)\nInitiatives:\n\nProvide “Visiting Scholar Scholarships” for 13 to 15 Somaliland medical personnel to receive training in Taiwan for up to three months\nConduct selection process jointly by Taiwan Medical Mission and HGH Director’s Office\nInvite selected personnel to participate in TMM’s 2024 public health programs\n\nRequired support:\n\nTMM: Scholarship funding for 13 to 15 medical personnel (3 batches of 5)\nCoordination with TMWH for training arrangements\nCollaboration with HGH for personnel selection and public health program participation\nMoU between HGH and TMWH\n13 scholarship candidates:\n\n\nBatch 1\n\nDr. Abdirahman Hohamed Osman (Hospital Director)\nDr. Khadar Good Nur (Infection Prevention Centre Director)\nDr. Mohamed Hassan Nur (Resident, Orthopedic)\nDr. Hassan Mohamed Nur (Resident, Orthopedic)\n\nBatch 2\n\nDr. Saed Mohamed Osman (Resident, Orthopedic)\nDr. Abdulrahman Adoosh Abdulaahi (Resident, Orthopedic)\nDr. Adnan Sayid Abdo (General Surgery) =&gt; laparoscopic training\nDr. Mustafe Ahmed Yusuf (Neurosurgery) =&gt; spine surgery\nDr. Idris Hassan Dahir (Cardiologist)\n\nBatch 3\n\nDr. Abdihamid Mohamed Ali (Neurosurgery) =&gt; cranial surgery\nMr. Mustafe (Technician, Pathology)\nMr. Ahmed (Nurse, OT director)\nDr. Omer Mohamed Bihi (Pathology)"
  },
  {
    "objectID": "2024Projects_TMM.html#medical-campaign",
    "href": "2024Projects_TMM.html#medical-campaign",
    "title": "2024 TMM Project",
    "section": "Medical campaign",
    "text": "Medical campaign\n\nTMM staff (長駐醫療) by demand\n\northopedic\ngeneral surgery\nOBGYN\npediatric\nemergency and intensive care\n\nMedical campaign (主題醫療) by HGH medical need\n\nOrthopedic:\n\nArthroscopic knee surgery (meniscus repair, ACL reconstruction)\nArthroscopic shoulder surgery (rotator cuff repair, labral repair)\nSpine surgery (laminectomy, discectomy, spinal fusion)\nFracture fixation (open reduction and internal fixation)\nRequired equipment: arthroscopic instruments\n\nGeneral Surgery:\n\nLaparoscopic cholecystectomy (gallbladder removal)\nLaparoscopic appendectomy\nLaparoscopic hernia repair (inguinal, umbilical, incisional)\nThyroidectomy\nRequired equipment: laparoscopic instruments and video set\n\nNeurosurgery (neurosurgery and maxillofacial department):\n\nCraniotomy for brain tumor resection\nVentriculoperitoneal shunt placement\nSpine surgery (laminectomy, discectomy, spinal fusion)\nCranioplasty for traumatic skull defects\nRequired equipment: craniotomy instruments and drill set\n\nChest Medicine\n\nTB Hospital\nNCD: asthma, chronic obstructive pulmonary disease (COPD)\nBronchoscopy for diagnostic and therapeutic purposes\nRequired equipment: bronchoscope instruments and video set\n\n\n門診候診區設置電視牆，長期播放衛教宣導資料(一般外科、胸腔內科、骨科、神外、婦產科)"
  },
  {
    "objectID": "2024Projects_TMM.html#telemedicine-and-medical-education",
    "href": "2024Projects_TMM.html#telemedicine-and-medical-education",
    "title": "2024 TMM Project",
    "section": "Telemedicine and medical education",
    "text": "Telemedicine and medical education\n\nHGH骨科專科醫師訓練計畫於2023/01/20正式開始\n2023/10主題醫療骨科專家郭宜潔來訪\n2024 預計安排四名骨科住院醫師，赴台接受三個月短期訓練\n\nDr. 郭宜潔建議: 請事業發展部先安排一個內部會議，擬定訓練計劃。再和HGH的醫師們會議討論、公告訓練計劃\n\n2024 July 骨科專家將再度來訪HGH，指導進階骨折手術、脊椎手術、關節鏡等\n每季一次進行個案討論 teleconference (一般外科、胸腔內科、骨科、神外、婦產科，內臟內科、病理科、感控室)"
  },
  {
    "objectID": "2024Projects_TMM.html#tmm-request",
    "href": "2024Projects_TMM.html#tmm-request",
    "title": "2024 TMM Project",
    "section": "TMM request",
    "text": "TMM request\n\n基於衛生部提供的 Nissan NP300 交通車，醫療團每一趟出車均需要司機，乘客座位三、四名，而計劃推展中，常常須要二組人馬出動(不同目的地)，加上因應八月份徐醫師到任，\n\n上班、下班，暫時均需要分為兩趟、甚至三趟行車。\n請示改變預算(旅運費)，以支付約每個月USD1,800的租車費用(司機、車、diesel)"
  },
  {
    "objectID": "2024Projects_TMM.html#taiwan-medical-mission",
    "href": "2024Projects_TMM.html#taiwan-medical-mission",
    "title": "2024 TMM Project",
    "section": "",
    "text": "Collaborative Synergy: The Power of TMM and HGH’s Daily Partnership\n攜手共創：駐索馬利蘭醫療團與哈格薩總醫院的夥伴關係\n來自臺灣的長駐醫療團，醫護人員與哈格薩總醫院的醫療團隊，每日並肩工作能產生非常大的價值與力量。在第一線的緊密合作，是索馬利蘭永續醫療發展的基石。透過共同努力，醫療團隊能深入了解駐地特有的挑戰、因地因時制宜，發現需求和改進的機會。\n透過紮根基層的參與，醫療團能夠發現關鍵問題，與本地醫護專家討論，然後創新設計出對應的方案。我們相信，最具影響力的計畫，是由深入醫院日常運作的專業人員，去發掘需求而產生的。這種模式能確保技術上合理，更能符合哈格薩總醫院的優先順序和發展方向。醫療團以專業的方式來發展計畫，結合兩地專家的專長，以實現醫療照護的提升。"
  },
  {
    "objectID": "index.html#online-registration-closed",
    "href": "index.html#online-registration-closed",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Online registration Closed",
    "text": "Online registration Closed\n(Lunch will be provided for registered participants only following the conference.)"
  },
  {
    "objectID": "index.html#online-registration-closed-20240510-2300",
    "href": "index.html#online-registration-closed-20240510-2300",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Online registration Closed [2024/05/10 23:00]",
    "text": "Online registration Closed [2024/05/10 23:00]\n(Lunch will be provided for registered participants only following the conference.)"
  },
  {
    "objectID": "abstract_uploads.html#photos",
    "href": "abstract_uploads.html#photos",
    "title": "Abstract and Keynote",
    "section": "Photos",
    "text": "Photos\n\nphotos during the conference"
  },
  {
    "objectID": "abstract_uploads.html#video-record",
    "href": "abstract_uploads.html#video-record",
    "title": "Abstract and Keynote",
    "section": "Video record",
    "text": "Video record\n\nvideo recorded during the conference"
  },
  {
    "objectID": "index.html#statistics-of-participants-and-questionair",
    "href": "index.html#statistics-of-participants-and-questionair",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Statistics of Participants, and Questionair",
    "text": "Statistics of Participants, and Questionair"
  },
  {
    "objectID": "index.html#statistics-of-participants-and-questionaire",
    "href": "index.html#statistics-of-participants-and-questionaire",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Statistics of Participants, and Questionaire",
    "text": "Statistics of Participants, and Questionaire"
  },
  {
    "objectID": "index.html#statistics-of-participants-and-questionnaire",
    "href": "index.html#statistics-of-participants-and-questionnaire",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Statistics of Participants, and Questionnaire",
    "text": "Statistics of Participants, and Questionnaire"
  },
  {
    "objectID": "questionnaire.html",
    "href": "questionnaire.html",
    "title": "2024MSC Feedback Questionnaire",
    "section": "",
    "text": "Name: \nEmail: \nWhich speaker’s presentation did you find most informative?  Select a speaker Dr. Jamal Tex Li-Hsing Chi Dr. Ahmed Abdi Hersi Dr. Chin-I Chen Dr. Omar Marshal Dr. Fadumo Ahmed Liban Dr. Abdillahi Abdi Ali  Dr. Yen-Hsiang Wang Dr. Ahmed Saed Ali Dr. Yu-Pin Chen Dr. Abdirashid Ismail \nHow satisfied were you with the overall conference?  Select your satisfaction level Very satisfied Satisfied Neutral Dissatisfied Very dissatisfied \nWhich topics would you like to see covered in future conferences?\n\nAny additional comments or suggestions?\n\nSubmit"
  },
  {
    "objectID": "Hussein2023_Dengue_EAH.html",
    "href": "Hussein2023_Dengue_EAH.html",
    "title": "Original Research Article",
    "section": "",
    "text": "Sero-prevalence of Dengue virus infection and associated factors among patients with febrile illness attending at Edna Adan University Hospital. Hargeisa, Somaliland, 2022: A cross-sectional study\n(article is available at Hussein et al., 2023)"
  },
  {
    "objectID": "Hussein2023_Dengue_EAH.html#summary",
    "href": "Hussein2023_Dengue_EAH.html#summary",
    "title": "Original Research Article",
    "section": "Summary",
    "text": "Summary\nThis study, conducted by Hussein Mohamoud Nour, Mohamed Abdiqadir Ahmed, and Alemayehu Bayray Kahsay, is the first scientific publication on dengue fever in Somaliland. The cross-sectional study aimed to estimate the prevalence of dengue fever by detecting DENV-specific antibodies (IgM/IgG) among patients with febrile illness attending Edna Adan University Hospital in Hargeisa, Somaliland, from October to November 2022.\n\nKey Results\n\nThe overall incidence rate of dengue virus infection among patients with febrile illness was 37% (20 out of 54 patients).\nA higher incidence rate of dengue fever (5.9%) was observed in patients older than 50 years, followed by 5.6% in patients aged between 41-50 years.\nAmong the dengue-positive patients, 50% tested positive for IgG, 35% for IgM, and 15% for both IgG and IgM.\nFactors such as gender (p&lt;0.007), presence of fever (p&lt;0.001), and retro-orbital pain were significantly associated with dengue seropositivity.\n\n\n\nDiscussion Highlights\n\nThis study confirms the circulation of DENV in Somaliland and the presence of the Aedes mosquito species in all regions of the country.\nThe incidence rate of 37% is comparable to studies conducted in India (31.5%) and Eritrea (33.3%), but higher than those reported in north-southern Nigeria (18%), Jordan (24.6%), and Lagos (24.9%).\nThe high prevalence of dengue IgG (50%) indicates that a large proportion of the population has been exposed to DENV during the outbreak in the country.\nThe study emphasizes the need for improved vector control measures, entomology studies, and a strong surveillance system in Somaliland, given the impact of climate change on the emergence and re-emergence of vector-borne diseases.\nFuture large-scale investigations and molecular detection are warranted to discover different virus serotypes and better understand the epidemiology of dengue fever in Somaliland.\n\nIn conclusion, this study provides the first evidence of dengue virus infection circulation in Somaliland and highlights the need for enhanced prevention, control, and surveillance measures to address this emerging public health threat.\n\n\nSevere dengue\nThe correlation between re-infection with a different DENV serotype and severe dengue can be explained by the antibody-dependent enhancement (ADE) phenomenon. When an individual is infected with one DENV serotype, they develop antibodies specific to that serotype. However, if they are later infected with a different DENV serotype, the pre-existing antibodies may not neutralize the virus effectively. Instead, these antibodies can enhance the entry of the virus into host cells, leading to increased viral replication and a more severe form of the disease, known as severe dengue or dengue hemorrhagic fever (DHF).\nFactors contributing to severe dengue include:\n\nPrevious infection with a different DENV serotype, leading to ADE.\nHost genetic factors that may influence the immune response to DENV infection.\nVirulence of the specific DENV strain causing the infection.\nAge of the patient, with children and older adults being more susceptible to severe dengue.\nPresence of comorbidities, such as diabetes, hypertension, or chronic kidney disease.\n\n\n\nCritical challenge questions for the author, Hussein Mohamoud Nour:\n\nWhat was the timing of blood sample collection for the study participants in relation to the onset of fever? This is crucial because the presence of NS1 antigen, IgM, and IgG antibodies varies depending on the stage of infection.\n\nNS1 antigen is detectable early in the course of infection, typically from day 1 to day 9 after the onset of symptoms.\nIgM antibodies appear around 3-5 days after the onset of symptoms and can persist for several weeks to a few months.\nIgG antibodies develop about a week after the onset of symptoms and can persist for several years.\n\nWhy was NS1 antigen not checked in this study? NS1 antigen testing is a valuable tool for early diagnosis of dengue fever, as it can be detected before the appearance of antibodies. Including NS1 antigen testing could have provided a more comprehensive picture of the prevalence of dengue virus infection in the study population.\nIs there a possibility of underestimating the number of cases based on IgM or IgG antibodies if blood samples were drawn at the time of admission? If blood samples were collected very early in the course of infection, IgM and IgG antibodies might not have developed yet, leading to false-negative results and an underestimation of the true prevalence of dengue virus infection.\n\nAddressing these questions would help clarify the study’s methodology and strengthen the interpretation of the findings. Furthermore, the inclusion of NS1 antigen testing in future studies could provide a more accurate assessment of the burden of dengue fever in Somaliland."
  },
  {
    "objectID": "2024MSC_statistics.html",
    "href": "2024MSC_statistics.html",
    "title": "2024 Multi-Specialty Conference (2024MSC) Feedback Analysis Report",
    "section": "",
    "text": "Introduction\nThe 2024 Multi-Specialty Conference (2024MSC) brought together healthcare professionals from various specialties to discuss critical topics in public health. This report analyzes the feedback received from the conference participants and provides an overview of the event’s success.\n\n\nParticipant Demographics\n\n\n\n\n\n\n\nThe conference attracted participants from diverse specialty backgrounds. The majority of the attendees were 48 doctors, followed by 23 nurses, and other healthcare professionals (4%). Total 15 speakers (including VIP remarks), and 59 persons in audience registered online.\n\n\nSpecialties of Speakers and Participants\n\n\n\n\n\n\nspecialty\nn\n\n\n\n\nOrthopedics\n17\n\n\nGeneral Surgery\n14\n\n\nInternal Medicine\n11\n\n\nOther\n9\n\n\nOMS\n4\n\n\nCardiology\n3\n\n\nGeneral Practice\n3\n\n\nPediatrics\n3\n\n\nRadiology\n2\n\n\nEye\n1\n\n\nNephrology\n1\n\n\nNeurology\n1\n\n\nNeurosurgery\n1\n\n\nOBGYN\n1\n\n\nPathology\n1\n\n\nPharmacy\n1\n\n\nRehabilitation\n1\n\n\n\n\n\nThe 2024 Multi-Specialty Conference (2024MSC) attracted a diverse range of healthcare professionals from various specialties. An analysis of the specialty distribution among speakers and participants who registered before 11 May, 2024, was conducted to gain insights into the conference’s interdisciplinary nature.\nThe data revealed that the most well-represented specialty was Orthopedics, with 17 individuals. This highlights the conference’s strong focus on musculoskeletal health and related surgical interventions, such as arthroscopic surgery in HGH.\nGeneral Surgery followed closely, with 14 participants, reflecting the conference’s emphasis on surgical disciplines, especially in minimal invasive laparoscopic training centre in HGH.\nInternal Medicine had a notable presence, with 11 attendees, indicating the conference’s attention to medical specialties dealing with the diagnosis, treatment, and prevention of adult diseases, such as noncommunicable diseases (NCDs) and Dengue fever.\nOther specialties represented at the conference included Oral and Maxillofacial Surgery (OMS) (4 participants), Radiology (2 participants), Pathology (1 participants), and one doctor working in tropical medicine. The presence of these specialties underscores the conference’s commitment to fostering collaboration and knowledge exchange across various medical and surgical domains.\nInterestingly, the data also revealed the participation of professionals from other essential areas of healthcare, such as Pharmacy (1 participants) and Nursing (3 participants in Cardiology). This diversity in specialties emphasizes the conference’s recognition of the interdisciplinary nature of healthcare and the importance of involving multiple disciplines in addressing complex medical challenges.\nFurthermore, the conference attracted participants from specialties such as Neurology (1 participants), Nephrology (1 participants), and Pediatrics (3 participants), showcasing the conference’s comprehensive approach to healthcare across different age groups and organ systems.\nIn conclusion, the specialty distribution among speakers and participants at the 2024 Multi-Specialty Conference demonstrates the event’s success in bringing together a wide array of healthcare professionals. The strong representation of Internal Medicine, General Surgery, and Orthopedics, along with the participation of various other medical and surgical specialties, highlights the conference’s commitment to fostering interdisciplinary collaboration and knowledge sharing. This diversity in specialties positions the conference as a platform for addressing the complex and multifaceted challenges in healthcare, ultimately contributing to improved patient care and outcomes.\n\n\nTop Welcomed Speakers\nBased on the feedback received, the top four speakers of the 2024MSC were:\n\nDr. Fadumo Ahmed Liban\nDr. Chin-I Chen\nDr. Abdilahi Abdi Ali\nDr. Jamal Tex LH Chi\n\nThese speakers were highly appreciated by the audience for their informative and engaging presentations. The bar chart visualizes the number of votes each top speaker received.\n\n\n\n\n\n\n\n\nSatisfaction Levels\nThe conference received positive feedback from the participants regarding their overall satisfaction.\nThe high percentage of “Very satisfied” and “Satisfied” responses indicates that the conference met the expectations of the majority of the attendees. The bar chart represents the satisfaction levels graphically.\n\n\n\n\n\n\nThe satisfaction levels were as follows:\n\nVery satisfied: 55%\nSatisfied: 45%\nNeutral: 0%\n\n\n\nFeedback and Comments\nThe participants provided valuable feedback and suggestions for future conferences. Some of the notable comments include:\n\n“I am very thrilled the work that you done” - Dr. Abdirahman, HGH director\n“Very good conference. Such conferences are much needed in Somaliland.” - Dr. Hassan Nur\n“Oncology department is missing from the HGH, which needs to be established.” - Dr. Abdillahi Abdi Ali\n“Topics should include research, articles, and cases done in hospitals of Somaliland.” Dr. Nouh Ismail\n“Please make this conference regular and invite those Doctors who always make positive change in their community and those who always make a research and are going to publish studies by sharing their knowledge with others.” - Dr. Faadumo\n\nThe comments highlight the importance of the conference in addressing healthcare issues in Somaliland and suggest areas for improvement, such as including more research-based presentations and establishing an oncology department at the Hargeisa Group Hospital.\nThe other comments:\n\n\n\n\n\n\n\n\n\nCommenter\nComment\n\n\n\n\nTex Chi\nwaiting for 2025MSC\n\n\nWang Yen Hsiang\nVery good conference\n\n\nNimco Abdilahi\nmahasanid\n\n\nHassan nur\nWell organized even thank you . Such conference are much needed in somaliland .\n\n\nDr. Abdillahi Abdi Ali\nArticles and publications should be focused than text book presentations.\n\n\nDr. Idiris Abdi Ali\nOncology department is missing from the HGH, which needs to be stablished.\n\n\nDr.Nouh Ismail\n1. Topics should includes research, articles and case done in hospitals of somaliland./2. Lectures should contain relevent pictures\n\n\nDr Abdirahman\nIam very thrilled the work that you done\n\n\nFaadumo\nPlease make this conference regularly and invite those Doctors who always make posative change in their communitg and those who always make a research and gonna to publish studies by sharing their knowledge to others.\n\n\n\n\n\n\n\nConclusion\nThe 2024 Multi-Specialty Conference successfully brought together healthcare professionals from various specialties to discuss important public health topics. The positive feedback received from the participants demonstrates the conference’s impact and the need for similar events in the future. The organizing committee will take the feedback and suggestions into consideration to improve the upcoming conferences and continue to contribute to the advancement of healthcare in Somaliland.\nWe wish see you soon on 2025MSC in Somaliland!\nIn sha Allah, إن شاء الله"
  },
  {
    "objectID": "index.html#statistics-of-participants-and-feedback",
    "href": "index.html#statistics-of-participants-and-feedback",
    "title": "2024 Multidisciplinary Specialty Conference",
    "section": "Statistics of Participants, and Feedback",
    "text": "Statistics of Participants, and Feedback\nAfter conference…"
  },
  {
    "objectID": "2024Project_ADFA_MOFA.html",
    "href": "2024Project_ADFA_MOFA.html",
    "title": "Project OT construction in HGH",
    "section": "",
    "text": "A clear agreement between the Taiwan Ministry of Foreign Affairs (MOFA) and Australian Doctors for Africa (ADFA) regarding the operation theater (OT) construction plan at Hargeisa Group Hospital (HGH). The following points should be considered when drafting the agreement:\nBased on “Taiwan Centre” contruction plan at HGH (Plan A) by survey and planning in 2023,\n\nScope of the project: The agreement should clearly define the scope of the project, which involves the construction of four operation theater rooms (Plan B) at HGH.\nFinancial contributions: The agreement should outline the financial contributions from both ADFA and the Taiwan Embassy, with the budget being sourced from Taiwan MOFA. It should specify the exact amount or percentage of the total cost that each party will cover.\nResponsibilities: The agreement should delineate the responsibilities of each party involved. For example, ADFA may be responsible for overseeing the construction process, while TMM, under the guidance of the Taiwan Embassy and with approval from Taiwan MOFA, may be responsible for suggesting and sourcing essential medical equipment for the OTs.\n\n(hospital building and civil engineering structures from Taiwan)\n\nTimeline: The agreement should include a detailed timeline for the project, specifying key milestones such as the start and completion dates of construction, as well as the installation of medical equipment.\nCommunication and reporting: The agreement should establish clear communication channels between ADFA, TMM, and the Taiwan Embassy, as well as reporting requirements to ensure transparency and accountability throughout the project.\nIntellectual property and branding: The agreement should address any intellectual property rights and branding guidelines, such as the use of logos and acknowledgment of each party’s contributions in public communications related to the project.\nDispute resolution: The agreement should include a dispute resolution mechanism to address any potential conflicts or disagreements that may arise during the course of the project.\nSustainability and future collaboration: The agreement may also outline plans for future collaboration between ADFA and TMM to ensure the long-term sustainability and effectiveness of the OTs at HGH.\n\nBy carefully considering these points and drafting a comprehensive agreement, Taiwan MOFA and ADFA can establish a strong foundation for a successful collaboration on the OT construction project at HGH. This agreement will help ensure that all parties involved have a clear understanding of their roles, responsibilities, and expectations, ultimately contributing to the project’s success and the improvement of healthcare services in Somaliland."
  },
  {
    "objectID": "2024Project_DengueFever_Hargeisa.html",
    "href": "2024Project_DengueFever_Hargeisa.html",
    "title": "2024 Project Dengue Fever",
    "section": "",
    "text": "Part III: MoHD Healthcare System Organizational Structure in Somaliland\n\\begin{tikzpicture}[\n    level 1/.style={sibling distance=40mm},\n    level 2/.style={sibling distance=20mm},\n    level 3/.style={sibling distance=15mm},\n    every node/.style={rectangle,draw,align=center}\n  ]\n\n  \\node {Ministry of Health Development (MoHD)}\n    child {node {Regional Medical Officer\\\\(Maroodijeeh Region)}}\n    child {node {Other Regional\\\\Medical Officers}};\n\n  \\node [below=of {Regional Medical Officer\\\\(Maroodijeeh Region)}] (HargeisaDistrict) {Hargeisa District Medical Office}\n    child {node {31 May}}\n    child {node {26 June}}\n    child {node {Ahmed Dhagah}}\n    child {node {Ahmed Moallim Haruun}}\n    child {node {Gacan Libaax}}\n    child {node {Ibrahim Kodbuur}}\n    child {node {Mohamoud Haibe}}\n    child {node {Mohamed Moge}};\n\n  \\node [left=of HargeisaDistrict] {Public Sector Health System}\n    child {node {Primary Health Units (PHUs)}}\n    child {node {Health Centers (HCs)}}\n    child {node {Referral Health Centers (RHCs)}}\n    child {node {Regional Hospitals}}\n    child {node {Specialist Hospitals\\\\(TB, Mental, FGM)}}\n    child {node {Hargeisa Group Hospital (HGH)}};\n\n\\end{tikzpicture}"
  },
  {
    "objectID": "2024Project_HGH_laparoscopicCentre.html",
    "href": "2024Project_HGH_laparoscopicCentre.html",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "",
    "text": "The Taiwan Medical Mission (TMM) in the Republic of Somaliland, in collaboration with the Hargeisa Group Hospital (HGH), proposes the establishment of a Laparoscopic Training Center to enhance surgical care and improve patient outcomes in the region. This initiative aims to introduce and develop laparoscopic surgery techniques among the general surgery department at HGH, under the guidance of Dr. (Andrew) Yen-Hsiang Wang, a visiting surgeon from Taipei Municipal Wanfang Hospital (TMWH), Taiwan.\n\n\nDr. (Andrew) Yen-Hsiang Wang, a general surgeon from TMWH, has been working with the TMM in Somaliland for more than three months. During this time, he has collaborated with the local general surgery team, participating in outpatient clinics, surgeries, and ward rounds. The initial assessment has revealed a significant opportunity to fulfill the shared aspirations of the TMM and the local general surgeons: the development of laparoscopic surgery in Hargeisa Group Hospital. Currently, at least six attending physicians at HGH have had exposure to laparoscopic surgery during their specialist training in neighboring Ethiopia. However, due to the lack of necessary equipment at HGH, they have been unable to perform laparoscopic procedures. The attending physicians and residents in the general surgery department at HGH have expressed a strong interest in developing laparoscopic surgery. Their proficiency in a wide range of open surgical techniques makes laparoscopy an area where Taiwanese surgeons can showcase their expertise."
  },
  {
    "objectID": "2024Project_HGH_laparoscopicCentre.html#project-overview",
    "href": "2024Project_HGH_laparoscopicCentre.html#project-overview",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "",
    "text": "The Taiwan Medical Mission (TMM) in the Republic of Somaliland, in collaboration with the Hargeisa Group Hospital (HGH), proposes the establishment of a Laparoscopic Training Center to enhance surgical care and improve patient outcomes in the region. This initiative aims to introduce and develop laparoscopic surgery techniques among the general surgery department at HGH, under the guidance of Dr. (Andrew) Yen-Hsiang Wang, a visiting surgeon from Taipei Municipal Wanfang Hospital (TMWH), Taiwan.\n\n\nDr. (Andrew) Yen-Hsiang Wang, a general surgeon from TMWH, has been working with the TMM in Somaliland for more than three months. During this time, he has collaborated with the local general surgery team, participating in outpatient clinics, surgeries, and ward rounds. The initial assessment has revealed a significant opportunity to fulfill the shared aspirations of the TMM and the local general surgeons: the development of laparoscopic surgery in Hargeisa Group Hospital. Currently, at least six attending physicians at HGH have had exposure to laparoscopic surgery during their specialist training in neighboring Ethiopia. However, due to the lack of necessary equipment at HGH, they have been unable to perform laparoscopic procedures. The attending physicians and residents in the general surgery department at HGH have expressed a strong interest in developing laparoscopic surgery. Their proficiency in a wide range of open surgical techniques makes laparoscopy an area where Taiwanese surgeons can showcase their expertise."
  },
  {
    "objectID": "2024Project_HGH_laparoscopicCentre.html#project-objectives",
    "href": "2024Project_HGH_laparoscopicCentre.html#project-objectives",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Project Objectives",
    "text": "Project Objectives\n\nEstablish a Laparoscopic Training Center at Hargeisa Group Hospital.\nTrain attending physicians and residents in laparoscopic surgical techniques.\nFoster collaboration and knowledge exchange between Taiwanese and Somaliland surgeons."
  },
  {
    "objectID": "2024Project_HGH_laparoscopicCentre.html#implementation-plan",
    "href": "2024Project_HGH_laparoscopicCentre.html#implementation-plan",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Implementation Plan",
    "text": "Implementation Plan\n\nDr. Wang will develop a comprehensive laparoscopic surgery training curriculum, tailored to the needs and resources of HGH.\nThe TMM kindly requests the Teaching Department of TMWH to support a laparoscopic simulator and instruments.\nDr. Wang will conduct hands-on training sessions, demonstrations, and supervised laparoscopic procedures during his time in Somaliland.\n\n\n\nLaparoscopic Simulator:\nFeatures:\n\nRealistic 2D graphics and tactile feedback\nAdjustable difficulty levels for various training scenarios\nComprehensive curriculum with guided tasks and performance metrics\nCompatibility with a wide range of laparoscopic instruments\n\n\nLaparoscopic Instrument Set for Simulator:\n\n5mm Maryland dissector (x1)\n5mm curved scissors (x1)\n5mm atraumatic grasper (x1)\n5mm Babcock forceps (x1)\n5mm Hasson trocar (x2)\nLight cable (x1)\nCamera (x1)\nAndroid Go tablet (x1)\nNeedle holder (x1)\nGrasping forceps (x2)"
  },
  {
    "objectID": "2024Project_HGH_laparoscopicCentre.html#future-prospects",
    "href": "2024Project_HGH_laparoscopicCentre.html#future-prospects",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Future Prospects",
    "text": "Future Prospects\nIn 2025, Dr. Mrr Kuan, a general surgeon from Tong General Hospital (Taiwan), is expected to join the TMM in Somaliland. The establishment of the Laparoscopic Training Centre will lay the foundation for continued training and development in minimally invasive surgery.\nThe TMM will work towards securing funds for the procurement of laparoscopic equipment, ensuring the sustainability and long-term impact of the project."
  },
  {
    "objectID": "2024Project_HGH_laparoscopicCentre.html#budget-planning-for-laparoscopic-equipment-estimated-if-made-in-india",
    "href": "2024Project_HGH_laparoscopicCentre.html#budget-planning-for-laparoscopic-equipment-estimated-if-made-in-india",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Budget Planning for Laparoscopic Equipment (estimated, if Made in India)",
    "text": "Budget Planning for Laparoscopic Equipment (estimated, if Made in India)\n\n\n\n\n\n\n\n\n\nItem\nQuantity\nUnit Price (USD)\nTotal (USD)\n\n\n\n\nLaparoscopic Trolley\n1\n$1,500\n$1,500\n\n\nLaparoscopic Camera System\n1\n$6,000\n$6,000\n\n\nLaparoscopic Light Source\n1\n$1,200\n$1,200\n\n\nLaparoscopic Insufflator\n1\n$1,500\n$1,500\n\n\nLaparoscopic Monitor\n2\n$800\n$1,600\n\n\nLaparoscopic Instrument Set\n2\n$3,000\n$6,000\n\n\nLaparoscopic Suction-Irrigation\n1\n$500\n$500\n\n\nLaparoscopic Electrodes\n2 sets\n$300\n$600\n\n\nLaparoscopic Trocars\n2 sets\n$400\n$800\n\n\nLaparoscopic Needle Holders\n2\n$200\n$400\n\n\nLaparoscopic Clip Applicators\n2\n$250\n$500\n\n\nLaparoscopic Veress Needles\n2\n$50\n$100\n\n\nLaparoscopic Graspers\n2 sets\n$400\n$800\n\n\nLaparoscopic Scissors\n2 sets\n$300\n$600\n\n\nLaparoscopic Knot Pushers\n2\n$100\n$200\n\n\nTotal Budget\n\n\nUSD22,300\n\n\n\nNote: Prices are estimated based on average costs of laparoscopic equipment made in India. Actual prices may vary depending on the specific manufacturer, model, and negotiated discounts.\nThis budget plan covers the essential equipment required to establish a functional laparoscopic surgery unit at Hargeisa Group Hospital. The procurement of high-quality, cost-effective equipment from Indian manufacturers will ensure the sustainability and long-term success of the Laparoscopic Training Centre initiative."
  },
  {
    "objectID": "2024Project_HGH_laparoscopicCentre.html#conclusion",
    "href": "2024Project_HGH_laparoscopicCentre.html#conclusion",
    "title": "Empowering Surgeons, Transforming Lives: The Laparoscopic Training Initiative in Hargeisa Group Hospital",
    "section": "Conclusion",
    "text": "Conclusion\nThe establishment of a Laparoscopic Training Centre at Hargeisa Group Hospital represents a significant step towards improving surgical care and patient outcomes in Somaliland. Through collaboration, training, and knowledge exchange, this initiative will empower local surgeons, transform lives, and contribute to the overall development of the healthcare system in the region."
  },
  {
    "objectID": "2024Projects_TMM.html#progress-report-20240527",
    "href": "2024Projects_TMM.html#progress-report-20240527",
    "title": "2024 TMM Project",
    "section": "Progress Report (2024/05/27)",
    "text": "Progress Report (2024/05/27)"
  },
  {
    "objectID": "2024Project_HPV.html",
    "href": "2024Project_HPV.html",
    "title": "Cervical Cancer in Somaliland: Burden, Barriers, and Opportunities for Prevention",
    "section": "",
    "text": "Background:\nCervical cancer is a leading cause of cancer deaths among women in Africa, with an estimated age-standardized incidence rate of 25.1 per 100,000 in Somalia (Bruni et al., 2023). Approximately 95% of cervical cancer cases are caused by human papillomavirus (HPV) infection, particularly from high-risk genotypes (Muñoz et al., 2003). Despite this high regional burden, specific data on cervical cancer epidemiology in Somaliland is limited. The tertiary hospital in Somalia recorded a total of 1306 cancer cases from 2017 to 2020. Among these instances, 13.3% were cervical cancer and 13.1% were breast cancer. Cervical cancer ranked as the second most prevalent cancer in women, while breast cancer ranked third (Tahtabasi et al., 2020). Local healthcare providers at Hargeisa Group Hospital (HGH) anecdotally report cervical cancer as rare, contrasting with findings from Somali immigrant populations in the United States and Europe showing higher disease rates (Grimm et al., 2017, Idehen et al., 2017).\nThe key points regarding cervical cancer prevention and control strategies in Somaliland:\n\nKnowledge and awareness about cervical cancer, its risk factors, screening methods like HPV DNA, Pap smears, and prevention through HPV vaccination is very low among Somali women (Altunkurek et al., 2024; Grimm et al., 2017; Ghebre et al., 2015). Many Somali women are not familiar with cervical cancer screening tests and concepts.\nThere is a lack of national cervical cancer screening programs and HPV vaccination programs in Somalia (Altunkurek et al., 2024) and Somaliland. Constraints in implementing and sustaining screening programs have limited the effectiveness of secondary prevention efforts.\nPrimary prevention through HPV vaccination is identified as a cost-effective preventive measure, but none of the Somali students surveyed had received the HPV vaccine (Altunkurek et al., 2024). Establishing national HPV vaccination strategies is recommended in Somaliland.\nBarriers to cervical cancer screening among Somali women include limited knowledge, language difficulties, fear of the test, embarrassment exposing one’s body, negative past experiences, and cultural factors like preferring female providers (Grimm et al., 2017; Ghebre et al., 2015).\nEfforts are needed to increase awareness through culturally-appropriate health education programs targeting Somali women and their families (especially Somali Men) about cervical cancer, HPV, and prevention methods (Altunkurek et al., 2024; Ghebre et al., 2015).\nInvolving Somali men, who are often the key decision-makers in households, in cervical cancer prevention education could help increase uptake of screening and HPV vaccination among Somali women and adolescents (University of Minnesota, 2015).\n\nIn summary, the literature highlights low levels of cervical cancer awareness and limited access to screening and vaccination services as major gaps in Somaliland and Somalia. Implementing national prevention programs, educational interventions tailored to Somali communities, and involving male household decision-makers are recommended strategies to improve cervical cancer control efforts in line with WHO goals (Altunkurek et al., 2024; University of Minnesota, 2015; Ghebre et al., 2015).\nAccurate local data is critical for informing prevention and control strategies aligned with WHO’s global cervical cancer elimination targets. HPV infection, the primary cause of cervical cancer, can be detected through screening tests like Pap smears and HPV DNA assays. Screening provides an opportunity to identify precancerous lesions and early-stage cancers amenable to treatment.\n\n\nObjectives:\n\nDetermine the prevalence of HPV infection and cervical abnormalities among women attending HGH\nRaise awareness of cervical cancer burden and value of screening among HGH clinicians\nEstablish feasibility of implementing routine cervical cancer screening in the HGH setting\nTrain HGH pathologist doctors on organizing pathology data and contributing to cancer registries\n\n\n\nMethods:\nWe propose a pilot cross-sectional study of 500 women aged 30-49 presenting to HGH obstetrics and gynecology clinics. After informed consent, participants will undergo: - Pap smear and HPV DNA testing - Brief risk factor survey - Education on cervical cancer prevention\nPap smears will be processed and interpreted locally by trained HGH laboratory staff, with quality assurance review by TMM pathologists. HPV DNA samples will be analyzed using a validated PCR-based assay.\nResults will be reported back to participants with appropriate follow-up recommendations. Aggregated, de-identified data will be shared with HGH clinicians, highlighting the proportion of women with positive screening results.\nHGH pathologist doctors will receive training on systematically documenting and organizing pathology data from cervical specimens. They will learn best practices for contributing this data to hospital-based and national cancer registries to track cervical cancer trends over time.\n\n\nPotential Challenges:\n\nLow perceived need for screening among clinicians\nCultural sensitivity around discussing sexually transmitted infections\nLimited laboratory infrastructure and personnel\n\n\n\nStrategies:\n\nEngage HGH leadership as champions to promote screening\nFrame messaging around cancer prevention benefits\nProvide intensive laboratory training and remote telepathology support\n\n\n\nExpected Outcomes:\nQuantifying the burden of HPV infection and cervical abnormalities in this pilot study will provide critical local data to inform future screening implementation. We anticipate identifying a substantial number of high-risk women who can benefit from treatment and surveillance. Uncovering a higher than expected burden would challenge assumptions about low cervical cancer incidence in Somaliland and reinforce the need for routine screening aligned with WHO elimination goals. Successful completion will demonstrate the feasibility and value of screening in this setting.\nImproved pathology data management and cancer registry reporting by HGH pathologists will enable ongoing monitoring of cervical cancer epidemiology. This data can guide resource allocation and evaluate the impact of prevention efforts over time.\n\n\nBudget Considerations:\n\nPap smear and HPV DNA testing supplies\nLaboratory equipment and training\nPatient/provider education materials\nData management and analysis software\nPersonnel time for study coordination, specimen processing, and results reporting\nTraining for HGH pathologists on data organization and cancer registry reporting\n\n\n\nReferences:\nBruni L, Albero G, Serrano B, Mena M, Collado JJ, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Somalia. Summary Report 10 March 2023. [1 June 2024 Accessed]\nGhebre, R. G., Sewali, B., Osman, S., Adawe, A., Nguyen, H. T., Okuyemi, K. S., & Joseph, A. (2015). Cervical cancer: barriers to screening in the Somali community in Minnesota. Journal of immigrant and minority health, 17(3), 722-728.\nGrimm B, Alnaji N, Watanabe-Galloway S, Leypoldt M. Cervical Cancer Attitudes and Knowledge in Somali Refugees in Nebraska. Pedagogy in Health Promotion. 2017;3(1_suppl):81S-87S. doi:10.1177/2373379917698673\nIdehen, E. E., Korhonen, T., Castaneda, A., Juntunen, T., Kangasniemi, M., Pietilä, A. M., & Koponen, P. (2017). Factors associated with cervical cancer screening participation among immigrants of Russian, Somali and Kurdish origin: a population-based study in Finland. BMC Women’s Health 17, 19 (2017). https://doi.org/10.1186/s12905-017-0375-1\nMuñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., … & Meijer, C. J. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348(6), 518-527. doi: 10.1056/NEJMoa021641. PMID: 12571259.\nUniversity of Minnesota. (2015). Men May Be Key to Cervical Cancer Prevention Among Somali Women and Children. Retrieved from https://www.sph.umn.edu/news/men-may-key-cervical-cancer-prevention-among-somali-women-children/\nŞeyma Zehra Altunkurek, Samira Hassan Mohamed. Knowledge, Awareness and Behaviors of Somalian Female University Students regarding Cervical Cancer, HPV and the HPV Vaccine: A Cross-Sectional Study. Clin. Exp. Obstet. Gynecol. 2024, 51(2), 41. https://doi.org/10.31083/j.ceog5102041\nTahtabasi M, Mohamud Abdullahi I, Kalayci M, Gedi Ibrahim I, Er S. Cancer Incidence and Distribution at a Tertiary Care Hospital in Somalia from 2017 to 2020: An Initial Report of 1306 Cases. Cancer Manag Res. 2020 Sep 28;12:8599-8611. doi: 10.2147/CMAR.S277202. PMID: 33061565; PMCID: PMC7534047."
  },
  {
    "objectID": "2024Projects_TMM.html#appendix",
    "href": "2024Projects_TMM.html#appendix",
    "title": "2024 TMM Project",
    "section": "Appendix",
    "text": "Appendix"
  },
  {
    "objectID": "2024Projects_TMM.html#visiting-scholarships-for-training-in-taiwan-1",
    "href": "2024Projects_TMM.html#visiting-scholarships-for-training-in-taiwan-1",
    "title": "2024 TMM Project",
    "section": "Visiting Scholarships for Training in Taiwan",
    "text": "Visiting Scholarships for Training in Taiwan\n\nProject: Capacity Building for Somaliland Medical Personnel\nCollaborators: Taipei Municipal Wanfang Hospital (TMWH), Taiwan Medical Mission (TMM), and Hargeisa Group Hospital (HGH)\nInitiatives:\n\nProvide “Visiting Scholar Scholarships” for 13 to 15 Somaliland medical personnel to receive training in Taiwan for up to three months\nConduct selection process jointly by Taiwan Medical Mission and HGH Director’s Office\nInvite selected personnel to participate in TMM’s 2024 public health programs\n\nRequired support:\n\nTMM: Scholarship funding for 13 to 15 medical personnel (3 batches of 5)\nCoordination with TMWH for training arrangements\nCollaboration with HGH for personnel selection and public health program participation\nMoU between HGH and TMWH\n13 scholarship candidates:\n\n\nBatch 1\n\nDr. Abdirahman Hohamed Osman (Hospital Director)\nDr. Khadar Good Nur (Infection Prevention Centre Director)\nDr. Mohamed Hassan Nur (Resident, Orthopedic)\nDr. Hassan Mohamed Nur (Resident, Orthopedic)\n\nBatch 2\n\nDr. Saed Mohamed Osman (Resident, Orthopedic)\nDr. Abdulrahman Adoosh Abdulaahi (Resident, Orthopedic)\nDr. Adnan Sayid Abdo (General Surgery) =&gt; laparoscopic training\nDr. Mustafe Ahmed Yusuf (Neurosurgery) =&gt; spine surgery\nDr. Idris Hassan Dahir (Cardiologist)\n\nBatch 3\n\nDr. Abdihamid Mohamed Ali (Neurosurgery) =&gt; cranial surgery\nMr. Mustafe (Technician, Pathology)\nMr. Ahmed (Nurse, OT director)\nDr. Omer Mohamed Bihi (Pathology)"
  },
  {
    "objectID": "2024Projects_TMM.html#hargeisa-group-hospital-hgh-intensive-care-unit-icu-survey-20240526",
    "href": "2024Projects_TMM.html#hargeisa-group-hospital-hgh-intensive-care-unit-icu-survey-20240526",
    "title": "2024 TMM Project",
    "section": "Hargeisa Group Hospital (HGH) Intensive Care Unit (ICU) Survey (2024/05/26)",
    "text": "Hargeisa Group Hospital (HGH) Intensive Care Unit (ICU) Survey (2024/05/26)\n\nBed Capacity and Patient Distribution\n\nAdult ICU:\n\nTotal bed capacity: 14 beds (7 for male patients and 7 for female patients)\nMost medical conditions treated: Cerebrovascular accidents (CVA), pneumonia, acute myocardial infarction (AMI), and major trauma\nElective post-operative patients are admitted sometimes (rare major surgery)\n\nPediatric ICU: 5 bed capacity\nNeonatal ICU\n\n\n\nMedical Staff of Adult ICU\n\nDr. Jacfar is the director of the ICU at HGH\n8 general practitioner (GP) doctors and 3 internist specialist doctors (including director, and Dr. Saed Ahmed) work in the ICU\nNo in-charge physician system; all 8 GP doctors collectively care for the 14 patients\nMedical students rotate through the ICU\n\n\n\nNursing Staff\n\nTotal number of nurses: 16\n\nShift A: 6 nurses\nShift B: 4 nurses\nShift C: 6 nurses\n\nResponsibilities: Vital signs monitoring every shift, nursing documentation every shift, and execution of medical orders\nAll 16 nurses collectively care for the 14 patients, with no primary care nursing system in place\n\n\n\nRespiratory Therapist\n\nOne respiratory therapist (RT) is available, working fixed hours during Shift A (Saturday to Thursday) and off on Fridays\nCurrently, there are no intubated patients, and the RT performs regular nursing duties\nThe RT is a Somalilander who received 10 months of training in the Philippines\n\n\n\nEquipment and Supplies\n\nOxygen supply: Cylinders, with dedicated personnel for transportation, supplied by the HGH oxygen concentrator\nMechanical ventilators: 3 Dräger ventilators (Dräger Evital XL), only one is operational but has not been used yet (tubing x 1 set, water wash re-usable)) (1 or 2 Mindray SV300 is in Emergency department)\nPortable ventilator: (availability uncertain)\nBiPAP (Bilevel ST CPAP): 1 unit (Yuwell YH-830; available; tubing x 1 set, water wash re-usable)\nCPAP: 1 unit (ResMed R370-4117; available but not yet used)\nSuction unit: 1 unit\nVital signs monitors: 11 monitors (ECG electrodes are lacking, and monitors are used only by orders)\nIV micro-pumps: 6 units\nDC shock (defibrillator): 1 unit (functionality questionable)\nUltrasound: 1 unit, plus several handheld ultrasound devices (Android tablets) donated and taught by SAHA Dr. Max\nArterial blood gas (ABG) machine: 1 unit (currently out of reagents)\nGlucometers: 4 units"
  },
  {
    "objectID": "2024Project_DengueFever_Hargeisa-tikz.html",
    "href": "2024Project_DengueFever_Hargeisa-tikz.html",
    "title": "2024 Dengue Fever Project",
    "section": "",
    "text": "#| echo: false\n# removal of titlepage\n\npdfseparate -f 2 -l 2 \"2024Project_DengueFever_Hargeisa-tikz.pdf\" \"2024Project_DengueFever_Hargeisa-tikz_p2.pdf\"\n\n# pdfseparate sample.pdf sample-%d.pdf"
  },
  {
    "objectID": "2024Project_DengueFever_Hargeisa-tikz.html#adminitrative-system-in-somaliland",
    "href": "2024Project_DengueFever_Hargeisa-tikz.html#adminitrative-system-in-somaliland",
    "title": "2024 Dengue Fever Project",
    "section": "",
    "text": "#| echo: false\n# removal of titlepage\n\npdfseparate -f 2 -l 2 \"2024Project_DengueFever_Hargeisa-tikz.pdf\" \"2024Project_DengueFever_Hargeisa-tikz_p2.pdf\"\n\n# pdfseparate sample.pdf sample-%d.pdf"
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html",
    "href": "2024_malaria_dengue_SOP.html",
    "title": "Bridging the Gap: A Proposed Standard Operating Procedure to Evaluating Malaria and Dengue Co-infection in Somaliland",
    "section": "",
    "text": "Malaria and dengue are two major mosquito-borne diseases that pose significant public health challenges in tropical and subtropical regions. The co-infection of these diseases has emerged as a growing concern due to their overlapping geographical distribution, shared clinical manifestations, and diagnostic challenges. This study aims to propose a standard operating procedure (SOP) for evaluating suspected malaria and dengue co-infection in low-resource settings, addressing the limitations of current rapid diagnostic tests (RDTs) and providing guidance on appropriate case management."
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html#abstract",
    "href": "2024_malaria_dengue_SOP.html#abstract",
    "title": "Bridging the Gap: A Proposed Standard Operating Procedure to Evaluating Malaria and Dengue Co-infection in Somaliland",
    "section": "",
    "text": "Malaria and dengue are two major mosquito-borne diseases that pose significant public health challenges in tropical and subtropical regions. The co-infection of these diseases has emerged as a growing concern due to their overlapping geographical distribution, shared clinical manifestations, and diagnostic challenges. This study aims to propose a standard operating procedure (SOP) for evaluating suspected malaria and dengue co-infection in low-resource settings, addressing the limitations of current rapid diagnostic tests (RDTs) and providing guidance on appropriate case management."
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html#introduction",
    "href": "2024_malaria_dengue_SOP.html#introduction",
    "title": "Bridging the Gap: A Proposed Standard Operating Procedure to Evaluating Malaria and Dengue Co-infection in Somaliland",
    "section": "Introduction",
    "text": "Introduction\nMalaria and dengue co-infection has become increasingly prevalent in endemic regions, particularly in parts of Asia, Africa, and the Americas[1]. The overlapping clinical symptoms and limitations of existing diagnostic tools make accurate detection and management of co-infections challenging[1][3]. Misdiagnosis or delayed treatment can lead to severe complications and poor outcomes[1][4]. Therefore, there is a pressing need for improved diagnostic strategies and standardized procedures for managing malaria and dengue co-infection in resource-limited settings."
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html#proposed-standard-operating-procedure",
    "href": "2024_malaria_dengue_SOP.html#proposed-standard-operating-procedure",
    "title": "Bridging the Gap: A Proposed Standard Operating Procedure to Evaluating Malaria and Dengue Co-infection in Somaliland",
    "section": "Proposed Standard Operating Procedure",
    "text": "Proposed Standard Operating Procedure\nBased on the reviewed literature, we propose the following SOP for evaluating fever with suspected malaria and dengue co-infection in low-resource settings:\n\nInitial Assessment\n\nObtain detailed history of fever onset, pattern, duration, and associated symptoms[1]\nRecord travel history, exposure risks, and epidemiological factors[1]\n\nRapid Diagnostic Testing\n\nPerform RDT for malaria, if available[1][2]\nPerform RDT for dengue NS1 antigen, if available[1][3][4][5]\n\nInterpretation of Rapid Test Results\n\nIf malaria RDT is positive, initiate antimalarial treatment as per guidelines[1][2]\nIf dengue NS1 RDT is positive, provide supportive treatment for dengue[1][3][4]\nIf both tests are positive, suspect malaria-dengue co-infection[1]\n\nAdditional Diagnostic Evaluation\n\nIf rapid tests are negative but clinical suspicion remains high:\n\nPerform microscopic examination of blood smear for malaria parasites[2]\nConsider dengue IgM/IgG serological tests[3][4][5]\nObtain other basic tests as available (CBC, LFTs, urinalysis)[2]\n\n\nManagement\n\nFor confirmed malaria cases, initiate antimalarial treatment promptly[1][2]\nFor confirmed dengue cases, provide supportive care (fluids, antipyretics)[1][3][4]\nFor suspected co-infections, treat for both malaria and dengue simultaneously[1]\nMonitor for warning signs of severe disease and complications[1][3][4]\nConsider hospitalization for severe cases or complications[1][2][3][4]\n\nDocumentation and Referral\n\nDocument all diagnostic tests, results, and treatment provided[2]\nIf diagnostic capabilities are limited or severe cases, refer to higher level of care[2]\nCite relevant guidelines for diagnosis and management[1][2][3][4][5]"
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html#implementation-challenges",
    "href": "2024_malaria_dengue_SOP.html#implementation-challenges",
    "title": "Bridging the Gap: A Proposed Standard Operating Procedure to Evaluating Malaria and Dengue Co-infection in Somaliland",
    "section": "Implementation Challenges",
    "text": "Implementation Challenges\nImplementing this SOP in low-resource settings may face several challenges:\n\nLimited availability and accessibility of rapid diagnostic tests for both malaria and dengue[1][3]\nInadequate laboratory infrastructure and trained personnel for confirmatory testing[3]\nPotential cross-reactivity and false-positive results of current RDTs[1]\nLack of a single combined rapid test for simultaneous detection of malaria and dengue co-infection[1][3]\nOverlapping clinical manifestations leading to misdiagnosis and delayed treatment[1][3]"
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html#discussion-and-conclusion",
    "href": "2024_malaria_dengue_SOP.html#discussion-and-conclusion",
    "title": "Bridging the Gap: A Proposed Standard Operating Procedure to Evaluating Malaria and Dengue Co-infection in Somaliland",
    "section": "Discussion and Conclusion",
    "text": "Discussion and Conclusion\nThe proposed SOP incorporates the use of RDTs for both malaria and dengue NS1 antigen detection as initial diagnostic tools, followed by additional confirmatory tests and appropriate management strategies. However, the limitations of current RDTs in accurately detecting co-infections highlight the need for improved point-of-care diagnostics[1][3].\nImplementing this SOP in low-resource settings requires addressing challenges such as limited access to diagnostic tools, inadequate laboratory infrastructure, and the need for training healthcare providers. Collaboration between public health authorities, researchers, and industry partners is essential to develop and validate a single combined rapid test for malaria and dengue co-infection[1][3].\nIn conclusion, the proposed SOP provides a framework for evaluating suspected malaria and dengue co-infection in low-resource settings, emphasizing the importance of rapid diagnostic testing, appropriate management, and referral when necessary. However, further research and development of improved diagnostic tools are crucial to accurately detect and manage co-infections, ultimately reducing the burden of these diseases in endemic regions."
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html#suggested-titles",
    "href": "2024_malaria_dengue_SOP.html#suggested-titles",
    "title": "Malaria and Dengue Co-infection: Diagnostic Challenges and Proposed Standard Operating Procedure for Somaliland",
    "section": "Suggested Titles",
    "text": "Suggested Titles\n\nNavigating the Diagnostic Landscape of Malaria and Dengue Co-infection: A Proposed Standard Operating Procedure for Low-Resource Settings\nBridging the Gap: A Standardized Approach to Evaluating Malaria and Dengue Co-infection in Resource-Limited Settings\nOvercoming Diagnostic Challenges in Malaria and Dengue Co-infection: A Practical Guide for Healthcare Providers in Low-Resource Settings"
  },
  {
    "objectID": "2024_malaria_dengue_SOP.html#references",
    "href": "2024_malaria_dengue_SOP.html#references",
    "title": "Bridging the Gap: A Proposed Standard Operating Procedure to Evaluating Malaria and Dengue Co-infection in Somaliland",
    "section": "References",
    "text": "References\n[1] Bhagat M, Kanhere S, Phadke V, George R. Concurrent malaria and dengue Fever: a need for rapid diagnostic methods. J Family Med Prim Care. 2014 Oct-Dec;3(4):446-8. doi: 10.4103/2249-4863.148146. PMID: 25657963; PMCID: PMC4311362. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311362/\n[2] Huits R, Soentjens P, Maniewski-Kelner U, Theunissen C, Van Den Broucke S, Florence E, Clerinx J, Vlieghe E, Jacobs J, Cnops L, Van Den Bossche D, Van Esbroeck M, Bottieau E. Clinical Utility of the Nonstructural 1 Antigen Rapid Diagnostic Test in the Management of Dengue in Returning Travelers With Fever. Open Forum Infect Dis. 2017 Jan 9;4(1):ofw273. doi: 10.1093/ofid/ofw273. PMID: 28480265; PMCID: PMC5414095. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5414095/\n[3] Gebremariam, T.T., Schallig, H.D.F.H., Kurmane, Z.M. et al. Increasing prevalence of malaria and acute dengue virus coinfection in Africa: a meta-analysis and meta-regression of cross-sectional studies. Malar J 22, 300 (2023). https://doi.org/10.1186/s12936-023-04723-y; https://malariajournal.biomedcentral.com/articles/10.1186/s12936-023-04723-y\n[4] Marsha S. Santoso, Benediktus Yohan, Dionisius Denis, Rahma F. Hayati, Sotianingsih Haryanto, Leily Trianty, Rintis Noviyanti, Martin L. Hibberd, R. Tedjo Sasmono, Diagnostic accuracy of 5 different brands of dengue virus non-structural protein 1 (NS1) antigen rapid diagnostic tests (RDT) in Indonesia, Diagnostic Microbiology and Infectious Disease, Volume 98, Issue 2, 2020,115116. https://www.sciencedirect.com/science/article/pii/S0732889320304934\n[5] Emilie Javelle, Philippe Gautret, Isabelle Leparc-Goffart. Letter to the editor: False-positive re- sults with rapid diagnostic tests (RDT) for dengue. Eurosurveillance, 2019, 24 (21), 10.2807/1560- 7917.ES.2019.24.21.1900304 . inserm-02374913 https://inserm.hal.science/inserm-02374913/document"
  },
  {
    "objectID": "2024Projects_TMM.html#progress-report-20240612",
    "href": "2024Projects_TMM.html#progress-report-20240612",
    "title": "2024 TMM Project",
    "section": "Progress Report (2024/06/12)",
    "text": "Progress Report (2024/06/12)"
  },
  {
    "objectID": "2022_2024_dengue_statistics_HGH.html",
    "href": "2022_2024_dengue_statistics_HGH.html",
    "title": "2022-2024 Dengue fever cases in Hargeisa Group Hospital (HGH)",
    "section": "",
    "text": "Hargeisa Group Hospital (HGH) conducted a retrospective analysis of dengue fever cases registered from October 2022 to June 2024. Demographic data, including age and sex, as well as clinical outcomes, such as outpatient or inpatient status and mortality, were collected. The criteria for hospital admission, as per the HGH Dengue Fever Clinical Management Guideline (2022), included patients with warning signs of severe infection, severe dengue infection, dengue infection with coexisting conditions, elevated hematocrit (Hct&gt;50%), leukopenia (WBC ≤5000 cells/mm³), thrombocytopenia (platelet count ≤100,000 cells/mm³), blood pressure &lt;90/60 mmHg, and altered consciousness."
  },
  {
    "objectID": "2022_2024_dengue_statistics_HGH.html#methods",
    "href": "2022_2024_dengue_statistics_HGH.html#methods",
    "title": "2022-2024 Dengue fever cases in Hargeisa Group Hospital (HGH)",
    "section": "",
    "text": "Hargeisa Group Hospital (HGH) conducted a retrospective analysis of dengue fever cases registered from October 2022 to June 2024. Demographic data, including age and sex, as well as clinical outcomes, such as outpatient or inpatient status and mortality, were collected. The criteria for hospital admission, as per the HGH Dengue Fever Clinical Management Guideline (2022), included patients with warning signs of severe infection, severe dengue infection, dengue infection with coexisting conditions, elevated hematocrit (Hct&gt;50%), leukopenia (WBC ≤5000 cells/mm³), thrombocytopenia (platelet count ≤100,000 cells/mm³), blood pressure &lt;90/60 mmHg, and altered consciousness."
  },
  {
    "objectID": "2022_2024_dengue_statistics_HGH.html#results",
    "href": "2022_2024_dengue_statistics_HGH.html#results",
    "title": "2022-2024 Dengue fever cases in Hargeisa Group Hospital (HGH)",
    "section": "Results:",
    "text": "Results:\nFrom October 2022 to June 2024, a total of 2,871 patients with dengue fever (probable or laboratory confirmed?) were registered at HGH. Among these patients, 1,232 (42.9%) were male, and 1,639 (57.1%) were female. The majority of patients (2,036, 70.9%) received outpatient medical services, while 835 (29.1%) required hospital admission due to the severity of their illness.\nThe age distribution of the patients was as follows: 1,723 (60.0%) were under 30 years old, 774 (27.0%) were between 31 and 50 years old, and 374 (13.0%) were over 50 years old.\nThe total number of dengue fever-related deaths was 23, with a higher mortality rate observed among female patients."
  },
  {
    "objectID": "2022_2024_dengue_statistics_HGH.html#discussion",
    "href": "2022_2024_dengue_statistics_HGH.html#discussion",
    "title": "2022-2024 Dengue fever cases in Hargeisa Group Hospital (HGH)",
    "section": "Discussion:",
    "text": "Discussion:\n\nThe high proportion of cases among females and younger age groups suggests that targeted interventions should focus on these populations.\nLimitations of this study include potential underreporting of cases, particularly among those with mild symptoms who may not seek medical care, and missing data on clinical characteristics and outcomes. Additionally, the study was conducted at OPD and ward for adults in Hargeisa Group hospital, which may not be representative of the entire population especially children under 18."
  },
  {
    "objectID": "2022_2024_dengue_statistics_HGH.html#recommendations",
    "href": "2022_2024_dengue_statistics_HGH.html#recommendations",
    "title": "2022-2024 Dengue fever cases in Hargeisa Group Hospital (HGH)",
    "section": "Recommendations:",
    "text": "Recommendations:\nBased on the findings of this study, we recommend the following:\n\nStrengthen vector control measures, particularly in areas with high dengue incidence, through community engagement and education on mosquito breeding site elimination.\nConduct targeted public health education campaigns focusing on dengue prevention and early recognition of symptoms, especially among females and younger age groups.\nImprove dengue surveillance systems to capture a more accurate representation of the burden of disease in Hargeisa through ICDF Hospital Information System (HIS) at OPD and emergency department. (see next page)\nEnhance the capacity of healthcare facilities to manage dengue cases effectively, with a focus on early identification and appropriate management of severe cases through laboratory confirmation.\nConduct further research to identify risk factors associated with severe dengue and mortality in the local context to inform targeted interventions.\n\nIn conclusion, this study highlights the increasing burden of dengue fever in Hargeisa and the need for strengthened prevention, control, and management strategies. Collaborative efforts between public health authorities, healthcare providers, and the community are essential to reduce the impact of dengue in the region."
  },
  {
    "objectID": "bidding.html",
    "href": "bidding.html",
    "title": "Evaluation and Selection Process for TMM Visiting Scholar Air Travel Procurement",
    "section": "",
    "text": "The Taiwan Medical Mission (TMM) has received quotations from several travel agencies for air tickets for visiting scholars. This report compares the bids against the key requirements outlined in the tender notice.\n\n\n\n\n\nrequirementsX..Otickett.1..X..Otickett.2..X..Otickett.3..X..Makkah..X..Liban.1..X..Liban.2..X..Liban.3..X..Merkato..X..SHUJA..X..Noble..X..Eurosom..X..Flyway.1..X..Flyway.2..X..Flyway.3..Up to 5 economy ticketsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsDepart from HGAMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsArrive at TPEMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsSegment 1: HGA to ADDMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsSegment 2: ADD to BKKMeetsMeetsMeetsNoMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsSegment 3: BKK to TPEMeetsMeetsMeetsNoMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsAvoid Hong Kong routingMeetsMeetsMeetsNoMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsDepart HGA by Jun 20 (flexible)MeetsMeetsMeetsUnknownJun 19Jun 20Jun 21Jun 20Jun 20Jun 20Jun 22Jun 20Jun 20Jun 20Return from TPE after Sep 20 (flexible)MeetsMeetsMeetsUnknownSep 21Sep 21Sep 21Sep 20Sep 20Sep 21Sep 21Sep 20Sep 21Sep 20Detailed itinerary providedYesYesYesNoYesYesYesYesYesYesYesYesYesYesBaggage allowance specifiedYesYesYesNoYes (46kg)Yes (46kg)Yes (46kg)Yes (46kg)Yes (46kg)Yes (46kg)UnknownYes (46kg)Yes (46kg)Yes (23kg)Itemized ticket price$1,790$1,990$1,780$1,400$1,934$2,007$1,934$1,960$1,905$1,900$1,970$2,250$1,600$1,750Reschedule/cancellation policyYesYesYesNoYesYesYesPartiallyPartiallyUnknownUnknownUnknownUnknownUnknownAdditional services informationLimitedLimitedLimitedNo24/7 Support24/7 Support24/7 SupportNoNoUnknownUnknownYesYesYes\n\n\n\n\n\nThe bids were evaluated based on their compliance with the specified route, travel dates, baggage allowance, pricing, terms and conditions, and additional services.\nRequired lead time for booking confirmation.\nNote: - Booking can be held for 24 hours but cannot be grantee due to Supply & Demands - Seats and Fares are not guaranteed and subject to change as per the availability at the time of booking.\n\n\n\nBased on the comparison of all bidders against the key requirements outlined in the tender notice, here is a summary: (ordered by receiving date of bidding)\n\nOtickett Travel:\n\nOffered three options, all meeting the core route, segment, and date requirements\nPrices ranged from $1,780 to $1,990 per ticket\nProvided detailed itineraries, baggage allowance, and some terms and conditions\nLacked information on booking lead time and additional services\nOverall, a strong contender with competitive pricing and compliance with most requirements\n\nLiban Travel:\n\nProvided three options, all meeting the core route, segment, and date requirements\nPrices ranged from $1,934 to $2,007 per ticket\nOffered detailed itineraries but lacked information on baggage allowance, terms and conditions, and additional services\nOption 2 mentioned a long transit time and had the highest price\nOptions 1 and 3 were competitive, but additional details would be needed for a full evaluation\n\nSHUJA Travel and Tourism:\n\nQuoted $1,905 per ticket, meeting all core requirements\nProvided a detailed itinerary, 46kg baggage allowance, and 10kg hand luggage\nOffered one-year ticket validity and some information on change and no-show fees\n\nFlyway Travel:\n\nProvides 24-hour support services to ensure customer satisfaction and availability\nProvided a detailed itinerary, 46kg baggage allowance (23kg in Option 3), and 10kg hand luggage\nFlight Options:\n\nOption 1 (Short Transit): $2,250 per person\nOption 2 (Long Transit at Addis Ababa): $1,600 per person\nOption 3 (Two Separate Tickets): $1,750 per person\n\n\n\n\n\n\nAfter evaluating all the bids, it’s important to note that the reschedule policy is a crucial factor, and the actual price may vary depending on availability at the time of booking. Therefore, the lowest quoted price should not be the sole determining factor in selecting the best offer.\nFlyway Travel’s Option 2 has the lowest price at $1,600, likely due to the long 13-hour transit time. However, this extended layover may not be ideal for the comfort and convenience of the traveling scholars.\nFlyway Travel’s Option 3, which offers two separate tickets for each trip (HGA-BKK-HGA and BKK-TPE-BKK), is not recommended as it would require re-checking luggage during the layover in Bangkok. This could lead to potential issues with baggage handling and increase the risk of lost or delayed luggage.\nConsidering all factors, including the reschedule policy, itinerary, and overall service, the three strongest candidates for this bidding process are:\n\nLiban Travel (Option 1 or 3): Offers competitive pricing, a detailed itinerary, 46kg baggage allowance, and a clear reschedule/cancellation policy. They also provide 24/7 customer support for booking.\nSHUJA Travel and Tourism: Provides a competitive price, detailed itinerary, 46kg baggage allowance, and a one-year ticket validity. They have a partial reschedule/cancellation policy, but more information may be needed on their additional services.\nFlyway Travel (Option 1): While having the highest price among the three candidates, they offer a detailed itinerary, 46kg baggage allowance, a 12-month ticket validity, and 24-hour support services. However, their reschedule/cancellation policy is not addressed, even they provide a 24-hour booking hold option.\n\n\n\n\nTMM should consider reaching out to the first candidate for further clarification on his policies and services to make a well-informed decision that best suits the needs and preferences of the visiting scholars.\n\nTMM proceeded to sign a contract with the selected travel agency, finalizing the air travel arrangements for the visiting scholars.\nThe contract included all relevant details, such as the agreed-upon itinerary, pricing, baggage allowance, and any additional services or support to be provided.\n\n\n\n\n\nTMM worked closely with the selected travel agency to book the flights and coordinate all necessary arrangements for the visiting scholars.\nThe travel agency provided timely updates and support to ensure a smooth and hassle-free travel experience for the scholars."
  },
  {
    "objectID": "bidding.html#comparison-table",
    "href": "bidding.html#comparison-table",
    "title": "Evaluation and Selection Process for TMM Visiting Scholar Air Travel Procurement",
    "section": "",
    "text": "requirementsX..Otickett.1..X..Otickett.2..X..Otickett.3..X..Makkah..X..Liban.1..X..Liban.2..X..Liban.3..X..Merkato..X..SHUJA..X..Noble..X..Eurosom..X..Flyway.1..X..Flyway.2..X..Flyway.3..Up to 5 economy ticketsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsDepart from HGAMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsArrive at TPEMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsSegment 1: HGA to ADDMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsSegment 2: ADD to BKKMeetsMeetsMeetsNoMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsSegment 3: BKK to TPEMeetsMeetsMeetsNoMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsAvoid Hong Kong routingMeetsMeetsMeetsNoMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsMeetsDepart HGA by Jun 20 (flexible)MeetsMeetsMeetsUnknownJun 19Jun 20Jun 21Jun 20Jun 20Jun 20Jun 22Jun 20Jun 20Jun 20Return from TPE after Sep 20 (flexible)MeetsMeetsMeetsUnknownSep 21Sep 21Sep 21Sep 20Sep 20Sep 21Sep 21Sep 20Sep 21Sep 20Detailed itinerary providedYesYesYesNoYesYesYesYesYesYesYesYesYesYesBaggage allowance specifiedYesYesYesNoYes (46kg)Yes (46kg)Yes (46kg)Yes (46kg)Yes (46kg)Yes (46kg)UnknownYes (46kg)Yes (46kg)Yes (23kg)Itemized ticket price$1,790$1,990$1,780$1,400$1,934$2,007$1,934$1,960$1,905$1,900$1,970$2,250$1,600$1,750Reschedule/cancellation policyYesYesYesNoYesYesYesPartiallyPartiallyUnknownUnknownUnknownUnknownUnknownAdditional services informationLimitedLimitedLimitedNo24/7 Support24/7 Support24/7 SupportNoNoUnknownUnknownYesYesYes"
  },
  {
    "objectID": "bidding.html#evaluation",
    "href": "bidding.html#evaluation",
    "title": "Evaluation and Selection Process for TMM Visiting Scholar Air Travel Procurement",
    "section": "",
    "text": "The bids were evaluated based on their compliance with the specified route, travel dates, baggage allowance, pricing, terms and conditions, and additional services.\nRequired lead time for booking confirmation.\nNote: - Booking can be held for 24 hours but cannot be grantee due to Supply & Demands - Seats and Fares are not guaranteed and subject to change as per the availability at the time of booking."
  },
  {
    "objectID": "bidding.html#summary",
    "href": "bidding.html#summary",
    "title": "Evaluation and Selection Process for TMM Visiting Scholar Air Travel Procurement",
    "section": "",
    "text": "Based on the comparison of all bidders against the key requirements outlined in the tender notice, here is a summary: (ordered by receiving date of bidding)\n\nOtickett Travel:\n\nOffered three options, all meeting the core route, segment, and date requirements\nPrices ranged from $1,780 to $1,990 per ticket\nProvided detailed itineraries, baggage allowance, and some terms and conditions\nLacked information on booking lead time and additional services\nOverall, a strong contender with competitive pricing and compliance with most requirements\n\nLiban Travel:\n\nProvided three options, all meeting the core route, segment, and date requirements\nPrices ranged from $1,934 to $2,007 per ticket\nOffered detailed itineraries but lacked information on baggage allowance, terms and conditions, and additional services\nOption 2 mentioned a long transit time and had the highest price\nOptions 1 and 3 were competitive, but additional details would be needed for a full evaluation\n\nSHUJA Travel and Tourism:\n\nQuoted $1,905 per ticket, meeting all core requirements\nProvided a detailed itinerary, 46kg baggage allowance, and 10kg hand luggage\nOffered one-year ticket validity and some information on change and no-show fees\n\nFlyway Travel:\n\nProvides 24-hour support services to ensure customer satisfaction and availability\nProvided a detailed itinerary, 46kg baggage allowance (23kg in Option 3), and 10kg hand luggage\nFlight Options:\n\nOption 1 (Short Transit): $2,250 per person\nOption 2 (Long Transit at Addis Ababa): $1,600 per person\nOption 3 (Two Separate Tickets): $1,750 per person"
  },
  {
    "objectID": "bidding.html#shortlisting",
    "href": "bidding.html#shortlisting",
    "title": "Evaluation and Selection Process for TMM Visiting Scholar Air Travel Procurement",
    "section": "",
    "text": "After evaluating all the bids, it’s important to note that the reschedule policy is a crucial factor, and the actual price may vary depending on availability at the time of booking. Therefore, the lowest quoted price should not be the sole determining factor in selecting the best offer.\nFlyway Travel’s Option 2 has the lowest price at $1,600, likely due to the long 13-hour transit time. However, this extended layover may not be ideal for the comfort and convenience of the traveling scholars.\nFlyway Travel’s Option 3, which offers two separate tickets for each trip (HGA-BKK-HGA and BKK-TPE-BKK), is not recommended as it would require re-checking luggage during the layover in Bangkok. This could lead to potential issues with baggage handling and increase the risk of lost or delayed luggage.\nConsidering all factors, including the reschedule policy, itinerary, and overall service, the three strongest candidates for this bidding process are:\n\nLiban Travel (Option 1 or 3): Offers competitive pricing, a detailed itinerary, 46kg baggage allowance, and a clear reschedule/cancellation policy. They also provide 24/7 customer support for booking.\nSHUJA Travel and Tourism: Provides a competitive price, detailed itinerary, 46kg baggage allowance, and a one-year ticket validity. They have a partial reschedule/cancellation policy, but more information may be needed on their additional services.\nFlyway Travel (Option 1): While having the highest price among the three candidates, they offer a detailed itinerary, 46kg baggage allowance, a 12-month ticket validity, and 24-hour support services. However, their reschedule/cancellation policy is not addressed, even they provide a 24-hour booking hold option."
  },
  {
    "objectID": "bidding.html#final-selection-and-contract-signing",
    "href": "bidding.html#final-selection-and-contract-signing",
    "title": "Evaluation and Selection Process for TMM Visiting Scholar Air Travel Procurement",
    "section": "",
    "text": "TMM should consider reaching out to the first candidate for further clarification on his policies and services to make a well-informed decision that best suits the needs and preferences of the visiting scholars.\n\nTMM proceeded to sign a contract with the selected travel agency, finalizing the air travel arrangements for the visiting scholars.\nThe contract included all relevant details, such as the agreed-upon itinerary, pricing, baggage allowance, and any additional services or support to be provided."
  },
  {
    "objectID": "bidding.html#booking-and-coordination",
    "href": "bidding.html#booking-and-coordination",
    "title": "Evaluation and Selection Process for TMM Visiting Scholar Air Travel Procurement",
    "section": "",
    "text": "TMM worked closely with the selected travel agency to book the flights and coordinate all necessary arrangements for the visiting scholars.\nThe travel agency provided timely updates and support to ensure a smooth and hassle-free travel experience for the scholars."
  },
  {
    "objectID": "2024_RadiPush_HGH.html",
    "href": "2024_RadiPush_HGH.html",
    "title": "Pathology Department Collaboration (TMWH/HGH)",
    "section": "",
    "text": "Agenda for Online Meeting: Pathology Department Collaboration\nDate: Wednesday, 19 June, 2024 (10:30-11:30)\nAttendees: Dr. Chen (Department Director, TMWH) and Dr. Omar (Department Director, HGH)\n\nOverview of HGH Pathology Department Capacity\n\nSurgical Pathology\n\nCase number per year\nCommon disease entities\n\nCytology\n\nCase number per year (Pap smear, fine-needle aspiration biopsy)\nChallenges and opportunities for improvement\n\nFrozen Section Diagnosis (no frozen service available)\n\nPathology Reporting System at HGH\n\nCurrent reporting format (MS Word .docx based)\nVision Assist online whole-slide images system (https://vision-suite.com/) for telepathology\n\nTechnical support and maintenance\n\n\nHuman Resources and Equipment\n\nStaffing\n\nOne pathologist doctor: Dr. Omar\nTwo (or three?) pathology technicians\nTraining needs and skill development plans\n\nEquipment Inventory\n\nfine-needle and core-needle biopsy services by Dr. Omar\nH&E staining process\n\nTissue processor for fixation and dehydration\nEmbedding station and paraffin dispenser\nMicrotome for sectioning\nWater bath for slide mounting\nSlide drying oven\nStaining racks and dishes\nMicroscopes for slide review\nReagents and consumables (e.g., formalin, xylene, ethanol, paraffin, hematoxylin, eosin)\n\nGaps in equipment and infrastructure (no IHC service, no frozen diagnosis)\n\n\nCollaboration Opportunities between HGH and TMWH Pathology Departments\n\nTelepathology consultation and second opinions\nTraining and education exchange programs (2024 visiting scholarship is ongoing)\nJoint research projects, statistics, and publications\nQuality assurance and standardization initiatives, national cancer control board\nOther areas of collaboration (to be discussed)\n\nAction Points (who/when)\n\nSummarize key discussion points and decisions\nAssign responsibilities and timelines for follow-up tasks (who/when)\nSchedule future meetings or communication channels"
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html",
    "href": "2024Project_HGH_pathology_LIMS.html",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "",
    "text": "This study presents a descriptive analysis of 110 pathological cases at Hargeisa Group Hospital (HGH) in Somaliland. The analysis covers surgical biopsies, fine-needle aspiration cytology (FNAC), cytology, and hematology cases. Key findings include a high prevalence of tuberculosis in lymph node specimens and anemia cases. The study also highlights the need for enhanced diagnostic capabilities and improved data management systems."
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html#data-collection",
    "href": "2024Project_HGH_pathology_LIMS.html#data-collection",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "Data Collection",
    "text": "Data Collection\nData were extracted in Microsoft Access database and collected from the pathology department of Hargeisa Group Hospital between August 2023 and June 2024. The dataset includes 110 cases across four categories: surgical biopsies, FNAC, cytology, and hematology."
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html#data-analysis",
    "href": "2024Project_HGH_pathology_LIMS.html#data-analysis",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "Data Analysis",
    "text": "Data Analysis\nData were managed by de-identification, cleaning, missing data management, and manual curation mentioned in “Data Interpretation with AI-powered approach”. Descriptive statistics were calculated using R (version 4.4.0), copiloted with Claude 3 Opus LLM. Data were analyzed for frequency distributions, age ranges, and gender distributions."
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html#surgical-biopsies",
    "href": "2024Project_HGH_pathology_LIMS.html#surgical-biopsies",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "Surgical Biopsies",
    "text": "Surgical Biopsies\n\n\nCode\nlibrary(knitr)\nlibrary(kableExtra)\n\nbiopsy_data &lt;- data.frame(\n  Category = c(\"Soft tissue lesions\", \"Gynecological specimens\", \"Gastrointestinal tract\", \"Breast\", \"Prostate\", \"Other\"),\n  Count = c(7, 6, 3, 2, 2, 4),\n  Percentage = c(29.2, 25.0, 12.5, 8.3, 8.3, 16.7)\n)\n\nkable(biopsy_data, \n      col.names = c(\"Category\", \"Count\", \"Percentage (%)\"),\n      align = c(\"l\", \"c\", \"c\"),\n      digits = 1) %&gt;%\n  kable_styling(bootstrap_options = c(\"striped\", \"hover\", \"condensed\"),\n                full_width = FALSE) %&gt;%\n  footnote(general = \"Total cases: 24. Age range: 2-80 years (mean: 41 years). Gender: 54.2% female.\")\n\n\n\nDistribution of Surgical Biopsy Cases \n\n\nCategory\nCount\nPercentage (%)\n\n\n\n\nSoft tissue lesions\n7\n29.2\n\n\nGynecological specimens\n6\n25.0\n\n\nGastrointestinal tract\n3\n12.5\n\n\nBreast\n2\n8.3\n\n\nProstate\n2\n8.3\n\n\nOther\n4\n16.7\n\n\n\nNote: \n\n\n\n\n Total cases: 24. Age range: 2-80 years (mean: 41 years). Gender: 54.2% female.\n\n\n\n\n\n\n\n\n\n\nSurgical Biopsy (24 cases): The surgical biopsies covered a diverse range of specimens, with soft tissue lesions (29.2%) and gynecological specimens (25.0%) being the most common. The age range was 2-80 years (mean: 41 years), with a slight female predominance (54.2%).\n\nSoft tissue lesions (n=7, 29.2%): Including cases of epidermal inclusion cyst, intramuscular myxoma, lobular capillary hemangioma, and carcinoma in situ (origin of tissue site: not in record).\nGynecological specimens (n=6, 25.0%): Including cases of ruptured ectopic pregnancy, gestational choriocarcinoma, partial hydatidiform mole, high-grade serous carcinoma of the ovary, and leiomyoma.\nGastrointestinal tract (n=3, 12.5%): Two cases of inflammatory bowel disease (Crohn’s disease) and one case of acute on chronic cholecystitis.\nBreast (n=2, 8.3%): One case of benign phyllodes tumor and one case of pseudoangiomatous stromal hyperplasia.\nProstate (n=2, 8.3%): Both cases were diagnosed as benign nodular prostatic hyperplasia."
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html#fnac",
    "href": "2024Project_HGH_pathology_LIMS.html#fnac",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "FNAC",
    "text": "FNAC\n\n\nCode\nlibrary(knitr)\nlibrary(kableExtra)\n\nfnac_data &lt;- data.frame(\n  Category = c(\"Lymph nodes\", \"Soft tissue lesions\", \"Breast lesions\", \"Thyroid\", \"Salivary gland\", \"Other\"),\n  Count = c(14, 13, 6, 5, 3, 5),\n  Percentage = c(30.4, 28.3, 13.0, 10.9, 6.5, 10.9)\n)\n\nkable(fnac_data, \n      col.names = c(\"Category\", \"Count\", \"Percentage (%)\"),\n      align = c(\"l\", \"c\", \"c\"),\n      digits = 1) %&gt;%\n  kable_styling(bootstrap_options = c(\"striped\", \"hover\", \"condensed\"),\n                full_width = FALSE) %&gt;%\n  footnote(general = paste(\"FNAC (46 cases): FNAC was most commonly performed on lymph nodes (30.4%) and soft tissue lesions (28.3%). The age range was 4-70 years (mean: 36 years), with a female predominance (56.5%).\", sep = \"\\n\"))\n\n\n\nDistribution of Fine Needle Aspiration Cytology (FNAC) Cases \n\n\nCategory\nCount\nPercentage (%)\n\n\n\n\nLymph nodes\n14\n30.4\n\n\nSoft tissue lesions\n13\n28.3\n\n\nBreast lesions\n6\n13.0\n\n\nThyroid\n5\n10.9\n\n\nSalivary gland\n3\n6.5\n\n\nOther\n5\n10.9\n\n\n\nNote: \n\n\n\n\n FNAC (46 cases): FNAC was most commonly performed on lymph nodes (30.4%) and soft tissue lesions (28.3%). The age range was 4-70 years (mean: 36 years), with a female predominance (56.5%).\n\n\n\n\n\n\n\n\n\n\nFNAC (46 cases): FNAC was most commonly performed on lymph nodes (30.4%) and soft tissue lesions (28.3%). The age range was 4-70 years (mean: 36 years), with a female predominance (56.5%).\n\nLymph nodes (n=14, 30.4%): Seven cases of granulomatous lymphadenitis consistent with tuberculosis, three cases of reactive lymphoid hyperplasia, and four cases of suppurative lymphadenitis/abscess.\nSoft tissue lesions (n=13, 28.3%): Predominantly lipomas and one case of keratinous cyst.\nBreast lesions (n=6, 13.0%): Three cases of fibroadenoma, one case of intraductal papilloma, one case of proliferative lesion with atypia, and one case of ductal carcinoma.\nThyroid (n=5, 10.9%): Three cases of nodular colloid goiter, one case suspicious for follicular neoplasm, and one thyroglossal cyst.\nSalivary gland (n=3, 6.5%): Including one case of high-grade mucoepidermoid carcinoma and two cases of chronic sialadenitis."
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html#cytology",
    "href": "2024Project_HGH_pathology_LIMS.html#cytology",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "Cytology",
    "text": "Cytology\n\n\nCode\nlibrary(knitr)\nlibrary(kableExtra)\n\ncytology_data &lt;- data.frame(\n  Category = c(\"Pleural fluid\", \"Peritoneal (Ascitic) fluid\"),\n  Count = c(5, 2),\n  Percentage = c(71.4, 28.6)\n)\n\nkable(cytology_data, \n      col.names = c(\"Category\", \"Count\", \"Percentage (%)\"),\n      align = c(\"l\", \"c\", \"c\"),\n      digits = 1) %&gt;%\n  kable_styling(bootstrap_options = c(\"striped\", \"hover\", \"condensed\"),\n                full_width = FALSE) %&gt;%\n  footnote(general = paste(\"Total cases: 7. Age range: 9-60 years (mean: 39 years).\",\n                           \"Gender: 57.1% male.\", sep = \"\\n\"))\n\n\n\nDistribution of Cytology Cases \n\n\n\n\n\n\n\nCategory\nCount\nPercentage (%)\n\n\n\n\nPleural fluid\n5\n71.4\n\n\nPeritoneal (Ascitic) fluid\n2\n28.6\n\n\n\nNote: \n\n\n\n\n Total cases: 7. Age range: 9-60 years (mean: 39 years).\nGender: 57.1% male.\n\n\n\n\n\n\n\n\n\n\nCytology (7 cases): Cytology specimens were predominantly pleural fluids (71.4%). The age range was 9-60 years (mean: 39 years), with a slight male predominance (57.1%).\n\nPleural fluid (n=5, 71.4%): Five cases were negative for malignancy, and one was hemorrhagic. One relative lymphocytosis suggested to do GeneXpert PCR testing\nPeritoneal (Ascitic) fluid (n=2, 28.6%): One case of acute suppurative inflammation and one malignant effusion."
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html#hematology",
    "href": "2024Project_HGH_pathology_LIMS.html#hematology",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "Hematology",
    "text": "Hematology\n\n\nCode\nlibrary(knitr)\nlibrary(kableExtra)\n\nhematology_data &lt;- data.frame(\n  Category = c(\"Anemias\", \"Thrombocytopenias\", \"Leukemias\", \"Other conditions\"),\n  Count = c(22, 7, 3, 1),\n  Percentage = c(66.7, 21.2, 9.0, 3.1)\n)\n\nkable(hematology_data, \n      col.names = c(\"Category\", \"Count\", \"Percentage (%)\"),\n      align = c(\"l\", \"c\", \"c\"),\n      digits = 1) %&gt;%\n  kable_styling(bootstrap_options = c(\"striped\", \"hover\", \"condensed\"),\n                full_width = FALSE) %&gt;%\n  footnote(general = paste(\"Total cases: 33. Age range: 1-94 years (mean: 39 years).\",\n                           \"Gender: 57.6% male.\",\n                           sep = \"\\n\"))\n\n\n\nDistribution of Hematology Cases \n\n\n\n\n\n\n\nCategory\nCount\nPercentage (%)\n\n\n\n\nAnemias\n22\n66.7\n\n\nThrombocytopenias\n7\n21.2\n\n\nLeukemias\n3\n9.0\n\n\nOther conditions\n1\n3.1\n\n\n\nNote: \n\n\n\n\n Total cases: 33. Age range: 1-94 years (mean: 39 years).\nGender: 57.6% male.\n\n\n\n\n\n\n\n\n\n\nHematology (33 cases): Anemias were the most common hematological disorder (66.7%), followed by thrombocytopenias (21.2%). The age range was 1-94 years (mean: 39 years), with a slight male predominance (57.6%).\n\nAnemias (n=22, 66.7%): Including macrocytic, microcytic, and hemolytic anemias.\nThrombocytopenias (n=7, 21.2%): Often associated with other hematological abnormalities. -Leukemias (n=3, 9.0%): Three cases of acute leukemia (two ALL, one AML with non APL type). A 4 y/o boy has confirmed ALL, his bone marrow biopsy revealed Partial Remission of ALL.\nOther conditions: Polycythemia vera (n=1, suggested to do JAK 2 Mutation test), leukomoid reaction (n=2), and cases with atypical lymphocytes.\n5 recommended for further bone marrow biopsy."
  },
  {
    "objectID": "2024Project_HGH_pathology_LIMS.html#data-interpretation-with-ai-powered-approach",
    "href": "2024Project_HGH_pathology_LIMS.html#data-interpretation-with-ai-powered-approach",
    "title": "Pathological Cases Analysis at Hargeisa Group Hospital: A Descriptive Study",
    "section": "Data Interpretation with AI-powered approach",
    "text": "Data Interpretation with AI-powered approach\nThe pathology reports, initially recorded as free-text entries, were processed using natural language processing (NLP) techniques to extract non-structured information. We employed the Claude 3.5 Sonnet large language model (LLM), developed by Anthropic, to interpret and categorize the unstructured text data. This AI (artificial intelligent) powered approach allowed for efficient and consistent extraction of key diagnostic information, specimen types, and patient demographics from the English language used in the reports. The LLM was prompted to identify and classify diagnoses, categorize specimens, and extract relevant clinical details. To ensure accuracy, a two-step validation process was implemented: first, the AI-generated interpretations were reviewed by a trained medical data analyst, and then all cases was selected for review by an experienced surgeon doctor. This process allowed us to leverage the efficiency of AI while maintaining high standards of medical accuracy. The structured data output from this NLP pipeline was then compiled into standardized data tables, facilitating subsequent statistical analysis using R (version 4.4.0). This methodology enabled us to transform complex narrative reports into quantifiable data points, ensuring a comprehensive and reliable basis for our descriptive statistical analysis while minimizing human error in data extraction and classification."
  },
  {
    "objectID": "2025_IHPA_TMM.html",
    "href": "2025_IHPA_TMM.html",
    "title": "2025_IHPA_TMM",
    "section": "",
    "text": "2025 國際醫療典範獎\n標題：在索馬利蘭的醫療外交：建立永續的健康合作關係\nI. 個人背景與動機 A. 醫學教育和早期職業生涯 我是祁力行,畢業於臺灣大學醫學院,專攻骨科。在臺大醫院完成住院醫師訓練後,我選擇了一條不同尋常的道路。\nB. 對國際醫療援助的熱忱 在醫學院時,我就對國際醫療援助充滿熱情。我參與過多次海外醫療義診,這些經歷讓我深刻體會到醫療資源分配不均的現實。\nC. 加入台灣醫療團（TMM）的契機 2020年,我得知TMM在索馬利蘭的計畫,毫不猶豫地加入。這是實現我夢想的機會,也是為國際醫療貢獻心力的平台。\n\n索馬利蘭醫療環境概況 A. 當地醫療資源匱乏的現狀 索馬利蘭的醫療條件極其艱難。醫院常常斷電斷水,醫療設備嚴重不足,醫護人員培訓也不完善。\n\nB. 主要健康挑戰 當地面臨多重健康挑戰,包括傳染病(如登革熱)、婦女健康問題、非傳染性疾病等。缺乏預防保健意識也是一大問題。\nC. 與當地衛生部（MoHD）和哈爾格薩集團醫院（HGH）的合作 我們與MoHD和HGH建立了密切合作關係,共同制定醫療計畫,培訓當地醫護人員。\n\nTMM在索馬利蘭的主要計劃 (略,依照大綱內容展開)\n創新方法與成就 A. 跨文化溝通和合作的策略 我們重視與當地文化的融合,學習索馬利語,尊重當地習俗,贏得了當地人的信任。\n\nB. 資源有限環境下的創新解決方案 我們利用遠程醫療技術,引入AI輔助診斷系統,最大化有限資源的使用效率。\nC. 可持續性醫療援助模式的建立 我們注重培養當地醫護人才,建立長期合作機制,確保項目的可持續性。\nD. 重要統計數據和成果展示 2023年,我們完成門診847人次、手術104例、培訓1,099名醫護人員。\nV. 挑戰與克服 (略,依照大綱內容展開)\n\n個人成長與反思 A. 專業技能的提升 在資源匱乏的環境中,我學會了更多創新診療方法,提高了應變能力。\n\nB. 對國際醫療合作的深入理解 我認識到醫療援助不僅是技術輸出,更是文化交流和互相學習的過程。\nC. 個人價值觀和世界觀的轉變 這段經歷讓我更加珍惜生命,也更深刻理解了醫療的社會價值。\n\n未來展望 A. TMM在索馬利蘭的長期發展計劃 我們計劃在2024年推動骨質疏鬆和子宮頸癌篩檢兩大主題計畫,並持續強化醫護培訓。\n\nB. 擴大影響力的策略 我們將加強與國際組織合作,擴大項目規模,惠及更多民眾。\nC. 個人職業發展和持續貢獻的願景 我希望繼續在國際醫療領域發展,為更多資源匱乏地區提供幫助。\n\n結論 A. 醫療外交在促進國際理解和合作中的重要性 醫療外交不僅改善了當地人民的健康,也增進了國際間的友好關係。\n\nB. 個人對醫療典範的理解和追求 醫療典範不僅是技術的精湛,更是對人類福祉的無私奉獻。\nC. 呼籲更多醫療專業人員參與國際醫療援助 我希望更多同仁能加入國際醫療援助,共同為世界健康貢獻力量。\n在索馬利蘭的這段經歷,讓我深刻體會到「這邊什麼都很困難,但做就對了」。我們將繼續努力,在索馬利蘭的醫療史上留下臺灣的貢獻。"
  },
  {
    "objectID": "2024Projects_TMM.html#progress-report-20240628",
    "href": "2024Projects_TMM.html#progress-report-20240628",
    "title": "2024 TMM Project",
    "section": "Progress Report (2024/06/28)",
    "text": "Progress Report (2024/06/28)"
  },
  {
    "objectID": "2024Projects_TMM.html#progress-report-20240710",
    "href": "2024Projects_TMM.html#progress-report-20240710",
    "title": "2024 TMM Project",
    "section": "Progress Report (2024/07/10)",
    "text": "Progress Report (2024/07/10)"
  },
  {
    "objectID": "2024Projects_TMM.html#projects-進度與瓶頸六大項",
    "href": "2024Projects_TMM.html#projects-進度與瓶頸六大項",
    "title": "2024 TMM Project",
    "section": "Projects 進度與瓶頸(六大項)",
    "text": "Projects 進度與瓶頸(六大項)\n*訓練\n\n1. Visiting Scholarships for Training in Taiwan\n\nProject: Capacity Building for Somaliland Medical Personnel\nCollaborators: Taipei Municipal Wanfang Hospital (TMWH), Taiwan Medical Mission (TMM), and Hargeisa Group Hospital (HGH)\nInitiatives:\n\nProvide “Visiting Scholar Scholarships” for 12 Somaliland medical personnel to receive training in Taiwan for up to three months\nConduct selection process jointly by Taiwan Medical Mission and HGH Director’s Office\nInvite selected personnel to participate in TMM’s 2024 public health programs\n\nRequired support:\n\nTMM: Scholarship funding for 12 medical personnel (one batch)\nCoordination with TMWH for training arrangements\nCollaboration with HGH for personnel selection and public health program participation\n\n\n\n\n\n\n\nAction points(who/when):\n\n\n\n(謝謝病理科陳主任指導)遠距視訊會議(2024/6/20，瞭解HGH pathology 之 staff 和設備，進一步溝通合作細節)。取得 Dr Omar 電子版的 病理報告，Microsoft Access database 並完成分析，近半年僅有 110 份報告，4/5 都未能存檔；所幸尚有紙本報告留存在 file folder (已經由Dr. Omar手工輸入，轉為 Excel file， 亦已於 2024MSC 研討會中初步 報告)\n\n- 110 名病例分析如下\nhttps://texchi2.github.io/2024MSC/2024Project_HGH_pathology_LIMS.html\n- 正在安排第一次 telepathology meeting for case discussion (Dr. Omar, **since 20 June**)\n\n- 正在邀請Dr. Omar 分享上述 Excel data (**Dr. Omar, since 20 June**)\n\n送訓科別(尚缺培訓計劃書):骨科、病理科\n送訓科別(已有培訓計劃書):一般外科(2 or 3名主治醫師)、ICU/胸腔內科(待進一步說明 Dr. Jacfar)、開刀房護理師(護理部擬定中)\n建議送訓科別: 神經外科、心臟內科、HGH研究中心(醫師、護理師、助產士)\n\n\n\n待遴選完成後，辦理健康檢查(Chest X-ray, Tuberculosis (TB) Sputum Test, Syphilis/VDRL, Measles/Rubella)，以利申請 90日之受訓，執行臨床實作) (預計為十月份開始受訓)(Taiwan Medical Mission / 2024/07)\nHGH 院長 Dr. Abdirahman: 希望能於八月份赴萬芳醫院(二週)，接受醫院經營管理之培訓。(TMWH / 2024/07)\n新成立的 HGH研究中心 research center: 並肩負 IRB 的功能\n\n\nonline virtual meeting with TMWH研究部, 訓練研究人員使用分析工具 / Train researchers in using analytical tools\nvisiting scholars (Taiwan Medical Mission / 2024/08)\n\n\n\n*示範\n\n\n2. 骨科關節鏡中心\nA. 由萬芳醫院骨科郭宜潔醫師/陳昱斌醫師指導HGH骨科團隊\n- 計畫內容:關節鏡膝關節手術\n- 所需設備: 膝關節鏡手術器械(ready)\n- 目前進度:2023年10月郭醫師親自示範手術技巧,培訓種子醫師;2024年8月骨科專家將再度蒞臨指導進階手術\n- 瓶頸: - 醫師學習曲線較長,需反覆練習; - 關節鏡設備維修保養需OT的醫學工程技術員、及開刀房主任（護理師)負責\nB. TOM 骨質疏鬆預防保健計畫\n- 計畫名稱:「TOM骨質疏鬆」篩檢與預防保健\n- 內容:利用股骨X光片,透過AI人工智慧計算T-score,評估骨質密度\n- 目前進度:已引進TOM系統,規劃舉辦義診活動推廣\n- 瓶頸:民眾對骨質疏鬆認知不足,由護理部支援，於院內骨科住院病患衛教宣導做起，並架設系統與網路讓 TOM上線\n\ncase control study in hip fracture\n\n先行建立骨質疏鬆檢測系統(TOM: pelvic x-ray 建議拍攝參數 kVp:85, mAs:30, SID:100cm),並完成設備與網路架設(intranet)。\n進行髖部骨折病例對照研究(Hip fracture Case control study),調查分析當地骨質疏鬆盛行現況。\n根據研究結果,與骨科團隊討論後續執行方向,擬定符合在地需求的骨鬆防治策略。\n\nAction points(who/when): TBD\n\n\n*示範\n\n\n3. 一般外科腹腔鏡手術訓練中心\n\n由醫療團王彥翔醫師與HGH Afnan醫師及一般外科醫師群(包括十月份將赴臺北的 Dr. Nouh)，合作推行\n背景:HGH一般外科醫師具豐富開刀經驗,但受限於資源,公立醫院尚無腹腔鏡設備\n\n所需設備:腹腔鏡手術器械與訓練模型\n\n目前進度:已由萬芳醫院提供腹腔鏡手術器械,讓HGH醫師熟悉操作;\n\nhome made DIY simulator box\nAction points(who/when):\n\n待課程規劃、器械整理後，開始訓練教學 (Taiwan Medical Mission / 2024/07)\n\n\n\n\n*公共衛生\n\n\n4. 登革熱重症管理與加護病房支援\n\n計畫名稱:強化登革熱病患照護與預後\n\n所需物資:動脈血液氣體分析試劑,供加護病房重症患者使用; 篩檢 dengue fever NS1 rapid diagnostic test (RDT); HGH laboratory (IgM/IgG antibody ELISA)\nVentilator and respiratory care in ICU: 李主任主題醫療(see appendix)\n目前進度:已向萬芳醫院提出申請\n瓶頸:\n\nMoHD, Director General, Dr. Hargeye 接洽中;\ndengue fever statistics (from 2022-2024 HGH NCD Dr. Ahmed Hersi) 獲得初步報告;\nWHO Dr. Deq, UNICEF: vector control 接洽中;\nprepare IECM (in somali language)\n試劑需定期補充,須建立長期供應管道=&gt; WHO prequalifies new dengue vaccine (https://www.who.int/news/item/15-05-2024-who-prequalifies-new-dengue-vaccine)\n\n\n\n\n\n\nAction points(who/when):\n\n2023年索馬利蘭 WHO Dengue fever 資料蒐集: (Taiwan Medical Mission)\n\n\nWHO Dr. Deq: 醫療團已於2024/06/18拜會\n\n建議與指示:\n\nWHO and TMM to maintain open communication and collaboration in supporting MoHD’s efforts to control the dengue fever outbreak in Somaliland.\nWHO: the shared data on dengue fever cases from October 2023 and identify potential areas for support in the surveillance system.\nDr. Deq strongly recommends that TMM focuses on supporting the weakest part of the Ministry of Health and Development (MoHD): the dengue fever surveillance system, from community and regional levels to MoHD.\nIntegrated Disease Surveillance and Response (IDSR): meeting minutes\n\n\n\n\n索馬利蘭衛生部/HGH: (Taiwan Medical Mission / 2024/06/27)\n\n2023年疫情資料整理是準備2024年行動的關鍵，包含檢測數據、陽性率、地區分佈。\n追蹤2023年快篩試劑RDTs的使用：受測者demographic data，快篩試劑分配方式，UNICEF培訓人員(110 health workers)的現狀，參考上述 as national adaptation，以做出2024應變的計劃。\n\n經查 HGH laboratory 取得僅 1512 test of dengue NS1 RDT: 陽性率 25.9%\n其他的 18,488 RDTs 分配方式不明(MoHD DG Dr. Hergeye 經當面詢問，答稱不清楚)\nMoHD public health department (已安排 [2024/07/04]會議，但當日 公衛主管 Mr. Mahdi Dahir Bahdoon 失約，未上班): IDSR surveillance\n\nTMM 資金利用：若不適合IRS(indoor residual spray)，預算資金可轉向其他更合適的防疫措施。\n\n2022-2024年(June) HGH 登革熱統計報告:(Taiwan Medical Mission / 2024/06/15)\n\n\n由SAHA NCD director Dr. Ahmed Hersi(紙本登記簿)提供其分析結果[2024/06/13]:\n\nFrom October 2022 to June 2024, a total of 2,871 patients with dengue fever (probable) were registered at HGH. Among these patients, 1,232 (42.9%) were male, and 1,639 (57.1%) were female.\nThe majority of patients (2,036, 70.9%) received outpatient medical services, while 835 (29.1%) required hospital admission due to the severity of their illness.\nThe age distribution of the patients was as follows: 1,723 (60.0%) were under 30 years old, 774 (27.0%) were between 31 and 50 years old, and 374 (13.0%) were over 50 years old.\nThe total number of dengue fever-related deaths was 23, with a higher mortality rate observed among female patients.\n\n已進一步向 Dr. Ahmed 索取raw data (since 14 June 2024) 以便進行完整分析陽性率、以及risk category of severe dengue。\n\n\n[2024/06/11] HGH 小兒科統計報告:(Dr. Mohamed and Dr. Guuled, and Dr Hamda)(revision by Taiwan Medical Mission / 2024/06/26)\n\n\n2024 May/June 累積的小兒登革熱案例(十八歲以下)，計有\n\n139 confirmed cases on May and June (by NS1 in private sector, or IgG/IgM test in HGH)\n8 severe dengue cases (5.8%): upper/lower GI bleeding, plasma leakage, myocarditis (due to congenital heart disease), encephalitis, diabetic ketoacidosis (in type 1 diabetes)\n0 mortality (0%)\n\n\n\nHGH dengue fever strategy SOP :(HGH / ongoing)\n\n現行 (2022) HGH Dengue fever management guideline\n\n\n\n\n\n索馬利蘭行政區劃分與醫療資源分佈:\n\n\n6 regions in Somaliland。\nMaroodijeeh Region分為2個District。\nHargeisa為一獨立District,下設8個行政區(Sub-district)。\n\n\n進行Hargeisa行政區域及各層級醫療機構分佈調查:\n\n\n\nHargeisa District 內各層級(RHC, HC, PHU or MCH)醫療機構家數\n\n3 regional hospital (Naaso Hablood Hospital, Gurmad Hospital, and Daryeel Hospital)\n3 Referral Health center (RHC), 3 Health Center (HC), 45 Primary Health Unit (PHU) non-functional, and 66 Maternal Child Health clinics (MCH)\n\n瞭解各行政區可及的醫療資源,作為登革熱防治規劃的參考。\n\n\nSomaliland Publications\n\n\n\n來自本土發表的文章: 醫療團已與作者取得聯繫 Mr. Hussein Mohamoud Nour 2022 Edna Adan University Hospital (EAH) statistics, a research article titled “Sero-prevalence of Dengue virus infection and associated factors among patients with febrile illness attending at Edna Adan University Hospital. Hargeisa, Somaliland, 2022: A cross-sectional study” published in the Journal of Women’s Health Care. (https://www.longdom.org/open-access-pdfs/seroprevalence-of-dengue-virus-infection-and-associated-factors-among-patients-with-febrile-illness-attending-at-edna-ad.pdf)\n[2024/06] dengue NS1 RDTs is only available in few private hospitals\n(尚未回應) 就教於當地專家 Dr Yusuf Mohamed (Infectious disease and tropical medicine) in Hargeisa, he attended 2024MSC as a participant)\n\n\n\n*公共衛生\n\n\n5. 三項癌症防治計畫(子宮頸癌、乳癌、肝癌)\n\nA. 子宮頸癌防治中心、乳癌\n\n由HGH Fatima醫師、台灣醫療團王彥翔醫師(一般外科)、黃郁昕醫師(婦產科團員)共同推動\n子宮頸癌篩檢:引進HPV DNA real-time PCR檢測、Pap smear抹片染色與細胞病理訓練課程\n子宮頸癌預防:引進HPV vaccine\n乳癌篩檢:乳房超音波檢查\n瓶頸:\n\ncancer registry and cancer statistics:\n\nSomalia tertiary hospital report: (2017-2020, n=1306; 13.1% breast cancer, 13.3% cervical cancer), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534047/\n2023/03/10 WHO ICO/IARC report for Somalia Statistics of HPV-related cancers, crude incident rate of cervical cancer 13.2 per 100,000 population, ranked 2nd (https://hpvcentre.net/statistics/reports/SOM_FS.pdf); IARC: International Agency for Research on Cancer. ICO: Catalan Institute of Oncology\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n2022 report by Needle hospital in Hargeisa: Gebrekirstos Hagos et al., 2023 (https://ecancer.org/en/journal/article/1642-cancer-care-in-needle-hospital-hargeisa-somaliland)\n\n病理科 Dr. Omar (report 2 cases in 2023)請求支援，病理切片遠距會議; Dr. Omar and Mr. Mustafe (technician) 亦在2024 送訓名單中 (visiting scholars)\nWHO’s suggested HPV疫苗需要尋求來源GAVI (Hargeisa primary school girls aged 9-14: 50,000 persons; 資料來源 2023 statistics from Ministry of Education and Science, MoES);\n民眾健康觀念需宣導，並必須與 sexual transmission 切割明確，以免因民情保守，讓 推行受到阻礙\n\n\n\n\nCurrent Information\n\nreviewed articles\n\n\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n分享HPV center相關文獻,作為推動子宮頸癌防治的參考(https://hpvcentre.net/statistics/reports/SOM_FS.pdf)\n\n\n調查HGH病理報告現況:\n\n\n了解組織切片檢查(biopsy)後,病理報告的完整性。\n調查是否有出具報告、判讀結果、或報告遺失等情形。\n建議先由萬芳醫院陳主任，與Dr. Omar 建立遠距病理討論(tele-pathology)，建立合作關係與互信\n評估是否可完整收集既有病理報告,以利後續分析。\n建議由駐地護理師協助整理及彙整相關資料。\n\n\n安排與索馬利蘭駐地病理科視訊會議(tele-pathology conference):\n\n\n邀請臺北病理科陳威宇主任,與索馬利蘭駐地團隊進行視訊討論。\nHGH 病理科現有 digital slide scanner。\nHGH 病理科僅有 H&E and cytology stain (Pap stain)服務，無IHC staining。\n就子宮頸癌防治、病理診斷等議題交換意見,提供專業建議。\nDr. Omar與病理技術員 Mr. Mustafe亦在2024送訓臺北的學員名單中。\n\n\n調查索馬利蘭HGH病理專科醫師Dr. Omar到任後(2023/02),病理檢體概況:\n\n\n\n統計Dr. Omar到任後,病理切片的數量、檢體種類、部位、類型等資訊。\n瞭解目前HGH病理科的檢驗量能與診斷需求。\n彙整調查結果,與臺北病理科陳主任討論,研擬合作策略。\nDr. Shih-Han Hung 萬芳醫院ENT洪主任，自2023/08 到訪之後，與Dr. Omar 持續連絡，或許已有相關的統計成果，與發表文章。建議請副院長詢問一下。\n\n\n子宮頸癌防治計畫推動方式:\n\n\nPap smear/Pap stain (ready)\nHPV DNA\nHPV vaccine\n建議由OBGYN director Dr. Fatima醫師主動啟動,透過宣導及篩檢提高覆蓋率。\n駐地護理師協助資料整理、追蹤及衛教等工作。\n\n醫療團持續提供技術指導及所需資源(reagents),確保計畫順利進行。\n\n\n\n\n子宮頸採檢、基因與細胞抹片檢查:\n\n\nHPV DNA test (HGH院內檢驗科，現有Qiagen Rotor-Gene Q real-time PCR 儀器): 須要另外採購 HPV DNA PCR reagents。\n由HGH病理科Dr. Omar負責判讀子宮頸抹片 Pap stain and cytology。\n萬芳醫院病理科提供相關教學及技術支援。\n定期盤點染色試劑存量,適時提出申請,避免斷貨。並持續培訓病理染色及判讀人員。\n萬芳醫院定期監督品質,確保判讀結果的可靠性。\n\n\n\nAction points(who/when):\n\n\n在2022 TMM 建立的基礎上，推進乳癌及子宮頸癌的預防和早期診斷。\n提升婦女健康，促進性別平等:\n\n\n透過社區健康工作者（Community Health Workers）和志工（Volunteers）散播健康資訊。\nRN Penny負責此部分的健康教育工作。\nReproductive Cancer是一個新的議題，RN Penny將幫忙找尋種子學員或社區成員來進行資訊傳播。\n確保民眾了解Cervical Cancer和Breast Cancer的篩檢工具及操作流程，並與WHO討論HPV檢測。\n設計完整的病患流程，了解哪些情況可以在當地醫院處理，哪些需要轉介。\n當地僅於私立醫院有mammography和chemotherapy 服務。希望與這些機構進行合作、並進一步討論價格議題。\n評估預算後，將推廣Cervical Cancer和 Breast Cancer服務，並建立IDEM資料庫。\n建立Database並確保資料庫的sustainability。\n建議將研究成果在國際期刊發表，確保公共衛生實踐的存在性。\n考慮未來Dr. YuHsin 離任後，如何確保計畫能夠持續。\n考量到索馬利蘭的病理科醫師人數(僅三名)，宜優先進行HPV DNA 篩檢。\nHGH laboratory 擁有real-time PCR cycler 機器(Qiagen Rotor-Gene Q, for research only)，但需購買耗材(HPV DNA kits)。\n與當地病理科醫師合作，建立持續合作關係。\n計畫Phase 1的預算，確保順利執行後，再進一步計畫Phase 2。(Taiwan Medical Mission / 2024/07)\n\n\n\n\nB. 索馬利蘭病毒性肝炎(Viral Hepatitis)篩檢與預防控制計畫\n\n經WHO Dr. Deq 主動提出合作意願，TMM並可邀請 NGO SAHA 合作\n協助索馬利蘭制定 HBV 和 HCV 篩檢與預防控制的 national policy\n建立以哈格爾薩總醫院(HGH)為核心的 HBV 和 HCV 管理模式 + MoHD IDSR\n提高醫護人員與民眾對 HBV 和 HCV 的認識和重視(健康飲食、不吸菸、不嚼食khat葉與菸草等，預防脂肪肝、有效預防肝臟發炎，阻止肝炎 、肝硬化、肝癌三部曲的危機。)\n製作索馬利蘭語的宣傳手冊 (Booklet)\n建立 HBV 帶原者的追蹤和 HCV病毒根除治療\n計畫成果指標：\n\n完成 HBV 和 HCV 國家策略文件的制定(WHO 建議)\nHGH (約500-700名醫護人員)院內完成 HBV/HCV 篩檢和 HBV 疫苗接種\n加強 HGH HBV/HCV 門診運作(2024/04 已新成立)，並擴展至其他公立醫療機構，以及格爾薩大學醫學生和護理系學生(未來的第一線醫事人員)\n製作並發放索馬利蘭語的健康教育手冊\nIDSR 建立 HBV 帶原者追蹤系統，並開始 HCV病毒根除治療\n\nAction Points (who/when)：\n\nHBV/HCV mini review:(Somalia, 2018)\n向 MoHD 申請: HGH 門診(HIS) 統計資料分析 (TMM / 2024年7月)\n與 WHO、NGO SAHA 和 MoHD 共同制定 HBV 和 HCV 國家策略框架 (TMM、WHO Dr. Deq、SAHA Dr. Max、MoHD 公衛主任 / 2024年8月)\n了解 HGH HBV/HCV 門診的運作方式 (TMM、HGH HBV/HCV 門診負責人 / 2024年7月)\n為 HGH 醫護人員進行 HBV/HCV 篩檢和 HBV 疫苗接種\n\n制定篩檢和接種計劃 (TMM、HGH 人力資源部 / 2024年8月)\n執行篩檢和接種 (HGH 醫療團隊、TMM / 2024年9月1日至2024年11月30日)\n\n制定 HBV 帶原者定期追蹤和治療方案 (TMM + SAHA、HGH HBV 門診負責人 / 2024年10月)\n開發索馬利蘭語健康教育手冊\n\n內容撰寫 (TMM 、萬芳醫院肝炎專家 / 2024年11月)\n翻譯和設計 (當地翻譯人員、設計師 / 2024年12月)\n印刷和發放 (TMM、HGH 行政部門 / 2024年12月)\n\n制定醫護人員 HBV 和 HCV 管理培訓課程\n\n課程設計 (萬芳醫院肝炎專家、SAHA Dr. Max, HGH Dr. Ahmed / 2024年9月)\n培訓執行 (萬芳醫院肝炎專家、HGH 醫護人員 / 2024年10月1日至2024年12月31日)\n\n協調 HBV 疫苗和 HCV 治療藥物的採購和供應 (TMM、MoHD national cold chain / 2024年10月1日至2024年12月31日持續進行)\n建立 HBV 和 HCV 監測和評估框架 (TMM、MoHD IDSR/ 2024年11月)\n定期與 WHO、SAHA、MoHD、HGH 和其他相關者進行策略協調會議 (TMM, Dr. Deq, Dr. Max, Mr. Mahdi Dahir Bahdoon. / 每季一次，從2024年9月開始)"
  },
  {
    "objectID": "2024Project_hepatitis.html",
    "href": "2024Project_hepatitis.html",
    "title": "Hepatitis in Somalia: A Mini Review",
    "section": "",
    "text": "This report summarizes the current situation of hepatitis B virus (HBV), hepatitis C virus (HCV), and other forms of viral hepatitis in Somalia, based on recent systematic reviews and meta-analyses."
  },
  {
    "objectID": "2024Project_hepatitis.html#introduction",
    "href": "2024Project_hepatitis.html#introduction",
    "title": "Hepatitis in Somalia: A Mini Review",
    "section": "",
    "text": "This report summarizes the current situation of hepatitis B virus (HBV), hepatitis C virus (HCV), and other forms of viral hepatitis in Somalia, based on recent systematic reviews and meta-analyses."
  },
  {
    "objectID": "2024Project_hepatitis.html#prevalence-of-viral-hepatitis",
    "href": "2024Project_hepatitis.html#prevalence-of-viral-hepatitis",
    "title": "Hepatitis in Somalia: A Mini Review",
    "section": "Prevalence of Viral Hepatitis",
    "text": "Prevalence of Viral Hepatitis\n\nHepatitis B (HBV)\nThe epidemiology of viral hepatitis in Somalia shows a high prevalence of all forms of viral hepatitis, with chronic hepatitis B being the most common cause of chronic liver disease (Hassan-Kadle, Osman, and Ogurtsov 2018; Organization 2017).\n\nOverall pooled prevalence: 18.9% (95% CI: 14% to 29%) (Hassan-Kadle, Osman, and Ogurtsov 2018)\nPrevalence in specific groups:\n\nPregnant women: 20.5%\nChildren: 5.7%\nPatients with chronic liver disease/hepatocellular carcinoma: 39.2% (Hassan-Kadle, Osman, and Ogurtsov 2018)\n\n\n\n\nHepatitis C (HCV)\n\nOverall pooled prevalence: 4.84% (95% CI: 3.02% to 7.67%) (Hassan-Kadle, Osman, and Ogurtsov 2018)\nPrevalence in patients with chronic liver disease/hepatocellular carcinoma: 29.82% (Hassan-Kadle, Osman, and Ogurtsov 2018)\n\n\n\nHepatitis D (HDV)\n\nOverall pooled prevalence: 28.99%\nPrevalence in patients with chronic liver disease/hepatocellular carcinoma: 43.77% (Hassan-Kadle, Osman, and Ogurtsov 2018)\n\n\n\nHepatitis A (HAV)\nWhile specific data for Hargeisa is not available, broader studies on Somalia provide insight:\n\nOverall pooled prevalence rate: 90.2% (95% CI: 77.8% to 96%) (Hassan-Kadle, Osman, and Ogurtsov 2018)\nAge-specific prevalence rates:\n\nless than 1 year old: 61.54%\n1-10 years old: 91.91%\n11-19 years old: 96.31%\n20-39 years old: 91.3%\nabove 40 years old: 86.96%\n\n\nThese high rates indicate that HAV is endemic in Somalia, with most people being exposed to the virus at a young age."
  },
  {
    "objectID": "2024Project_hepatitis.html#hepatitis-in-hemodialysis-patients",
    "href": "2024Project_hepatitis.html#hepatitis-in-hemodialysis-patients",
    "title": "Hepatitis in Somalia: A Mini Review",
    "section": "Hepatitis in Hemodialysis Patients",
    "text": "Hepatitis in Hemodialysis Patients\nA recent study on hemodialysis patients in Somalia found (Ahmed et al. 2021):\n\nHBV prevalence: 7.3%\nHCV prevalence: 3.2%\nCo-infection (HBV and HCV): 0.5%\n\nRisk factors associated with higher prevalence of HBV and HCV in hemodialysis patients included longer duration of hemodialysis, history of blood transfusion, and higher number of hemodialysis sessions per week (Ahmed et al. 2021)."
  },
  {
    "objectID": "2024Project_hepatitis.html#public-health-challenges",
    "href": "2024Project_hepatitis.html#public-health-challenges",
    "title": "Hepatitis in Somalia: A Mini Review",
    "section": "Public Health Challenges",
    "text": "Public Health Challenges\nThe high prevalence of viral hepatitis, especially HBV, highlights the need for urgent public health interventions and strategic policy directions to control the disease burden in Somalia (Hassan-Kadle, Osman, and Ogurtsov 2018).\nThe World Health Organization’s 2017 country profile for Somalia indicates limited infrastructure and policies for hepatitis testing and treatment (Organization 2017). As of 2015, there were:\n\nNo official guidelines for hepatitis B or C treatment\nNo estimates of people on antiviral treatment for either HBV or HCV"
  },
  {
    "objectID": "2024Project_hepatitis.html#conclusion",
    "href": "2024Project_hepatitis.html#conclusion",
    "title": "Hepatitis in Somalia: A Mini Review",
    "section": "Conclusion",
    "text": "Conclusion\nThese findings underscore the significant public health challenge posed by viral hepatitis in Somalia and the need for improved prevention, testing, and treatment strategies."
  },
  {
    "objectID": "2024Projects_TMM.html#projects-進度四大項",
    "href": "2024Projects_TMM.html#projects-進度四大項",
    "title": "2024 TMM Project",
    "section": "Projects 進度(四大項)",
    "text": "Projects 進度(四大項)\n*訓練\n\n1. Visiting Scholarships for Training in Taiwan\n\nProject: Capacity Building for Somaliland Medical Personnel\nCollaborators: Taipei Municipal Wanfang Hospital (TMWH), Taiwan Medical Mission (TMM), and Hargeisa Group Hospital (HGH)\nInitiatives:\n\nProvide “Visiting Scholar Scholarships” for 12 Somaliland medical personnel to receive training in Taiwan for up to three months\nConduct selection process jointly by Taiwan Medical Mission and HGH Director’s Office\nInvite selected personnel to participate in TMM’s 2024 public health programs\n\nRequired support:\n\nTMM: Scholarship funding for 12 medical personnel (one batch)\nCoordination with TMWH for training arrangements\nCollaboration with HGH for personnel selection and public health program participation\n\n\n\n\n\n\n\nAction points(who/when):\n\n\n\n(謝謝病理科陳主任指導)遠距視訊會議(2024/6/20，瞭解HGH pathology 之 staff 和設備，進一步溝通合作細節)。取得 Dr Omar 電子版的 病理報告，Microsoft Access database 並完成分析，近半年僅有 110 份報告，4/5 都未能存檔；所幸尚有紙本報告留存在 file folder (已經由Dr. Omar手工輸入，轉為 Excel file， 亦已於 2024MSC 研討會中初步 報告)\n\n- 110 名病例分析如下 &lt;a href=\"https://texchi2.github.io/2024MSC/2024Project_HGH_pathology_LIMS.html\" target=\"_blank\"&gt;(from MS Access database)&lt;/a&gt; \n\n\n- 正在安排第一次 telepathology meeting for case discussion (Dr. Omar, **since 20 June**)\n\n- 正在邀請Dr. Omar 分享上述 Excel data (**Dr. Omar, since 20 June**)\n\n送訓科別(尚缺培訓計劃書):骨科、病理科\n送訓科別(已有培訓計劃書):一般外科(2 or 3名主治醫師)、ICU/胸腔內科(待進一步說明 Dr. Jacfar)、開刀房護理師(護理部擬定中)\n建議送訓科別: 神經外科、心臟內科、HGH研究中心(醫師、護理師、助產士)\n\n\n\n一般外科腹腔鏡手術訓練中心 - 由醫療團王彥翔醫師與HGH Afnan醫師及一般外科醫師群(包括十月份將赴臺北的 Dr. Nouh)，合作推行 - 背景:HGH一般外科醫師具豐富開刀經驗,但受限於資源,公立醫院尚無腹腔鏡設備\n- 所需設備:萬芳醫院提供腹腔鏡手術器械與訓練模型(home made DIY simulator box)\n- Action points(who/when):\n\n待課程規劃、器械整理後，開始訓練教學 (Taiwan Medical Mission / 2024/07)\n通過認證者，得遴選為赴臺送訓的種子學員(上限三名)\n\n\n\n\n待遴選完成後，辦理健康檢查(Chest X-ray, Tuberculosis (TB) Sputum Test, Syphilis/VDRL, Measles/Rubella)，以利申請 90日之受訓，執行臨床實作) (預計為十月份開始受訓)(Taiwan Medical Mission / 2024/07)\nHGH 院長 Dr. Abdirahman: 希望能於八月份赴萬芳醫院(二週)，接受醫院經營管理之培訓。(TMWH / 2024/07)\n新成立的 HGH研究中心 research center: 並肩負 IRB 的功能\n\n\nonline virtual meeting with TMWH研究部, 訓練研究人員使用分析工具 / Train researchers in using analytical tools\nvisiting scholars (Taiwan Medical Mission / 2024/08)\n\n\n\n*示範\n\n\n2. 骨科關節鏡中心\nA. 由萬芳醫院骨科郭宜潔醫師/陳昱斌醫師指導HGH骨科團隊\n- 計畫內容:關節鏡膝關節手術\n- 所需設備: 膝關節鏡手術器械(ready)\n- 目前進度:2023年10月郭醫師親自示範手術技巧,培訓種子醫師;2024年8月骨科專家將再度蒞臨指導進階手術\n- 瓶頸: - 醫師學習曲線較長,需反覆練習; - 關節鏡設備維修保養需OT的醫學工程技術員、及開刀房主任（護理師)負責\nB. TOM 骨質疏鬆預防保健計畫\n- 計畫名稱:「TOM骨質疏鬆」篩檢與預防保健\n- 內容:利用股骨X光片,透過AI人工智慧計算T-score,評估骨質密度\n- 目前進度:已引進TOM系統,規劃舉辦義診活動推廣\n- 瓶頸:民眾對骨質疏鬆認知不足,由護理部支援，於院內骨科住院病患衛教宣導做起，並架設系統與網路讓 TOM上線\n\ncase control study in hip fracture\n\n先行建立骨質疏鬆檢測系統(TOM: pelvic x-ray 建議拍攝參數 kVp:85, mAs:30, SID:100cm),並完成設備與網路架設(intranet)。\n進行髖部骨折病例對照研究(Hip fracture Case control study),調查分析當地骨質疏鬆盛行現況。\n根據研究結果,與骨科團隊討論後續執行方向,擬定符合在地需求的骨鬆防治策略。\n\nAction points(who/when): TBD\n\n\n*公共衛生\n\n\n3. 登革熱重症管理與加護病房支援\n\n計畫名稱:強化登革熱病患照護與預後\n\n所需物資:動脈血液氣體分析試劑,供加護病房重症患者使用; 篩檢 dengue fever NS1 rapid diagnostic test (RDT); HGH laboratory (IgM/IgG antibody ELISA)\nVentilator and respiratory care in ICU: 李主任主題醫療(see appendix)\n目前進度:已向萬芳醫院提出申請\n瓶頸:\n\nMoHD, Director General, Dr. Hargeye 接洽中;\ndengue fever statistics (from 2022-2024 HGH NCD Dr. Ahmed Hersi) 獲得初步報告;\nWHO Dr. Deq, UNICEF: vector control 接洽中;\nprepare IECM (in somali language)\n試劑需定期補充,須建立長期供應管道=&gt; WHO prequalifies new dengue vaccine (https://www.who.int/news/item/15-05-2024-who-prequalifies-new-dengue-vaccine)\n\n\n\n\n\n\nAction points(who/when):\n\n2023年索馬利蘭 WHO Dengue fever 資料蒐集: (Taiwan Medical Mission)\n\n\nWHO Dr. Deq: 醫療團已於2024/06/18拜會\n\n建議與指示:\n\nWHO and TMM to maintain open communication and collaboration in supporting MoHD’s efforts to control the dengue fever outbreak in Somaliland.\nWHO: the shared data on dengue fever cases from October 2023 and identify potential areas for support in the surveillance system.\nDr. Deq strongly recommends that TMM focuses on supporting the weakest part of the Ministry of Health and Development (MoHD): the dengue fever surveillance system, from community and regional levels to MoHD.\nIntegrated Disease Surveillance and Response (IDSR): meeting minutes\n\n\n\n\n索馬利蘭衛生部/HGH: (Taiwan Medical Mission / 2024/06/27)\n\n2023年疫情資料整理是準備2024年行動的關鍵，包含檢測數據、陽性率、地區分佈。\n追蹤2023年快篩試劑RDTs的使用：受測者demographic data，快篩試劑分配方式，UNICEF培訓人員(110 health workers)的現狀，參考上述 as national adaptation，以做出2024應變的計劃。\n\n經查 HGH laboratory 取得僅 1512 test of dengue NS1 RDT: 陽性率 25.9%\n其他的 18,488 RDTs 分配方式不明(MoHD DG Dr. Hergeye 經當面詢問，答稱不清楚)\nMoHD public health department (已安排 [2024/07/04]會議，但當日 公衛主管 Mr. Mahdi Dahir Bahdoon 失約，未上班): IDSR surveillance\n\nTMM 資金利用：若不適合IRS(indoor residual spray)，預算資金可轉向其他更合適的防疫措施。\n\n2022-2024年(June) HGH 登革熱統計報告:(Taiwan Medical Mission / 2024/06/15)\n\n\n由SAHA NCD director Dr. Ahmed Hersi(紙本登記簿)提供其分析結果[2024/06/13]:\n\nFrom October 2022 to June 2024, a total of 2,871 patients with dengue fever (probable) were registered at HGH. Among these patients, 1,232 (42.9%) were male, and 1,639 (57.1%) were female.\nThe majority of patients (2,036, 70.9%) received outpatient medical services, while 835 (29.1%) required hospital admission due to the severity of their illness.\nThe age distribution of the patients was as follows: 1,723 (60.0%) were under 30 years old, 774 (27.0%) were between 31 and 50 years old, and 374 (13.0%) were over 50 years old.\nThe total number of dengue fever-related deaths was 23, with a higher mortality rate observed among female patients.\n\n已進一步向 Dr. Ahmed 索取raw data (since 14 June 2024) 以便進行完整分析陽性率、以及risk category of severe dengue。\n\n\n[2024/06/11] HGH 小兒科統計報告:(Dr. Mohamed and Dr. Guuled, and Dr Hamda)(revision by Taiwan Medical Mission / 2024/06/26)\n\n\n2024 May/June 累積的小兒登革熱案例(十八歲以下)，計有\n\n139 confirmed cases on May and June (by NS1 in private sector, or IgG/IgM test in HGH)\n8 severe dengue cases (5.8%): upper/lower GI bleeding, plasma leakage, myocarditis (due to congenital heart disease), encephalitis, diabetic ketoacidosis (in type 1 diabetes)\n0 mortality (0%)\n\n\n\nHGH dengue fever strategy SOP :(HGH / ongoing)\n\n現行 (2022) HGH Dengue fever management guideline\n\n\n\n\n\n索馬利蘭行政區劃分與醫療資源分佈:\n\n\n6 regions in Somaliland。\nMaroodijeeh Region分為2個District。\nHargeisa為一獨立District,下設8個行政區(Sub-district)。\n\n\n進行Hargeisa行政區域及各層級醫療機構分佈調查:\n\n\n\nHargeisa District 內各層級(RHC, HC, PHU or MCH)醫療機構家數\n\n3 regional hospital (Naaso Hablood Hospital, Gurmad Hospital, and Daryeel Hospital)\n3 Referral Health center (RHC), 3 Health Center (HC), 45 Primary Health Unit (PHU) non-functional, and 66 Maternal Child Health clinics (MCH)\n\n瞭解各行政區可及的醫療資源,作為登革熱防治規劃的參考。\n\n\nSomaliland Publications\n\n\n\n來自本土發表的文章: 醫療團已與作者取得聯繫 Mr. Hussein Mohamoud Nour 2022 Edna Adan University Hospital (EAH) statistics, a research article titled “Sero-prevalence of Dengue virus infection and associated factors among patients with febrile illness attending at Edna Adan University Hospital. Hargeisa, Somaliland, 2022: A cross-sectional study” published in the Journal of Women’s Health Care. (https://www.longdom.org/open-access-pdfs/seroprevalence-of-dengue-virus-infection-and-associated-factors-among-patients-with-febrile-illness-attending-at-edna-ad.pdf)\n[2024/06] dengue NS1 RDTs is only available in few private hospitals\n(尚未回應) 就教於當地專家 Dr Yusuf Mohamed (Infectious disease and tropical medicine) in Hargeisa, he attended 2024MSC as a participant)\n\n\n\n*公共衛生\n\n\n4. 三項癌症防治計畫(子宮頸癌、乳癌、肝癌)\n\nA. 子宮頸癌防治中心、乳癌\n\n由HGH Fatima醫師、台灣醫療團王彥翔醫師(一般外科)、黃郁昕醫師(婦產科團員)共同推動\n子宮頸癌篩檢:引進HPV DNA real-time PCR檢測、Pap smear抹片染色與細胞病理訓練課程\n子宮頸癌預防:引進HPV vaccine\n乳癌篩檢:乳房超音波檢查\n瓶頸:\n\ncancer registry and cancer statistics:\n\nSomalia tertiary hospital report: (2017-2020, n=1306; 13.1% breast cancer, 13.3% cervical cancer), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534047/\n2023/03/10 WHO ICO/IARC report for Somalia Statistics of HPV-related cancers, crude incident rate of cervical cancer 13.2 per 100,000 population, ranked 2nd (https://hpvcentre.net/statistics/reports/SOM_FS.pdf); IARC: International Agency for Research on Cancer. ICO: Catalan Institute of Oncology\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n2022 report by Needle hospital in Hargeisa: Gebrekirstos Hagos et al., 2023 (https://ecancer.org/en/journal/article/1642-cancer-care-in-needle-hospital-hargeisa-somaliland)\n\n病理科 Dr. Omar (report 2 cases in 2023)請求支援，病理切片遠距會議; Dr. Omar and Mr. Mustafe (technician) 亦在2024 送訓名單中 (visiting scholars)\nWHO’s suggested HPV疫苗需要尋求來源GAVI (Hargeisa primary school girls aged 9-14: 50,000 persons; 資料來源 2023 statistics from Ministry of Education and Science, MoES);\n民眾健康觀念需宣導，並必須與 sexual transmission 切割明確，以免因民情保守，讓 推行受到阻礙\n\n\n\n\nCurrent Information\n\nreviewed articles\n\n\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n分享HPV center相關文獻,作為推動子宮頸癌防治的參考(https://hpvcentre.net/statistics/reports/SOM_FS.pdf)\n\n\n調查HGH病理報告現況:\n\n\n了解組織切片檢查(biopsy)後,病理報告的完整性。\n調查是否有出具報告、判讀結果、或報告遺失等情形。\n建議先由萬芳醫院陳主任，與Dr. Omar 建立遠距病理討論(tele-pathology)，建立合作關係與互信\n評估是否可完整收集既有病理報告,以利後續分析。\n建議由駐地護理師協助整理及彙整相關資料。\n\n\n安排與索馬利蘭駐地病理科視訊會議(tele-pathology conference):\n\n\n邀請臺北病理科陳威宇主任,與索馬利蘭駐地團隊進行視訊討論。\nHGH 病理科現有 digital slide scanner。\nHGH 病理科僅有 H&E and cytology stain (Pap stain)服務，無IHC staining。\n就子宮頸癌防治、病理診斷等議題交換意見,提供專業建議。\nDr. Omar與病理技術員 Mr. Mustafe亦在2024送訓臺北的學員名單中。\n\n\n調查索馬利蘭HGH病理專科醫師Dr. Omar到任後(2023/02),病理檢體概況:\n\n\n\n統計Dr. Omar到任後,病理切片的數量、檢體種類、部位、類型等資訊。\n瞭解目前HGH病理科的檢驗量能與診斷需求。\n彙整調查結果,與臺北病理科陳主任討論,研擬合作策略。\nDr. Shih-Han Hung 萬芳醫院ENT洪主任，自2023/08 到訪之後，與Dr. Omar 持續連絡，或許已有相關的統計成果，與發表文章。建議請副院長詢問一下。\n\n\n子宮頸癌防治計畫推動方式:\n\n\nPap smear/Pap stain (ready)\nHPV DNA\nHPV vaccine\n建議由OBGYN director Dr. Fatima醫師主動啟動,透過宣導及篩檢提高覆蓋率。\n駐地護理師協助資料整理、追蹤及衛教等工作。\n\n醫療團持續提供技術指導及所需資源(reagents),確保計畫順利進行。\n\n\n\n\n子宮頸採檢、基因與細胞抹片檢查:\n\n\nHPV DNA test (HGH院內檢驗科，現有Qiagen Rotor-Gene Q real-time PCR 儀器): 須要另外採購 HPV DNA PCR reagents。\n由HGH病理科Dr. Omar負責判讀子宮頸抹片 Pap stain and cytology。\n萬芳醫院病理科提供相關教學及技術支援。\n定期盤點染色試劑存量,適時提出申請,避免斷貨。並持續培訓病理染色及判讀人員。\n萬芳醫院定期監督品質,確保判讀結果的可靠性。\n\n\n\nAction points(who/when):\n\n\n在2022 TMM 建立的基礎上，推進乳癌及子宮頸癌的預防和早期診斷。\n提升婦女健康，促進性別平等:\n\n\n透過社區健康工作者（Community Health Workers）和志工（Volunteers）散播健康資訊。\nRN Penny負責此部分的健康教育工作。\nReproductive Cancer是一個新的議題，RN Penny將幫忙找尋種子學員或社區成員來進行資訊傳播。\n確保民眾了解Cervical Cancer和Breast Cancer的篩檢工具及操作流程，並與WHO討論HPV檢測。\n設計完整的病患流程，了解哪些情況可以在當地醫院處理，哪些需要轉介。\n當地僅於私立醫院有mammography和chemotherapy 服務。希望與這些機構進行合作、並進一步討論價格議題。\n評估預算後，將推廣Cervical Cancer和 Breast Cancer服務，並建立IDEM資料庫。\n建立Database並確保資料庫的sustainability。\n建議將研究成果在國際期刊發表，確保公共衛生實踐的存在性。\n考慮未來Dr. YuHsin 離任後，如何確保計畫能夠持續。\n考量到索馬利蘭的病理科醫師人數(僅三名)，宜優先進行HPV DNA 篩檢。\nHGH laboratory 擁有real-time PCR cycler 機器(Qiagen Rotor-Gene Q, for research only)，但需購買耗材(HPV DNA kits)。\n與當地病理科醫師合作，建立持續合作關係。\n計畫Phase 1的預算，確保順利執行後，再進一步計畫Phase 2。(Taiwan Medical Mission / 2024/07)\n\n\n\n\nB. 索馬利蘭病毒性肝炎(Viral Hepatitis)篩檢與預防控制計畫\n\n經WHO Dr. Deq 主動提出合作意願，TMM並可邀請 NGO SAHA 合作\n協助索馬利蘭制定 HBV 和 HCV 篩檢與預防控制的 national policy\n建立以哈格爾薩總醫院(HGH)為核心的 HBV 和 HCV 管理模式 + MoHD IDSR\n提高醫護人員與民眾對 HBV 和 HCV 的認識和重視(健康飲食、不吸菸、不嚼食khat葉與菸草等，預防脂肪肝、有效預防肝臟發炎，阻止肝炎 、肝硬化、肝癌三部曲的危機。)\n製作索馬利蘭語的宣傳手冊 (Booklet)\n建立 HBV 帶原者的追蹤和 HCV病毒根除治療\n計畫成果指標：\n\n完成 HBV 和 HCV 國家策略文件的制定(WHO 建議)\nHGH (約500-700名醫護人員)院內完成 HBV/HCV 篩檢和 HBV 疫苗接種\n加強 HGH HBV/HCV 門診運作(2024/04 已新成立)，並擴展至其他公立醫療機構，以及格爾薩大學醫學生和護理系學生(未來的第一線醫事人員)\n製作並發放索馬利蘭語的健康教育手冊\nIDSR 建立 HBV 帶原者追蹤系統，並開始 HCV病毒根除治療\n\nAction Points (who/when)：\n\nHBV/HCV mini review:(Somalia, 2018)\n向 MoHD 申請: HGH 門診(HIS) 統計資料分析 (TMM / 2024年7月)\n與 WHO、NGO SAHA 和 MoHD 共同制定 HBV 和 HCV 國家策略框架 (TMM、WHO Dr. Deq、SAHA Dr. Max、MoHD 公衛主任 / 2024年8月)\n了解 HGH HBV/HCV 門診的運作方式 (TMM、HGH HBV/HCV 門診負責人 / 2024年7月)\n為 HGH 醫護人員進行 HBV/HCV 篩檢和 HBV 疫苗接種\n\n制定篩檢和接種計劃 (TMM、HGH 人力資源部 / 2024年8月)\n執行篩檢和接種 (HGH 醫療團隊、TMM / 2024年9月1日至2024年11月30日)\n\n制定 HBV 帶原者定期追蹤和治療方案 (TMM + SAHA、HGH HBV 門診負責人 / 2024年10月)\n開發索馬利蘭語健康教育手冊\n\n內容撰寫 (TMM 、萬芳醫院肝炎專家 / 2024年11月)\n翻譯和設計 (當地翻譯人員、設計師 / 2024年12月)\n印刷和發放 (TMM、HGH 行政部門 / 2024年12月)\n\n制定醫護人員 HBV 和 HCV 管理培訓課程\n\n課程設計 (萬芳醫院肝炎專家、SAHA Dr. Max, HGH Dr. Ahmed / 2024年9月)\n培訓執行 (萬芳醫院肝炎專家、HGH 醫護人員 / 2024年10月1日至2024年12月31日)\n\n協調 HBV 疫苗和 HCV 治療藥物的採購和供應 (TMM、MoHD national cold chain / 2024年10月1日至2024年12月31日持續進行)\n建立 HBV 和 HCV 監測和評估框架 (TMM、MoHD IDSR/ 2024年11月)\n定期與 WHO、SAHA、MoHD、HGH 和其他相關者進行策略協調會議 (TMM, Dr. Deq, Dr. Max, Mr. Mahdi Dahir Bahdoon. / 每季一次，從2024年9月開始)"
  },
  {
    "objectID": "2024Projects_TMM.html#tmm-行政",
    "href": "2024Projects_TMM.html#tmm-行政",
    "title": "2024 TMM Project",
    "section": "TMM 行政",
    "text": "TMM 行政\n\n基於衛生部提供的 Nissan NP300 交通車，醫療團每一趟出車均需要司機，乘客座位三、四名，而計劃推展中，常常須要二組人馬出動(不同目的地)，加上因應八月份徐醫師到任，\n\n上班、下班，暫時均需要分為兩趟、甚至三趟行車。\n請示預算(旅運費)，以支付約每個月USD1,800的租車費用(司機、車、diesel)"
  },
  {
    "objectID": "2024Projects_TMM.html#tmm-projects-進度四大項",
    "href": "2024Projects_TMM.html#tmm-projects-進度四大項",
    "title": "2024 TMM Project",
    "section": "TMM Projects 進度(四大項)",
    "text": "TMM Projects 進度(四大項)\n*公共衛生\n\n1. 登革熱追蹤管理暨加護病房重症支援\n\n登革熱追蹤管理 IDSR\n加護病房重症支援:\n\n動脈血液氣體分析試劑,供加護病房重症患者使用; 篩檢 dengue fever NS1 rapid diagnostic test (RDT); HGH laboratory (IgM/IgG antibody ELISA)\nVentilator and respiratory care in ICU: 李枝新主任主題醫療\n\n瓶頸(資訊破碎、不完整):\n\nMoHD, Director General, Dr. Hergeye, Public Health department 接洽中;\ndengue fever statistics;\n\nEpidemiological Overview: Case reports and trends\n\nOctober-December 2023: 2,635 cases (734 positive, 27.9%) (WHO, Somaliland)\nSeptember 2023-January 2024: 6,394 suspected cases (WHO, Somaliland)\nOctober 2022-June 2024: 2,871 cases at HGH, Hargeisa\n\nWHO provision of 20,000 RDTs (December 2023) =&gt; HGH laboratory usage: 1,512 tests (25.9% positive rate)\n\n\n\n\n\n\n\n\nAction points(who/when): [2024/07/24]:\n\n\n2023年Somaliland登革熱資料收集:\n\n與WHO和MoHD確認2023年完整資料可獲得性 (TMM / 2024/07/31)\n分析資料獲取困難點，提出解決方案 (TMM / 2024/08/15)\n\n2024年疫情準備:\n\n制定2024年登革熱應對計劃 (TMM / 2024/08/31)\n評估現有資源和準備程度 (TMM / 2024/08/15)\n建立疫情監測系統改進計劃 (TMM / 2024/09/15)\n\n萬芳醫院支援需求:\n\n列出所需技術支援清單 (TMM / 2024/07/31)\n與萬芳醫院討論遠距諮詢(感染科醫師) (TMWH / 2024/08/15)\n制定培訓計劃，提升當地醫護人員能力 (TMWH / 2024/09/30)\n\n資料分析和報告:\n\n分析HGH 2022年10月至2024年6月的2,871例病例資料 (TMM / 2024/08/31)\n評估WHO提供的20,000 RDTs使用情況，特別是HGH實驗室使用的1,512測試 (TMM / 2024/08/15)\n製作綜合報告，包括流行病學概況和趨勢分析 (TMM / 2024/09/30)\n\n資源管理:\n\n評估現有RDTs庫存和未來需求 (TMM / 2024/07/31)\n制定資源分配策略，確保有效利用有限的RDTs (TMM / 2024/08/15)\n\n\n[2024/07/10]\n\n2023年索馬利蘭 WHO Dengue fever 資料蒐集: (Taiwan Medical Mission)\n\n\n2635 cases of dengue fever were reported in Somaliland October to December 2023 of which 734 were tested positive (27.9%) for dengue by rapid diagnostic test (RDT) kit. The most affected districts are Hargeisa, Boroma and Gebiley. (https://reliefweb.int/report/somalia/who-somalia-health-emergency-programme-update-december-2023)\n6394 cases of suspected dengue fever were reported in Somaliland September 2023 to January 2024 (5 months period, peak on November 2023; https://reliefweb.int/report/somalia/cholera-dengue-diphtheria-disease-outbreak-response-somalia-hc-meeting-15-02-2024)\nWHO Dr. Deq: 醫療團已於2024/06/18拜會\n\n建議與指示:\n\nWHO and TMM to maintain open communication and collaboration in supporting MoHD’s efforts to control the dengue fever outbreak in Somaliland.\nWHO: the shared data on dengue fever cases from October 2023 and identify potential areas for support in the surveillance system.\nDr. Deq strongly recommends that TMM focuses on supporting the weakest part of the Ministry of Health and Development (MoHD): the dengue fever surveillance system, from community and regional levels to MoHD.\nIntegrated Disease Surveillance and Response (IDSR): meeting minutes\n\n\n\n\n索馬利蘭衛生部/HGH: (Taiwan Medical Mission / 2024/06/27)\n\n2023年疫情資料整理是準備2024年行動的關鍵，包含檢測數據、陽性率、地區分佈。\n追蹤December 2023年快篩試劑 20,000 test of RDTs的使用：受測者demographic data，快篩試劑分配方式，UNICEF培訓人員(110 health workers)的現狀，參考上述 as national adaptation，以做出2024應變的計劃。\n\n經查 HGH laboratory 取得僅 1512 test of dengue NS1 RDT (December 2023 to 27 June 2024): 陽性率 25.9%\n其他的 18,488 RDTs 分配方式不明(MoHD DG Dr. Hergeye 經當面詢問，答稱不清楚)\nMoHD public health department (已安排 [2024/07/04]會議，但當日 公衛主管 Mr. Mahdi Dahir Bahdoon 失約，未上班): IDSR surveillance\n\nTMM project 資金利用：若不適合IRS(indoor residual spray)，預算資金可轉向其他更合適的防疫措施 =&gt; IDSR\n\n2022-2024年(June) HGH 登革熱統計報告:(Taiwan Medical Mission / 2024/06/15)\n\n\n由 HGH NCD director Dr. Ahmed Hersi(紙本登記簿)提供其分析結果[2024/06/13]:\n\nFrom October 2022 to June 2024, a total of 2,871 patients with dengue fever were registered at HGH (test? unknown). Among these patients, 1,232 (42.9%) were male, and 1,639 (57.1%) were female.\nThe majority of patients (2,036, 70.9%) received outpatient medical services, while 835 (29.1%) required hospital admission due to the severity of their illness.\nThe age distribution of the patients was as follows: 1,723 (60.0%) were under 30 years old, 774 (27.0%) were between 31 and 50 years old, and 374 (13.0%) were over 50 years old.\nThe total number of dengue fever-related deaths was 23, with a higher mortality rate observed among female patients.\n\n已進一步向 Dr. Ahmed 索取raw data (since 14 June 2024) 以便進行完整分析陽性率、以及risk category of severe dengue。\n\n\n[2024/06/11] HGH 小兒科統計報告:(Dr. Mohamed and Dr. Guuled, and Dr Hamda)(revision by Taiwan Medical Mission / 2024/06/26)\n\n\n2024 May/June 累積的小兒登革熱案例(十八歲以下)，計有\n\n139 confirmed cases on May and June (by NS1 in private sector, or IgG/IgM test in HGH)\n8 severe dengue cases (5.8%): upper/lower GI bleeding, plasma leakage, myocarditis (due to congenital heart disease), encephalitis, diabetic ketoacidosis (in type 1 diabetes)\n0 mortality (0%)\n\n\n\nHGH dengue fever strategy SOP :(HGH / ongoing)\n\n現行 (2022) HGH Dengue fever management guideline\n\n\n\n\n索馬利蘭行政區劃分與醫療資源分佈:\n\n\n6 regions in Somaliland。\nMaroodijeeh Region分為2個District。\nHargeisa為一獨立District,下設8個行政區(Sub-district)。\n\n\n進行Hargeisa行政區域及各層級醫療機構分佈調查:\n\n\n\nHargeisa District 內各層級(RHC, HC, PHU or MCH)醫療機構家數\n\n3 regional hospital (Naaso Hablood Hospital, Gurmad Hospital, and Daryeel Hospital)\n3 Referral Health center (RHC), 3 Health Center (HC), 45 Primary Health Unit (PHU) non-functional, and 66 Maternal Child Health clinics (MCH)\n\n瞭解各行政區可及的醫療資源,作為登革熱防治規劃的參考。\n\n\nSomaliland Publications\n\n\n\n來自本土發表的文章: 醫療團已與作者取得聯繫 Mr. Hussein Mohamoud Nour 2022 Edna Adan University Hospital (EAH) statistics, a research article titled “Sero-prevalence of Dengue virus infection and associated factors among patients with febrile illness attending at Edna Adan University Hospital. Hargeisa, Somaliland, 2022: A cross-sectional study” published in the Journal of Women’s Health Care. (https://www.longdom.org/open-access-pdfs/seroprevalence-of-dengue-virus-infection-and-associated-factors-among-patients-with-febrile-illness-attending-at-edna-ad.pdf)\n[2024/06] dengue NS1 RDTs is only available in few private hospitals\n(尚未回應) 就教於當地專家 Dr Yusuf Mohamed (Infectious disease and tropical medicine) in Hargeisa, he attended 2024MSC as a participant)\n\n\n\n*訓練\n\n\n2. Visiting Scholarships for Training in Taiwan\n\nProject: Capacity Building for Somaliland Medical Personnel\nCollaborators: Taipei Municipal Wanfang Hospital (TMWH), Taiwan Medical Mission (TMM), and Hargeisa Group Hospital (HGH)\nInitiatives:\n\nProvide “Visiting Scholar Scholarships” for 12 Somaliland medical personnel to receive training in Taiwan for up to three months\nConduct selection process jointly by Taiwan Medical Mission and HGH Director’s Office\nInvite selected personnel to participate in TMM’s 2024 public health programs\n\nRequired support:\n\nTMM: Scholarship funding for 12 medical personnel (one batch)\nCoordination with TMWH for training arrangements\nCollaboration with HGH for personnel selection and public health program participation\n\n\n\n\n\n\n\nAction points(who/when):\n\n\n\n(謝謝病理科陳主任指導)遠距視訊會議(2024/6/20，瞭解HGH pathology 之 staff 和設備，進一步溝通合作細節)。取得 Dr Omar 電子版的 病理報告，Microsoft Access database 並完成分析，近半年僅有 110 份報告，4/5 都未能存檔；所幸尚有紙本報告留存在 file folder (已經由Dr. Omar手工輸入，轉為 Excel file， 亦已於 2024MSC 研討會中初步 報告): 110 名病例分析 from MS Access database\n\n\n正在安排第一次 telepathology meeting for case discussion (Dr. Omar, since 20 June)\n正在邀請Dr. Omar 分享上述 Excel data (Dr. Omar, since 20 June)\n\n\n送訓科別(尚缺培訓計劃書):神經外科、病理科、骨科\n送訓科別(已有培訓計劃書):一般外科(2 or 3名主治醫師)、ICU/胸腔內科(待進一步說明 Dr. Jacfar)、開刀房護理師(一名)\n建議送訓科別: 心臟內科(例如，心臟內科醫師的培訓需要考慮HGH現有的設備情況，如超音波機器的類型。)\n為確保受訓者回國後能實際運用所學技能的重要性。各科的培訓計畫中，須明確訂立每位受訓者回國後的服務目標。\n\n\n\n\n一般外科腹腔鏡手術訓練中心 - 由醫療團王彥翔醫師與HGH Afnan醫師及一般外科醫師群(包括十月份將赴臺北的 Dr. Nouh)，合作推行 - 背景:HGH一般外科醫師具豐富開刀經驗,但受限於資源,公立醫院尚無腹腔鏡設備\n- 所需設備:萬芳醫院提供腹腔鏡手術器械與訓練模型(home made DIY simulator box)\n- Action points(who/when):\n\n待課程規劃、器械整理後，開始訓練教學 (Taiwan Medical Mission / 2024/07)\n通過認證者，得遴選為赴臺送訓的種子學員(上限三名)\n\n\n\n\n待遴選完成後，辦理健康檢查(Chest X-ray, Tuberculosis (TB) Sputum Test, Syphilis/VDRL, Measles/Rubella)，以利申請 90日之受訓，執行臨床實作) (預計為十月份開始受訓)(Taiwan Medical Mission / 2024/07)\n\n\n\n\n*公共衛生\n\n\n3. 三項癌症防治計畫(子宮頸癌、乳癌、肝癌)\n\nA. 子宮頸癌防治中心、乳癌\n\n由HGH Fatima醫師、台灣醫療團王彥翔醫師(一般外科)、黃郁昕醫師(婦產科團員)共同推動\n子宮頸癌篩檢:引進HPV DNA real-time PCR檢測、Pap smear抹片染色與細胞病理訓練課程\n子宮頸癌預防:引進HPV vaccine\n乳癌篩檢:乳房超音波檢查\n瓶頸:\n\ncancer registry and cancer statistics:\n\nSomalia tertiary hospital report: (2017-2020, n=1306; 13.1% breast cancer, 13.3% cervical cancer), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534047/\n2023/03/10 WHO ICO/IARC report for Somalia Statistics of HPV-related cancers, crude incident rate of cervical cancer 13.2 per 100,000 population, ranked 2nd (https://hpvcentre.net/statistics/reports/SOM_FS.pdf); IARC: International Agency for Research on Cancer. ICO: Catalan Institute of Oncology\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n2022 report by Needle hospital in Hargeisa: Gebrekirstos Hagos et al., 2023 (https://ecancer.org/en/journal/article/1642-cancer-care-in-needle-hospital-hargeisa-somaliland)\n\n病理科 Dr. Omar (report 2 cases in 2023)請求支援，病理切片遠距會議; Dr. Omar and Mr. Mustafe (technician) 亦在2024 送訓名單中 (visiting scholars)\nWHO’s suggested HPV疫苗需要尋求來源GAVI (Hargeisa primary school girls aged 9-14: 50,000 persons; 資料來源 2023 statistics from Ministry of Education and Science, MoES);\n民眾健康觀念需宣導，並必須與 sexual transmission 切割明確，以免因民情保守，讓 推行受到阻礙\n\n\n\n\nCurrent Information\n\nreviewed articles\n\n\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n分享HPV center相關文獻,作為推動子宮頸癌防治的參考(https://hpvcentre.net/statistics/reports/SOM_FS.pdf)\n\n\n調查HGH病理報告現況:\n\n\n了解組織切片檢查(biopsy)後,病理報告的完整性。\n調查是否有出具報告、判讀結果、或報告遺失等情形。\n建議先由萬芳醫院陳主任，與Dr. Omar 建立遠距病理討論(tele-pathology)，建立合作關係與互信\n評估是否可完整收集既有病理報告,以利後續分析。\n建議由駐地護理師協助整理及彙整相關資料。\n\n\n安排與索馬利蘭駐地病理科視訊會議(tele-pathology conference):\n\n\n邀請臺北病理科陳威宇主任,與索馬利蘭駐地團隊進行視訊討論。\nHGH 病理科現有 digital slide scanner。\nHGH 病理科僅有 H&E and cytology stain (Pap stain)服務，無IHC staining。\n就子宮頸癌防治、病理診斷等議題交換意見,提供專業建議。\nDr. Omar與病理技術員 Mr. Mustafe亦在2024送訓臺北的學員名單中。\n\n\n調查索馬利蘭HGH病理專科醫師Dr. Omar到任後(2023/02),病理檢體概況:\n\n\n\n統計Dr. Omar到任後,病理切片的數量、檢體種類、部位、類型等資訊。\n瞭解目前HGH病理科的檢驗量能與診斷需求。\n彙整調查結果,與臺北病理科陳主任討論,研擬合作策略。\nDr. Shih-Han Hung 萬芳醫院ENT洪主任，自2023/08 到訪之後，與Dr. Omar 持續連絡，或許已有相關的統計成果，與發表文章。建議請副院長詢問一下。\n\n\n子宮頸癌防治計畫推動方式:\n\n\nPap smear/Pap stain (ready)\nHPV DNA\nHPV vaccine\n建議由OBGYN director Dr. Fatima醫師主動啟動,透過宣導及篩檢提高覆蓋率。\n駐地護理師協助資料整理、追蹤及衛教等工作。\n\n醫療團持續提供技術指導及所需資源(reagents),確保計畫順利進行。\n\n\n\n\n子宮頸採檢、基因與細胞抹片檢查:\n\n\nHPV DNA test (HGH院內檢驗科，現有Qiagen Rotor-Gene Q real-time PCR 儀器): 須要另外採購 HPV DNA PCR reagents。\n由HGH病理科Dr. Omar負責判讀子宮頸抹片 Pap stain and cytology。\n萬芳醫院病理科提供相關教學及技術支援。\n定期盤點染色試劑存量,適時提出申請,避免斷貨。並持續培訓病理染色及判讀人員。\n萬芳醫院定期監督品質,確保判讀結果的可靠性。\n\n\n\nAction Points(who/when):\n\n\n分拆子宮頸癌和乳癌預防及早期診斷計畫 (Dr. Huang / 2024/07/13)\n提升婦女健康，促進性別平等:\n\n設計社區健康工作者（Community Health Workers）和志工（Volunteers）培訓計畫 (RN Penny / 2024/08/15)\n製作 Reproductive Cancer 健康教育材料 (RN Penny / 2024/08/31)\n與 WHO 討論 HPV 檢測流程 (Dr. Huang / 2024/08/15)\n設計完整的病患轉診流程 (Dr. Wang / 2024/08/31)\n與私立醫院討論 mammography 和 chemotherapy 服務合作 (Dr. Huang / 2024/09/15)\n建立 IDEM 資料庫計畫 (TMM / 2024/09/30)\n\n確保計畫持續性:\n\n在Dr. Huang 離開前可以做哪些; 離開之後誰可以做什麼 (2024/11)\n與萬芳醫院婦產科及家醫科討論主題醫療支援可能性 (Dr. Huang / 2024/07/11)\n試擬定當地計劃經理人聘用計畫 (Dr. Huang / 2024/08/15)\n設計當地病理科醫師培訓計畫 (TMWH / 2024/07/31)\n\n預算和設備:\n\n修改預算，分別列出子宮頸癌和乳癌項目 (Dr. Huang / 2024/07/12)\n加快必要設備採購流程，包括 HPV DNA kits (TMWH / 2024/08/01)\n完成 2024 年 Phase 1 預算 (Dr. Huang / 2024/08/31)\n編製 2025 年 Phase 2 計劃與預算書 (Dr. Huang / 2024/11/20)\n\n研究和報告:\n\n制定研究計畫，準備SCI國際期刊發表 (Dr. Huang / 2024/10/31)\n完成 2024 年期中報告 (Dr. Huang / 2024/11/20)\n\n\n\n\n\n\nB. 索馬利蘭病毒性肝炎(Viral Hepatitis)篩檢與預防控制計畫\n\n經WHO Dr. Deq 主動提出合作意願，TMM並可邀請 NGO SAHA 合作\n協助索馬利蘭制定 HBV 和 HCV 篩檢與預防控制的 national policy\nHGH最近成立了HBV門診\n建立以哈格爾薩總醫院(HGH)為核心的 HBV 和 HCV 管理模式 + MoHD IDSR\n提高醫護人員與民眾對 HBV 和 HCV 的認識和重視(健康飲食、不吸菸、不嚼食khat葉與菸草等，預防脂肪肝、有效預防肝臟發炎，阻止肝炎 、肝硬化、肝癌三部曲的危機。)\n製作索馬利蘭語的宣傳手冊 (Booklet)\n建立 HBV 帶原者的追蹤和 HCV病毒根除治療\n計畫成果指標：\n\n完成 HBV 和 HCV 國家策略文件的制定(WHO 建議)\nHGH (約500-700名醫護人員)院內完成 HBV/HCV 篩檢和 HBV 疫苗接種\n加強 HGH HBV/HCV 門診運作(2024/04 已新成立)，並擴展至其他公立醫療機構，以及格爾薩大學醫學生和護理系學生(未來的第一線醫事人員)\n製作並發放索馬利蘭語的健康教育手冊\nIDSR 建立 HBV 帶原者追蹤系統，並開始 HCV病毒根除治療\n\nAction Points (who/when)：\n\nHBV/HCV mini review: (Somalia, 2018)\n向 MoHD 申請: HGH 門診(HIS) 統計資料分析 (TMM / 2024年7月)\n從國家公共衛生部門、醫院實驗室和現有的HBV門診收集HBV/HCV盛行率等數據\n與 WHO、NGO SAHA 和 MoHD 共同制定 HBV 和 HCV 國家策略框架 (TMM、WHO Dr. Deq、SAHA Dr. Max、MoHD 公衛主任 / 2024年8月)\n了解 HGH HBV/HCV 門診的運作方式 (TMM、HGH HBV/HCV 門診負責人 / 2024年7月)\n審查醫療團2024預算，看是否可能重新分配資金以支持HBV/HCV篩檢和疫苗接種。\n為 HGH 醫護人員進行 HBV/HCV 篩檢和 HBV 疫苗接種\n\n制定篩檢和接種計劃 (TMM、HGH 人力資源部 / 2024年8月)\n執行篩檢和接種 (HGH 醫療團隊、TMM / 2024年9月1日至2024年11月30日)\n\n制定 HBV 帶原者定期追蹤和治療方案 (TMM + SAHA、HGH HBV 門診負責人 / 2024年10月)\n開發索馬利蘭語健康教育手冊\n\n內容撰寫 (TMM 、萬芳醫院肝炎專家 / 2024年11月)\n翻譯和設計 (當地翻譯人員、設計師 / 2024年12月)\n印刷和發放 (TMM、HGH 行政部門 / 2024年12月)\n\n制定醫護人員 HBV 和 HCV 管理培訓課程\n\n課程設計 (萬芳醫院肝炎專家、SAHA Dr. Max, HGH Dr. Ahmed / 2024年9月)\n培訓執行 (萬芳醫院肝炎專家、HGH 醫護人員 / 2024年10月1日至2024年12月31日)\n\n協調 HBV 疫苗和 HCV 治療藥物的採購和供應 (TMM、MoHD national cold chain / 2024年10月1日至2024年12月31日持續進行)\n建立 HBV 和 HCV 監測和評估框架 (TMM、MoHD IDSR/ 2024年11月)\n定期與 WHO、SAHA、MoHD、HGH 和其他相關者進行策略協調會議 (TMM, Dr. Deq, Dr. Max, Mr. Mahdi Dahir Bahdoon. / 每季一次，從2024年9月開始)\n\n\n\n*示範\n\n\n\n4. 骨質健康計劃\nA. 由萬芳醫院骨科郭宜潔醫師/陳昱斌醫師指導HGH骨科團隊\n- 計畫內容:關節鏡膝關節手術\n- 所需設備: 膝關節鏡手術器械(ready)\n- 目前進度:2023年10月郭醫師親自示範手術技巧,培訓種子醫師;2024年8月骨科專家將再度蒞臨指導進階手術\n- 瓶頸: - 醫師學習曲線較長,需反覆練習; - 關節鏡設備維修保養需OT的醫學工程技術員、及開刀房主任（護理師)負責\nB. TOM 骨質疏鬆預防保健計畫\n- 計畫名稱:「TOM骨質疏鬆」篩檢與預防保健\n- 內容:利用股骨X光片,透過AI人工智慧計算T-score/Z-score,評估骨質密度\n- 目前進度:已引進Taiwan Osteoporosis Master (TOM)系統,規劃舉辦義診以推廣活動\n- 瓶頸:民眾對骨質疏鬆認知不足,由骨科與放射科醫師支援，於院內骨科門診、骨科住院病患衛教宣導做起，並架設系統與網路讓 TOM上線\n\ncase control study in hip fracture (retrospective)\n\n先行建立骨質疏鬆檢測系統(TOM: pelvic x-ray 建議拍攝參數 kVp:85, mAs:30, SID:100cm),並完成設備與網路架設(intranet)。\n首月執行義診服務，由醫療團補貼放射科股骨X光片及放射科主治醫師的診斷費用。\n進行髖部骨折病例對照研究(Hip fracture Case control study),調查分析當地骨質疏鬆盛行現況。\n根據研究結果,與骨科團隊討論後續執行方向,擬定符合在地需求的骨鬆防治策略。\n\nAction points(who/when): TMM / 2024/08"
  },
  {
    "objectID": "20240715_SAHA_TMM_agenda.html",
    "href": "20240715_SAHA_TMM_agenda.html",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis in Hargeisa",
    "section": "",
    "text": "Date: 15 July 2024 Time: 10:00-11:00 Location: Cafe Barbera, Hargeisa Participants: Dr. Tex Chi (TMM), Dr. Abdirahman Madar (SAHA)\n\n\n\nBrief introductions\nOverview of current hepatitis situation in Hargeisa\nHBV/HCV mini review: (Somali, 2018) https://texchi2.github.io/2024MSC/2024Project_hepatitis.html\n\n\n\n\n\nDiscussion of “Pangenotypic direct-acting antiviral agents for hepatitis C infection in public healthcare workers in Somalia: A real-world effectiveness analysis”\nFunding request of 25,000 USD\nRole of Dr. Max Fraden as Principal Investigator\n\n\n\n\n\nOverview of TMM’s Hepatitis/Hepatoma Project\nDiscussion of WHO suggestions on HBV and HCV prevalence at HGH (HIS, statistics office)\nUpdate on newly established HBV clinic (vaccination) at HGH\nTaiwan’s commitment to eliminating hepatitis C by 2025\n\n\n\n\n\nIdentifying synergies between SAHA’s project and TMM’s focus\nExploring ways to support and cooperate with MoHD\nDiscussing potential for joint data collection and analysis\nConsidering shared resources and expertise\n\n\n\n\n\nAssign responsibilities for data collection on HBV/HCV prevalence\nDiscuss budget review and potential reallocation for screening, AAD drugs (HCV), and HBV vaccination\nSet timeline for follow-up and next meeting\n\n\n\n\n\nBrief discussion on other healthcare priorities, including cancer and other NCDs, such as cervical cancer, breast cancer.\nExplore potential for future collaborations in these areas"
  },
  {
    "objectID": "20240715_SAHA_TMM_agenda.html#introduction-and-overview-5-minutes",
    "href": "20240715_SAHA_TMM_agenda.html#introduction-and-overview-5-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis in Hargeisa",
    "section": "",
    "text": "Brief introductions\nOverview of current hepatitis situation in Hargeisa\nHBV/HCV mini review: (Somali, 2018) https://texchi2.github.io/2024MSC/2024Project_hepatitis.html"
  },
  {
    "objectID": "20240715_SAHA_TMM_agenda.html#sahas-proposed-project-10-minutes",
    "href": "20240715_SAHA_TMM_agenda.html#sahas-proposed-project-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis in Hargeisa",
    "section": "",
    "text": "Discussion of “Pangenotypic direct-acting antiviral agents for hepatitis C infection in public healthcare workers in Somalia: A real-world effectiveness analysis”\nFunding request of 25,000 USD\nRole of Dr. Max Fraden as Principal Investigator"
  },
  {
    "objectID": "20240715_SAHA_TMM_agenda.html#tmms-current-focus-and-plans-10-minutes",
    "href": "20240715_SAHA_TMM_agenda.html#tmms-current-focus-and-plans-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis in Hargeisa",
    "section": "",
    "text": "Overview of TMM’s Hepatitis/Hepatoma Project\nDiscussion of WHO suggestions on HBV and HCV prevalence at HGH (HIS, statistics office)\nUpdate on newly established HBV clinic (vaccination) at HGH\nTaiwan’s commitment to eliminating hepatitis C by 2025"
  },
  {
    "objectID": "20240715_SAHA_TMM_agenda.html#potential-areas-of-cooperation-10-minutes",
    "href": "20240715_SAHA_TMM_agenda.html#potential-areas-of-cooperation-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis in Hargeisa",
    "section": "",
    "text": "Identifying synergies between SAHA’s project and TMM’s focus\nExploring ways to support and cooperate with MoHD\nDiscussing potential for joint data collection and analysis\nConsidering shared resources and expertise"
  },
  {
    "objectID": "20240715_SAHA_TMM_agenda.html#action-points-and-next-steps-10-minutes",
    "href": "20240715_SAHA_TMM_agenda.html#action-points-and-next-steps-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis in Hargeisa",
    "section": "",
    "text": "Assign responsibilities for data collection on HBV/HCV prevalence\nDiscuss budget review and potential reallocation for screening, AAD drugs (HCV), and HBV vaccination\nSet timeline for follow-up and next meeting"
  },
  {
    "objectID": "20240715_SAHA_TMM_agenda.html#other-healthcare-needs-in-somaliland-5-minutes",
    "href": "20240715_SAHA_TMM_agenda.html#other-healthcare-needs-in-somaliland-5-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis in Hargeisa",
    "section": "",
    "text": "Brief discussion on other healthcare priorities, including cancer and other NCDs, such as cervical cancer, breast cancer.\nExplore potential for future collaborations in these areas"
  },
  {
    "objectID": "2024Projects_TMM.html#progress-report-202407",
    "href": "2024Projects_TMM.html#progress-report-202407",
    "title": "2024 TMM Project",
    "section": "Progress Report (2024/07/??)",
    "text": "Progress Report (2024/07/??)"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html",
    "href": "20240721_WHO_SAHA_TMM_agenda.html",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Date: 21 July 2024 Time: 09:30-11:00 Location: WHO office, Hargeisa Participants: Dr. Deq (WHO), Dr. Tex Chi (TMM), Dr. Abdirahman Madar (SAHA)\n\n\n\nBrief introductions\nOverview of current hepatitis situation in Hargeisa\nHBV/HCV mini review: (Somali, 2018) https://texchi2.github.io/2024MSC/2024Project_hepatitis.html\nDengue fever: Epidemiological Overview in Somaliland (Case reports and trends)\n\nOctober-December 2023: 2,635 cases (734 positive, 27.9%) (WHO, Somaliland)\nSeptember 2023-January 2024: 6,394 suspected cases (WHO, Somaliland)\nOctober 2022-June 2024: 2,871 cases at HGH, Hargeisa\n\nWHO provision of 20,000 RDTs (December 2023) =&gt; HGH laboratory usage: 1,512 tests (25.9% positive rate)\n\n\n\n\n\n\n\n\nDiscussion of “Pangenotypic direct-acting antiviral agents for hepatitis C infection in public healthcare workers in Somaliland: A real-world effectiveness analysis”\nFunding request of 25,000 USD\nRole of Dr. Max Fraden as Principal Investigator\nProject feasibility and resource availability\n\n\n\n\n\nOverview of TMM’s Hepatitis B Project\nDiscussion of WHO suggestions on HBV and HCV prevalence at HGH (HIS, statistics office, blood bank)\nUpdate on newly established HBV clinic (vaccination) at HGH\nTaiwan’s commitment to eliminating hepatitis C by 2025\nCurrent dengue control measures and IDSR implementation status\n\n\n\n\n\nIdentifying synergies between SAHA’s project and TMM’s focus\nExploring ways to support and cooperate with Public Health department of MoHD\nDiscussing potential for IRB, joint data collection and analysis\nConsidering shared resources and expertise\nIntegration of dengue fever surveillance into IDSR\nCapacity building for both hepatitis and dengue control\n\n\n\n\n\nStrategies for public education on hepatitis and dengue prevention\nInvolving community leaders in control efforts\n\n\n\n\n\nDiscuss budget review and potential reallocation for:\n\nHCV screening and DAAs drugs (Sofosbuvir 400 mg and velpatasvir 100 mg orally daily for 12 weeks)\nHBV vaccination\nDengue control and IDSR improvement\n\n\n\n\n\n\nAssign responsibilities for data collection on HBV/HCV prevalence\nOutline key priorities for dengue control and IDSR improvement\nSet timeline for project milestones and follow-up meetings\n\nTotal Time: 90 minutes"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html#introduction-and-overview-10-minutes",
    "href": "20240721_WHO_SAHA_TMM_agenda.html#introduction-and-overview-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Brief introductions\nOverview of current hepatitis situation in Hargeisa\nHBV/HCV mini review: (Somali, 2018) https://texchi2.github.io/2024MSC/2024Project_hepatitis.html\nDengue fever: Epidemiological Overview in Somaliland (Case reports and trends)\n\nOctober-December 2023: 2,635 cases (734 positive, 27.9%) (WHO, Somaliland)\nSeptember 2023-January 2024: 6,394 suspected cases (WHO, Somaliland)\nOctober 2022-June 2024: 2,871 cases at HGH, Hargeisa\n\nWHO provision of 20,000 RDTs (December 2023) =&gt; HGH laboratory usage: 1,512 tests (25.9% positive rate)"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html#sahas-proposed-hcv-project-15-minutes",
    "href": "20240721_WHO_SAHA_TMM_agenda.html#sahas-proposed-hcv-project-15-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Discussion of “Pangenotypic direct-acting antiviral agents for hepatitis C infection in public healthcare workers in Somaliland: A real-world effectiveness analysis”\nFunding request of 25,000 USD\nRole of Dr. Max Fraden as Principal Investigator\nProject feasibility and resource availability"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html#tmms-current-focus-and-plans-15-minutes",
    "href": "20240721_WHO_SAHA_TMM_agenda.html#tmms-current-focus-and-plans-15-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Overview of TMM’s Hepatitis B Project\nDiscussion of WHO suggestions on HBV and HCV prevalence at HGH (HIS, statistics office, blood bank)\nUpdate on newly established HBV clinic (vaccination) at HGH\nTaiwan’s commitment to eliminating hepatitis C by 2025\nCurrent dengue control measures and IDSR implementation status"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html#potential-areas-of-cooperation-20-minutes",
    "href": "20240721_WHO_SAHA_TMM_agenda.html#potential-areas-of-cooperation-20-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Identifying synergies between SAHA’s project and TMM’s focus\nExploring ways to support and cooperate with Public Health department of MoHD\nDiscussing potential for IRB, joint data collection and analysis\nConsidering shared resources and expertise\nIntegration of dengue fever surveillance into IDSR\nCapacity building for both hepatitis and dengue control"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html#community-engagement-and-awareness-10-minutes",
    "href": "20240721_WHO_SAHA_TMM_agenda.html#community-engagement-and-awareness-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Strategies for public education on hepatitis and dengue prevention\nInvolving community leaders in control efforts"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html#resource-allocation-and-funding-10-minutes",
    "href": "20240721_WHO_SAHA_TMM_agenda.html#resource-allocation-and-funding-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Discuss budget review and potential reallocation for:\n\nHCV screening and DAAs drugs (Sofosbuvir 400 mg and velpatasvir 100 mg orally daily for 12 weeks)\nHBV vaccination\nDengue control and IDSR improvement"
  },
  {
    "objectID": "20240721_WHO_SAHA_TMM_agenda.html#action-points-and-next-steps-10-minutes",
    "href": "20240721_WHO_SAHA_TMM_agenda.html#action-points-and-next-steps-10-minutes",
    "title": "TMM and SAHA Cooperation on Viral Hepatitis and IDSR in Hargeisa",
    "section": "",
    "text": "Assign responsibilities for data collection on HBV/HCV prevalence\nOutline key priorities for dengue control and IDSR improvement\nSet timeline for project milestones and follow-up meetings\n\nTotal Time: 90 minutes"
  },
  {
    "objectID": "2024TMM_health-certificate-quarto.html",
    "href": "2024TMM_health-certificate-quarto.html",
    "title": "Health Certificate for Medical Practice Application",
    "section": "",
    "text": "(Hospital’s Name, Address, Tel, Fax)"
  },
  {
    "objectID": "2024TMM_health-certificate-quarto.html#a.-chest-x-ray-for-tuberculosis",
    "href": "2024TMM_health-certificate-quarto.html#a.-chest-x-ray-for-tuberculosis",
    "title": "Health Certificate for Medical Practice Application",
    "section": "A. Chest X-ray for Tuberculosis:",
    "text": "A. Chest X-ray for Tuberculosis:\nFindings:\nResult: □ Passed □ TB suspect □ Pending □ Failed\n□ Not required for pregnant women or children under 12 years of age"
  },
  {
    "objectID": "2024TMM_health-certificate-quarto.html#b.-stool-examination-for-parasites",
    "href": "2024TMM_health-certificate-quarto.html#b.-stool-examination-for-parasites",
    "title": "Health Certificate for Medical Practice Application",
    "section": "B. Stool Examination for Parasites:",
    "text": "B. Stool Examination for Parasites:\n□ Positive, Species: _________________ □ Negative\n□ Other parasites that do not require treatment: _________________\n□ Not required for applicants from countries/areas listed in Appendix 3"
  },
  {
    "objectID": "2024TMM_health-certificate-quarto.html#c.-serological-tests-for-syphilis",
    "href": "2024TMM_health-certificate-quarto.html#c.-serological-tests-for-syphilis",
    "title": "Health Certificate for Medical Practice Application",
    "section": "C. Serological Tests for Syphilis:",
    "text": "C. Serological Tests for Syphilis:\nTests: a. □ RPR □ VDRL □ Positive, Titers _______ □ Negative, Titers _______ b. □ TPHA □ TPPA □ FTA-abs □ TPLA □ EIA □ CIA □ Positive, Titers _______ □ Negative, Titers _______ c. □ Other ___________________ □ Positive, Titers _______ □ Negative, Titers _______\nResult: □ Passed □ Failed\n□ Not required for children under 15 years of age"
  },
  {
    "objectID": "2024TMM_health-certificate-quarto.html#d.-proof-of-positive-measles-and-rubella-antibody-or-measles-and-rubella-vaccination-certificates",
    "href": "2024TMM_health-certificate-quarto.html#d.-proof-of-positive-measles-and-rubella-antibody-or-measles-and-rubella-vaccination-certificates",
    "title": "Health Certificate for Medical Practice Application",
    "section": "D. Proof of Positive Measles and Rubella Antibody or Measles and Rubella Vaccination Certificates:",
    "text": "D. Proof of Positive Measles and Rubella Antibody or Measles and Rubella Vaccination Certificates:\n\nAntibody Tests Measles Antibody □ Positive □ Negative □ Equivocal Rubella Antibody □ Positive □ Negative □ Equivocal\nVaccination Certificates □ Measles Vaccination Certificate □ Rubella Vaccination Certificate\n□ Having contraindications, not suitable for vaccination"
  },
  {
    "objectID": "2024Projects_TMM.html#tmm-projects-809b9b85",
    "href": "2024Projects_TMM.html#tmm-projects-809b9b85",
    "title": "2024 TMM Project",
    "section": "TMM Projects <80>(<9b><9b><85>)",
    "text": "TMM Projects &lt;80&gt;(&lt;9b&gt;&lt;9b&gt;&lt;85&gt;)\n*&lt;85&gt;&lt;85&gt;&lt;9b&gt;&lt;94&gt;&lt;9f&gt;\n\n1. &lt;99&gt;&lt;9d&gt;&lt;86&gt;&lt;90&gt;&lt;86&gt;&lt;9a&gt;&lt;8a&gt;&lt;97&gt;&lt;85&gt;&lt;88&gt;&lt;87&gt;&lt;8d&gt;&lt;97&gt;&lt;87&gt;&lt;94&gt;&lt;8f&gt;\n\n&lt;99&gt;&lt;9d&gt;&lt;86&gt;&lt;90&gt;&lt;86&gt; IDSR\n&lt;8a&gt;&lt;97&gt;&lt;85&gt;&lt;88&gt;&lt;87&gt;&lt;8d&gt;&lt;97&gt;&lt;87&gt;&lt;94&gt;&lt;8f&gt;:\n\n&lt;8b&gt;&lt;95&gt;&lt;84&gt;&lt;88&gt;&lt;80&gt;&lt;94&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;8a&gt;&lt;91&gt;,&lt;9b&gt;&lt;8a&gt;&lt;97&gt;&lt;85&gt;&lt;88&gt;&lt;87&gt;&lt;8d&gt;&lt;97&gt;&lt;87&gt;&lt;82&gt;&lt;80&gt;&lt;85&gt;&lt;94&gt;;  dengue fever NS1 rapid diagnostic test (RDT); HGH laboratory (IgM/IgG antibody ELISA)\nVentilator and respiratory care in ICU: &lt;9d&gt;&lt;8e&gt;&lt;9e&gt;&lt;9d&gt;&lt;96&gt;&lt;8c&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;\n\n&lt;93&gt;(&lt;87&gt;&lt;8a&gt;&lt;8e&gt;&lt;80&gt;&lt;81&gt;&lt;8d&gt;&lt;8c&gt;&lt;95&gt;):\n\nMoHD, Director General, Dr. Hergeye, Public Health department &lt;8e&gt;;\ndengue fever statistics;\n\nEpidemiological Overview: Case reports and trends\n\nOctober-December 2023: 2,635 cases (734 positive, 27.9%) (WHO, Somaliland)\nSeptember 2023-January 2024: 6,394 suspected cases (WHO, Somaliland)\nOctober 2022-June 2024: 2,871 cases at HGH, Hargeisa\n\nWHO provision of 20,000 RDTs (December 2023) =&gt; HGH laboratory usage: 1,512 tests (25.9% positive rate)\n\n\n\n (image courtesy: https://reliefweb.int/report/somalia/cholera-dengue-diphtheria-disease-outbreak-response-somalia-hc-meeting-15-02-2024) \n\n\n\nAction points(who/when): [2024/07/24]:\n\n\n2023Somaliland&lt;99&gt;&lt;9d&gt;&lt;86&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;94&gt;&lt;9b&gt;&lt;86&gt;:\n\n&lt;88&gt;&lt;87&gt;WHO&lt;92&gt;&lt;8c&gt;MoHD&lt;8d&gt;2023&lt;8c&gt;&lt;95&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;8f&gt;&lt;8d&gt;&lt;97&gt;&lt;80&gt; (TMM / 2024/07/31)\n&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;8d&gt;&lt;8f&gt;&lt;96&gt;&lt;9b&gt;&lt;9b&gt;&lt;9e&gt;&lt;8c&gt;&lt;8f&gt;&lt;90&gt;&lt;87&gt;&lt;96&gt;&lt;88&gt; (TMM / 2024/08/15)\n\n2024&lt;96&gt;&lt;83&gt;&lt;85&gt;&lt;96&gt;&lt;82&gt;&lt;99&gt;:\n\n&lt;88&gt;&lt;9a&gt;2024&lt;99&gt;&lt;9d&gt;&lt;86&gt;&lt;87&gt;&lt;89&gt;&lt;8d&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt; (TMM / 2024/08/31)\n&lt;95&gt;&lt;8f&gt;&lt;9c&gt;&lt;89&gt;&lt;87&gt;&lt;90&gt;&lt;92&gt;&lt;8c&gt;&lt;96&gt;&lt;82&gt;&lt;99&gt;&lt;8b&gt; (TMM / 2024/08/15)\n&lt;8b&gt;&lt;96&gt;&lt;83&gt;&lt;85&gt;&lt;9b&gt;&lt;94&gt;&lt;80&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt; (TMM / 2024/09/15)\n\n&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;94&gt;&lt;8f&gt;&lt;9c&gt;&lt;80&gt;&lt;82&gt;:\n\n&lt;88&gt;&lt;97&gt;&lt;87&gt;&lt;89&gt;&lt;80&gt;&lt;9c&gt;&lt;80&gt;&lt;8a&gt;&lt;80&gt;&lt;93&gt;&lt;94&gt;&lt;8f&gt;&lt;85&gt;&lt;96&gt; (TMM / 2024/07/31)\n&lt;88&gt;&lt;87&gt;&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;8e&gt;&lt;96&gt;&lt;81&gt;&lt;9d&gt;(&lt;84&gt;&lt;9f&gt;&lt;9f&gt;&lt;93&gt;&lt;91&gt;&lt;86&gt;) (TMWH / 2024/08/15)\n&lt;88&gt;&lt;9a&gt;&lt;9f&gt;&lt;93&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt;&lt;8c&gt;&lt;8f&gt;&lt;90&gt;&lt;8d&gt;&lt;87&gt;&lt;95&gt;&lt;9c&gt;&lt;86&gt;&lt;93&gt;&lt;83&gt;&lt;8a&gt;&lt;9b&gt; (TMWH / 2024/09/30)\n\n&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;92&gt;&lt;8c&gt;&lt;91&gt;&lt;8a&gt;:\n\n&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;HGH 202210&lt;9c&gt;&lt;88&gt;&lt;87&gt;20246&lt;9c&gt;&lt;88&gt;&lt;9a&gt;&lt;84&gt;2,871&lt;8b&gt;&lt;97&gt;&lt;85&gt;&lt;8b&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt; (TMM / 2024/08/31)\n&lt;95&gt;WHO&lt;8f&gt;&lt;90&gt;&lt;9b&gt;&lt;9a&gt;&lt;84&gt;20,000 RDTs&lt;94&gt;&lt;83&gt;&lt;85&gt;&lt;81&gt;&lt;8c&gt;&lt;89&gt;&lt;88&gt;&lt;98&gt;HGH&lt;97&gt;&lt;94&gt;&lt;9a&gt;&lt;84&gt;1,512 (TMM / 2024/08/15)\n&lt;9c&gt;&lt;9c&gt;&lt;90&gt;&lt;88&gt;&lt;91&gt;&lt;8a&gt;&lt;8c&gt;&lt;8c&gt;&lt;85&gt;&lt;8b&gt;&lt;81&gt;&lt;8c&gt;&lt;97&gt;&lt;85&gt;&lt;82&gt;&lt;81&gt;&lt;92&gt;&lt;8c&gt;&lt;8b&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt; (TMM / 2024/09/30)\n\n&lt;87&gt;&lt;90&gt;&lt;90&gt;&lt;86&gt;:\n\n&lt;95&gt;&lt;8f&gt;&lt;9c&gt;&lt;89&gt;RDTs&lt;98&gt;&lt;92&gt;&lt;8c&gt;&lt;9c&gt;&lt;86&gt;&lt;9c&gt;&lt;80&gt;&lt;82&gt; (TMM / 2024/07/31)\n&lt;88&gt;&lt;9a&gt;&lt;87&gt;&lt;90&gt;&lt;88&gt;&lt;86&gt;&lt;85&gt;&lt;8d&gt;&lt;96&gt;&lt;95&gt;&lt;8c&gt;&lt;9d&gt;&lt;9c&gt;&lt;89&gt;&lt;95&gt;&lt;88&gt;&lt;88&gt;&lt;94&gt;&lt;9c&gt;&lt;89&gt;&lt;99&gt;&lt;90&gt;&lt;9a&gt;&lt;84&gt;RDTs (TMM / 2024/08/15)\n\n\n[2024/07/10]\n\n2023&lt;88&gt;&lt;98&gt; WHO Dengue fever &lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;92&gt;&lt;90&gt;&lt;9b&gt;&lt;86&gt;: (Taiwan Medical Mission)\n\n\n2635 cases of dengue fever were reported in Somaliland October to December 2023 of which 734 were tested positive (27.9%) for dengue by rapid diagnostic test (RDT) kit. The most affected districts are Hargeisa, Boroma and Gebiley. (https://reliefweb.int/report/somalia/who-somalia-health-emergency-programme-update-december-2023)\n6394 cases of suspected dengue fever were reported in Somaliland September 2023 to January 2024 (5 months period, peak on November 2023; https://reliefweb.int/report/somalia/cholera-dengue-diphtheria-disease-outbreak-response-somalia-hc-meeting-15-02-2024)\nWHO Dr. Deq: &lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;&lt;96&gt;2024/06/18&lt;8b&gt;&lt;9c&gt;&lt;9c&gt;&lt;83&gt;\n\n&lt;88&gt;&lt;87&gt;&lt;8c&gt;&lt;87&gt;:\n\nWHO and TMM to maintain open communication and collaboration in supporting MoHD’s efforts to control the dengue fever outbreak in Somaliland.\nWHO: the shared data on dengue fever cases from October 2023 and identify potential areas for support in the surveillance system.\nDr. Deq strongly recommends that TMM focuses on supporting the weakest part of the Ministry of Health and Development (MoHD): the dengue fever surveillance system, from community and regional levels to MoHD.\nIntegrated Disease Surveillance and Response (IDSR): meeting minutes\n\n\n\n\n&lt;88&gt;&lt;98&gt;&lt;9b&gt;&lt;94&gt;&lt;9f&gt;&lt;83&gt;/HGH: (Taiwan Medical Mission / 2024/06/27)\n\n2023&lt;96&gt;&lt;83&gt;&lt;85&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;95&gt;&lt;90&gt;&lt;86&gt;&lt;98&gt;&lt;96&gt;&lt;82&gt;&lt;99&gt;2024&lt;8c&gt;&lt;8b&gt;&lt;95&gt;&lt;9a&gt;&lt;84&gt;&lt;97&gt;&lt;9c&gt;&lt;8d&gt;&lt;8c&gt;&lt;8c&gt;&lt;85&gt;&lt;90&gt;&lt;95&gt;&lt;93&gt;&lt;9a&gt;&lt;80&gt;&lt;81&gt;&lt;99&gt;&lt;80&gt;&lt;8e&gt;&lt;87&gt;&lt;80&gt;&lt;81&gt;&lt;9c&gt;&lt;8d&gt;&lt;80&gt;&lt;88&gt;&lt;86&gt;&lt;88&gt;&lt;80&gt;&lt;82&gt;\nDecember 2023&lt;8a&gt;&lt;91&gt; 20,000 test of RDTs&lt;9a&gt;&lt;84&gt;&lt;94&gt;&lt;9a&gt;&lt;8f&gt;&lt;97&gt;&lt;80&gt;&lt;85&gt;demographic data&lt;8c&gt;&lt;8a&gt;&lt;91&gt;&lt;88&gt;&lt;86&gt;&lt;85&gt;&lt;8d&gt;&lt;96&gt;&lt;8f&gt;&lt;8c&gt;UNICEF&lt;9f&gt;&lt;93&gt;&lt;93&gt;(110 health workers)&lt;9a&gt;&lt;84&gt;&lt;8f&gt;&lt;8b&gt;&lt;80&gt;&lt;8c&gt;&lt;8f&gt;&lt;83&gt;&lt;80&gt;&lt;83&gt;&lt;8a&gt; as national adaptation&lt;8c&gt;&lt;81&gt;&lt;9a&gt;&lt;87&gt;2024&lt;87&gt;&lt;89&gt;&lt;8a&gt;&lt;9a&gt;&lt;84&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt;&lt;80&gt;&lt;82&gt;\n\n&lt;93&gt;&lt;9f&gt; HGH laboratory &lt;8f&gt;&lt;96&gt;&lt;97&gt;&lt;83&gt;&lt;85&gt; 1512 test of dengue NS1 RDT (December 2023 to 27 June 2024): &lt;99&gt;&lt;80&gt;&lt;8e&gt;&lt;87&gt; 25.9%\n&lt;85&gt;&lt;96&gt;&lt;9a&gt;&lt;84&gt; 18,488 RDTs &lt;88&gt;&lt;86&gt;&lt;85&gt;&lt;8d&gt;&lt;96&gt;&lt;8f&gt;&lt;8d&gt;&lt;98&gt;&lt;8e&gt;(MoHD DG Dr. Hergeye &lt;93&gt;&lt;95&gt;&lt;9d&gt;&lt;95&gt;&lt;8f&gt;&lt;8c&gt;&lt;94&gt;&lt;8d&gt;&lt;85&gt;&lt;9a&gt;)\nMoHD public health department (&lt;89&gt;&lt;8e&gt;&lt;92&gt; [2024/07/04]&lt;9c&gt;&lt;83&gt;&lt;8c&gt;&lt;86&gt;&lt;95&gt;&lt;97&gt; &lt;85&gt;&lt;9b&gt; Mr. Mahdi Dahir Bahdoon &lt;84&gt;&lt;8c&gt;&lt;9c&gt;&lt;8a&gt;&lt;8f&gt;): IDSR surveillance\n\nTMM project &lt;87&gt;&lt;87&gt;&lt;91&gt;&lt;88&gt;&lt;94&gt;&lt;9a&gt;&lt;8b&gt;&lt;8d&gt;&lt;81&gt;&lt;90&gt;&lt;88&gt;IRS(indoor residual spray)&lt;8c&gt;&lt;90&gt;&lt;97&gt;&lt;87&gt;&lt;87&gt;&lt;91&gt;&lt;8f&gt;&lt;89&gt;&lt;90&gt;&lt;91&gt;&lt;85&gt;&lt;96&gt;&lt;9b&gt;&lt;90&gt;&lt;88&gt;&lt;81&gt;&lt;9a&gt;&lt;84&gt;&lt;98&gt;&lt;96&gt;&lt;8e&gt;&lt;96&gt; =&gt; IDSR\n\n2022-2024(June) HGH &lt;99&gt;&lt;9d&gt;&lt;86&gt;&lt;88&gt;&lt;91&gt;&lt;8a&gt;:(Taiwan Medical Mission / 2024/06/15)\n\n\n&lt;94&gt; HGH NCD director Dr. Ahmed Hersi(&lt;99&gt;&lt;9c&gt;&lt;99&gt;&lt;98&gt;)&lt;8f&gt;&lt;90&gt;&lt;9b&gt;&lt;85&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;90&gt;&lt;9e&gt;&lt;9c&gt;[2024/06/13]:\n\nFrom October 2022 to June 2024, a total of 2,871 patients with dengue fever were registered at HGH (test? unknown). Among these patients, 1,232 (42.9%) were male, and 1,639 (57.1%) were female.\nThe majority of patients (2,036, 70.9%) received outpatient medical services, while 835 (29.1%) required hospital admission due to the severity of their illness.\nThe age distribution of the patients was as follows: 1,723 (60.0%) were under 30 years old, 774 (27.0%) were between 31 and 50 years old, and 374 (13.0%) were over 50 years old.\nThe total number of dengue fever-related deaths was 23, with a higher mortality rate observed among female patients.\n\n&lt;80&gt;&lt;80&gt;&lt;90&gt;&lt;91&gt; Dr. Ahmed &lt;8f&gt;&lt;96&gt;raw data (since 14 June 2024) &lt;80&gt;&lt;8c&gt;&lt;8c&gt;&lt;95&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;99&gt;&lt;80&gt;&lt;8e&gt;&lt;87&gt;&lt;80&gt;&lt;81&gt;&lt;8f&gt;&lt;8a&gt;risk category of severe dengue&lt;80&gt;&lt;82&gt;\n\n\n[2024/06/11] HGH &lt;8f&gt;&lt;85&gt;&lt;92&gt;&lt;91&gt;&lt;88&gt;&lt;91&gt;&lt;8a&gt;:(Dr. Mohamed and Dr. Guuled, and Dr Hamda)(revision by Taiwan Medical Mission / 2024/06/26)\n\n\n2024 May/June &lt;8d&gt;&lt;9a&gt;&lt;84&gt;&lt;8f&gt;&lt;85&gt;&lt;92&gt;&lt;99&gt;&lt;9d&gt;&lt;86&gt;&lt;88&gt;&lt;8b&gt;(&lt;8d&gt;&lt;81&gt;&lt;85&gt;&lt;8b&gt;)&lt;8c&gt;&lt;88&gt;&lt;9c&gt;&lt;89&gt;\n\n139 confirmed cases on May and June (by NS1 in private sector, or IgG/IgM test in HGH)\n8 severe dengue cases (5.8%): upper/lower GI bleeding, plasma leakage, myocarditis (due to congenital heart disease), encephalitis, diabetic ketoacidosis (in type 1 diabetes)\n0 mortality (0%)\n\n\n\nHGH dengue fever strategy SOP :(HGH / ongoing)\n\n&lt;8f&gt;&lt;8c&gt; (2022) HGH Dengue fever management guideline\n\n\n\n\n&lt;88&gt;&lt;98&gt;&lt;8c&gt;&lt;94&gt;&lt;8d&gt;&lt;80&gt;&lt;8a&gt;&lt;83&gt;&lt;88&gt;&lt;86&gt;&lt;88&gt;&lt;87&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;87&gt;&lt;90&gt;&lt;88&gt;&lt;86&gt;&lt;88&gt;:\n\n\n6 regions in Somaliland&lt;80&gt;&lt;82&gt;\nMaroodijeeh Region&lt;88&gt;&lt;86&gt;&lt;82&gt;2&lt;80&gt;&lt;8b&gt;District&lt;80&gt;&lt;82&gt;\nHargeisa&lt;82&gt;&lt;80&gt;&lt;8d&gt;&lt;8b&gt;District,&lt;8b&gt;8&lt;80&gt;&lt;8b&gt;&lt;8c&gt;&lt;94&gt;&lt;8d&gt;&lt;80&gt;(Sub-district)&lt;80&gt;&lt;82&gt;\n\n\n&lt;80&gt;&lt;8c&gt;Hargeisa&lt;8c&gt;&lt;94&gt;&lt;8d&gt;&lt;80&gt;&lt;9f&gt;&lt;9f&gt;&lt;8f&gt;&lt;8a&gt;&lt;90&gt;&lt;84&gt;&lt;9a&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9f&gt;&lt;8b&gt;&lt;88&gt;&lt;86&gt;&lt;88&gt;&lt;9f&gt;:\n\n\n\nHargeisa District &lt;85&gt;&lt;90&gt;&lt;84&gt;&lt;9a&gt;(RHC, HC, PHU or MCH)&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9f&gt;&lt;8b&gt;&lt;95&gt;\n\n3 regional hospital (Naaso Hablood Hospital, Gurmad Hospital, and Daryeel Hospital)\n3 Referral Health center (RHC), 3 Health Center (HC), 45 Primary Health Unit (PHU) non-functional, and 66 Maternal Child Health clinics (MCH)\n\n&lt;9e&gt;&lt;90&gt;&lt;84&gt;&lt;8c&gt;&lt;94&gt;&lt;8d&gt;&lt;80&gt;&lt;8f&gt;&lt;8f&gt;&lt;8a&gt;&lt;9a&gt;&lt;84&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;87&gt;&lt;90&gt;,&lt;9c&gt;&lt;82&gt;&lt;99&gt;&lt;9d&gt;&lt;86&gt;&lt;98&gt;&lt;8f&gt;&lt;8a&gt;&lt;83&gt;&lt;9a&gt;&lt;84&gt;&lt;8f&gt;&lt;83&gt;&lt;80&gt;&lt;83&gt;&lt;80&gt;&lt;82&gt;\n\n\nSomaliland Publications\n\n\n\n&lt;86&gt;&lt;87&gt;&lt;9c&gt;&lt;9c&gt;&lt;9f&gt;&lt;99&gt;&lt;9a&gt;&lt;84&gt;&lt;96&gt;&lt;87&gt;: &lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;&lt;88&gt;&lt;87&gt;&lt;9c&gt;&lt;80&gt;&lt;85&gt;&lt;8f&gt;&lt;96&gt;&lt;97&gt;&lt;81&gt; Mr. Hussein Mohamoud Nour 2022 Edna Adan University Hospital (EAH) statistics, a research article titled “Sero-prevalence of Dengue virus infection and associated factors among patients with febrile illness attending at Edna Adan University Hospital. Hargeisa, Somaliland, 2022: A cross-sectional study” published in the Journal of Women’s Health Care. (https://www.longdom.org/open-access-pdfs/seroprevalence-of-dengue-virus-infection-and-associated-factors-among-patients-with-febrile-illness-attending-at-edna-ad.pdf)\n[2024/06] dengue NS1 RDTs is only available in few private hospitals\n(&lt;9a&gt;&lt;9c&gt;&lt;9b&gt;&lt;9e&gt;&lt;87&gt;&lt;89&gt;) &lt;95&gt;&lt;99&gt;&lt;96&gt;&lt;95&gt;&lt;9c&gt;&lt;88&gt; Dr Yusuf Mohamed (Infectious disease and tropical medicine) in Hargeisa, he attended 2024MSC as a participant)\n\n\n\n*&lt;93&gt;\n\n\n2. Visiting Scholarships for Training in Taiwan\n\nProject: Capacity Building for Somaliland Medical Personnel\nCollaborators: Taipei Municipal Wanfang Hospital (TMWH), Taiwan Medical Mission (TMM), and Hargeisa Group Hospital (HGH)\nInitiatives:\n\nProvide “Visiting Scholar Scholarships” for 12 Somaliland medical personnel to receive training in Taiwan for up to three months\nConduct selection process jointly by Taiwan Medical Mission and HGH Director’s Office\nInvite selected personnel to participate in TMM’s 2024 public health programs\n\nRequired support:\n\nTMM: Scholarship funding for 12 medical personnel (one batch)\nCoordination with TMWH for training arrangements\nCollaboration with HGH for personnel selection and public health program participation\n\n\n\n\n\n\n\nAction points(who/when):\n\n\n\n(&lt;9d&gt;&lt;9d&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;99&gt;&lt;8c&gt;&lt;87&gt;&lt;8e&gt;)&lt;81&gt;&lt;9d&gt;&lt;96&gt;&lt;8a&gt;&lt;9c&gt;&lt;83&gt;(2024/6/20&lt;8c&gt;&lt;9e&gt;HGH pathology &lt;8b&gt; staff &lt;92&gt;&lt;8c&gt;&lt;82&gt;&lt;99&gt;&lt;8c&gt;&lt;80&gt;&lt;80&gt;&lt;9d&gt;&lt;80&gt;&lt;9a&gt;&lt;90&gt;&lt;88&gt;&lt;9c&gt;&lt;80&gt;)&lt;80&gt;&lt;82&gt;&lt;8f&gt;&lt;96&gt;&lt;97&gt; Dr Omar &lt;9b&gt;&lt;90&gt;&lt;89&gt;&lt;88&gt;&lt;9a&gt;&lt;84&gt; &lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;8a&gt;&lt;8c&gt;Microsoft Access database &lt;8c&gt;&lt;88&gt;&lt;90&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;8c&gt;&lt;91&gt;&lt;8d&gt;&lt;8a&gt;&lt;83&gt;&lt;85&gt;&lt;9c&gt;&lt;89&gt; 110 &lt;91&gt;&lt;8a&gt;&lt;8c&gt;4/5 &lt;83&gt;&lt;9c&gt;&lt;83&gt;&lt;98&gt;&lt;94&gt;&lt;9b&gt;&lt;89&gt;&lt;80&gt;&lt;9a&gt;&lt;9c&gt;&lt;89&gt;&lt;99&gt;&lt;9c&gt;&lt;91&gt;&lt;8a&gt;&lt;95&gt;&lt;99&gt;&lt;98&gt;&lt;9c&gt; file folder (&lt;93&gt;&lt;94&gt;Dr. Omar&lt;89&gt;&lt;8b&gt;&lt;85&gt;&lt;8c&gt;&lt;89&gt;&lt;82&gt; Excel file&lt;8c&gt; &lt;96&gt; 2024MSC &lt;94&gt;&lt;8e&gt;&lt;9c&gt;&lt;83&gt;&lt;88&gt;&lt;9d&gt; &lt;91&gt;&lt;8a&gt;): 110 &lt;90&gt;&lt;8d&gt;&lt;97&gt;&lt;85&gt;&lt;8b&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt; from MS Access database\n\n\n&lt;9c&gt;&lt;89&gt;&lt;8e&gt;&lt;92&gt;&lt;80&gt; telepathology meeting for case discussion (Dr. Omar, since 20 June)\n&lt;9c&gt;&lt;82&gt;&lt;80&gt;&lt;8b&gt;Dr. Omar &lt;88&gt;&lt;86&gt;&lt;8a&gt; Excel data (Dr. Omar, since 20 June)\n\n\n&lt;80&gt;&lt;81&gt;&lt;93&gt;&lt;91&gt;&lt;88&gt;(&lt;9a&gt;&lt;9f&gt;&lt;93&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt;&lt;9b&gt;):&lt;9e&gt;&lt;93&gt;&lt;96&gt;&lt;91&gt;&lt;80&gt;&lt;81&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;80&gt;&lt;81&gt;&lt;91&gt;\n&lt;80&gt;&lt;81&gt;&lt;93&gt;&lt;91&gt;&lt;88&gt;(&lt;9c&gt;&lt;89&gt;&lt;9f&gt;&lt;93&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt;&lt;9b&gt;):&lt;80&gt;&lt;88&gt;&lt;96&gt;&lt;91&gt;(2 or 3&lt;90&gt;&lt;8d&gt;&lt;86&gt;)&lt;80&gt;&lt;81&gt;ICU/&lt;83&gt;&lt;85&gt;&lt;94&gt;&lt;85&gt;&lt;91&gt;(&lt;85&gt;&lt;80&gt;&lt;80&gt;&lt;98&gt;&lt;8e&gt; Dr. Jacfar)&lt;80&gt;&lt;81&gt;&lt;96&gt;&lt;8b&gt;&lt;88&gt;&lt;80&gt;&lt;88&gt;&lt;90&gt;&lt;86&gt;(&lt;80&gt;&lt;90&gt;&lt;8d&gt;)\n&lt;80&gt;&lt;81&gt;&lt;93&gt;&lt;91&gt;&lt;88&gt;: &lt;83&gt;&lt;87&gt;&lt;9f&gt;&lt;85&gt;&lt;91&gt;(&lt;8b&gt;&lt;82&gt;&lt;8c&gt;&lt;83&gt;&lt;87&gt;&lt;9f&gt;&lt;85&gt;&lt;91&gt;&lt;86&gt;&lt;9a&gt;&lt;84&gt;&lt;9f&gt;&lt;93&gt;&lt;9c&gt;&lt;80&gt;&lt;81&gt;&lt;80&gt;&lt;83&gt;&lt;85&gt;HGH&lt;8f&gt;&lt;9c&gt;&lt;89&gt;&lt;9a&gt;&lt;84&gt;&lt;82&gt;&lt;99&gt;&lt;83&gt;&lt;85&gt;&lt;81&gt;&lt;8c&gt;&lt;82&gt;&lt;85&gt;&lt;9f&gt;&lt;9f&gt;&lt;99&gt;&lt;9a&gt;&lt;84&gt;&lt;9e&gt;&lt;9e&gt;&lt;8b&gt;&lt;80&gt;&lt;82&gt;)\n&lt;82&gt;&lt;9d&gt;&lt;8f&gt;&lt;97&gt;&lt;93&gt;&lt;80&gt;&lt;85&gt;&lt;9b&gt;&lt;9e&gt;&lt;9c&gt;&lt;8b&gt;&lt;8c&gt;&lt;83&gt;&lt;9a&gt;&lt;9b&gt;&lt;81&gt;&lt;8b&gt;&lt;94&gt;&lt;89&gt;&lt;80&gt;&lt;8a&gt;&lt;80&gt;&lt;83&gt;&lt;9a&gt;&lt;84&gt;&lt;87&gt;&lt;8d&gt;&lt;81&gt;&lt;80&gt;&lt;80&gt;&lt;82&gt;&lt;90&gt;&lt;84&gt;&lt;91&gt;&lt;9a&gt;&lt;84&gt;&lt;9f&gt;&lt;93&gt;&lt;88&gt;&lt;95&gt;&lt;8c&gt;&lt;88&gt;&lt;98&gt;&lt;8e&gt;&lt;82&gt;&lt;8b&gt;&lt;8f&gt;&lt;8d&gt;&lt;8f&gt;&lt;97&gt;&lt;93&gt;&lt;80&gt;&lt;85&gt;&lt;9b&gt;&lt;9e&gt;&lt;9c&gt;&lt;8b&gt;&lt;8c&gt;&lt;9a&gt;&lt;84&gt;&lt;9c&gt;&lt;8d&gt;&lt;8b&gt;&lt;99&gt;&lt;9b&gt;&lt;99&gt;&lt;80&gt;&lt;82&gt;\n\n\n\n\n&lt;80&gt;&lt;88&gt;&lt;96&gt;&lt;91&gt;&lt;85&gt;&lt;85&gt;&lt;94&gt;&lt;8f&gt;&lt;89&gt;&lt;8b&gt;&lt;93&gt;&lt;93&gt;&lt;83&gt; - &lt;94&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;&lt;8e&gt;&lt;8b&gt;&lt;94&gt;&lt;86&gt;&lt;88&gt;&lt;87&gt;HGH Afnan&lt;86&gt;&lt;8f&gt;&lt;8a&gt;&lt;80&gt;&lt;88&gt;&lt;96&gt;&lt;91&gt;&lt;86&gt;(&lt;8c&gt;&lt;85&gt;&lt;8b&gt;&lt;8d&gt;&lt;81&gt;&lt;9c&gt;&lt;88&gt;&lt;87&gt;&lt;87&gt;&lt;8c&gt;&lt;97&gt;&lt;9a&gt;&lt;84&gt; Dr. Nouh)&lt;8c&gt;&lt;90&gt;&lt;88&gt;&lt;9c&gt;&lt;8e&gt;&lt;8c&gt; - &lt;83&gt;&lt;8c&gt;&lt;99&gt;:HGH&lt;80&gt;&lt;88&gt;&lt;96&gt;&lt;91&gt;&lt;86&gt;&lt;85&gt;&lt;90&gt;&lt;8c&gt;&lt;96&gt;&lt;8b&gt;&lt;88&gt;&lt;80&gt;&lt;93&gt;&lt;97&gt;,&lt;86&gt;&lt;8f&gt;&lt;97&gt;&lt;99&gt;&lt;90&gt;&lt;96&gt;&lt;87&gt;&lt;90&gt;,&lt;85&gt;&lt;8b&gt;&lt;86&gt;&lt;99&gt;&lt;9a&gt;&lt;84&gt;&lt;85&gt;&lt;85&gt;&lt;94&gt;&lt;8f&gt;&lt;82&gt;&lt;99&gt;\n- &lt;89&gt;&lt;80&gt;&lt;9c&gt;&lt;80&gt;&lt;82&gt;&lt;99&gt;:&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;8f&gt;&lt;90&gt;&lt;9b&gt;&lt;85&gt;&lt;85&gt;&lt;94&gt;&lt;8f&gt;&lt;89&gt;&lt;8b&gt;&lt;93&gt;&lt;99&gt;&lt;88&gt;&lt;87&gt;&lt;93&gt;&lt;9e&gt;&lt;8b&gt;(home made DIY simulator box)\n- Action points(who/when):\n\n&lt;85&gt;&lt;8b&gt;&lt;8f&gt;&lt;8a&gt;&lt;83&gt;&lt;80&gt;&lt;81&gt;&lt;99&gt;&lt;95&gt;&lt;90&gt;&lt;86&gt;&lt;8c&gt;&lt;8c&gt;&lt;96&gt;&lt;8b&gt;&lt;8b&gt;&lt;93&gt;&lt;95&gt;&lt;99&gt; (Taiwan Medical Mission / 2024/07)\n&lt;80&gt;&lt;9a&gt;&lt;81&gt;&lt;8e&gt;&lt;8d&gt;&lt;89&gt;&lt;80&gt;&lt;85&gt;&lt;8c&gt;&lt;97&gt;&lt;81&gt;&lt;81&gt;&lt;82&gt;&lt;87&gt;&lt;80&gt;&lt;81&gt;&lt;93&gt;&lt;9a&gt;&lt;84&gt;&lt;90&gt;&lt;93&gt;(&lt;8a&gt;&lt;99&gt;&lt;90&gt;&lt;89&gt;&lt;90&gt;&lt;8d&gt;)\n\n\n\n\n&lt;85&gt;&lt;81&gt;&lt;81&gt;&lt;8c&gt;&lt;88&gt;&lt;90&gt;&lt;8c&gt;&lt;8c&gt;&lt;90&gt;&lt;86&gt;&lt;81&gt;&lt;9f&gt;(Chest X-ray, Tuberculosis (TB) Sputum Test, Syphilis/VDRL, Measles/Rubella)&lt;8c&gt;&lt;88&gt;&lt;94&gt;&lt;8b&gt; 90&lt;97&gt;&lt;8b&gt;&lt;8f&gt;&lt;97&gt;&lt;93&gt;&lt;8c&gt;&lt;9f&gt;&lt;8c&gt;&lt;87&gt;&lt;8a&gt;&lt;9c&gt;) (&lt;90&gt;&lt;88&gt;&lt;82&gt;&lt;8d&gt;&lt;81&gt;&lt;9c&gt;&lt;88&gt;&lt;96&gt;&lt;8b&gt;&lt;8b&gt;&lt;8f&gt;&lt;97&gt;&lt;93&gt;)(Taiwan Medical Mission / 2024/07)\n\n\n\n\n*&lt;85&gt;&lt;85&gt;&lt;9b&gt;&lt;94&gt;&lt;9f&gt;\n\n\n3. &lt;89&gt;&lt;85&gt;&lt;99&gt;&lt;8c&gt;&lt;97&gt;&lt;87&gt;&lt;98&gt;&lt;88&gt;&lt;95&gt;(&lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;80&gt;&lt;81&gt;&lt;99&gt;&lt;8c&gt;&lt;80&gt;&lt;81&gt;&lt;82&gt;&lt;9d&gt;&lt;99&gt;&lt;8c&gt;)\n\nA. &lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;98&gt;&lt;83&gt;&lt;80&gt;&lt;81&gt;&lt;99&gt;&lt;8c&gt;\n\n&lt;94&gt;HGH Fatima&lt;86&gt;&lt;80&gt;&lt;81&gt;&lt;8f&gt;&lt;81&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;&lt;8e&gt;&lt;8b&gt;&lt;94&gt;&lt;86&gt;(&lt;80&gt;&lt;88&gt;&lt;96&gt;&lt;91&gt;)&lt;80&gt;&lt;81&gt;&lt;83&gt;&lt;83&gt;&lt;81&gt;&lt;98&gt;&lt;95&gt;&lt;86&gt;(&lt;94&gt;&lt;91&gt;&lt;9c&gt;&lt;98&gt;&lt;93&gt;)&lt;85&gt;&lt;90&gt;&lt;8c&gt;&lt;8e&gt;&lt;8b&gt;&lt;95&gt;\n&lt;90&gt;&lt;99&gt;&lt;8c&gt;:&lt;95&gt;&lt;80&gt;HPV DNA real-time PCR&lt;80&gt;&lt;81&gt;Pap smear&lt;8a&gt;&lt;89&gt;&lt;87&gt;&lt;9f&gt;&lt;93&gt;&lt;89&gt;&lt;88&gt;&lt;87&gt;&lt;83&gt;&lt;9e&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;93&gt;&lt;8b&gt;\n&lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;90&gt;&lt;98&gt;:&lt;95&gt;&lt;80&gt;HPV vaccine\n&lt;99&gt;&lt;8c&gt;:&lt;88&gt;&lt;85&gt;&lt;9f&gt;&lt;9f&gt;\n&lt;93&gt;:\n\ncancer registry and cancer statistics:\n\nSomalia tertiary hospital report: (2017-2020, n=1306; 13.1% breast cancer, 13.3% cervical cancer), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534047/\n2023/03/10 WHO ICO/IARC report for Somalia Statistics of HPV-related cancers, crude incident rate of cervical cancer 13.2 per 100,000 population, ranked 2nd (https://hpvcentre.net/statistics/reports/SOM_FS.pdf); IARC: International Agency for Research on Cancer. ICO: Catalan Institute of Oncology\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n2022 report by Needle hospital in Hargeisa: Gebrekirstos Hagos et al., 2023 (https://ecancer.org/en/journal/article/1642-cancer-care-in-needle-hospital-hargeisa-somaliland)\n\n&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt; Dr. Omar (report 2 cases in 2023)&lt;8b&gt;&lt;82&gt;&lt;94&gt;&lt;8f&gt;&lt;8c&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;88&gt;&lt;87&gt;&lt;89&gt;&lt;87&gt;&lt;81&gt;&lt;9d&gt;&lt;9c&gt;&lt;83&gt;; Dr. Omar and Mr. Mustafe (technician) &lt;9c&gt;2024 &lt;80&gt;&lt;81&gt;&lt;93&gt;&lt;90&gt;&lt;8d&gt;&lt;96&gt; (visiting scholars)\nWHO’s suggested HPV&lt;96&gt;&lt;8b&gt;&lt;97&gt;&lt;9c&gt;&lt;80&gt;&lt;81&gt;&lt;8b&gt;&lt;82&gt;&lt;86&gt;&lt;90&gt;GAVI (Hargeisa primary school girls aged 9-14: 50,000 persons; &lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;86&gt;&lt;90&gt; 2023 statistics from Ministry of Education and Science, MoES);\n&lt;91&gt;&lt;9c&gt;&lt;81&gt;&lt;80&gt;&lt;9c&gt;&lt;80&gt;&lt;8e&gt;&lt;8c&gt;&lt;85&gt;&lt;88&gt;&lt;88&gt;&lt;87&gt; sexual transmission &lt;88&gt;&lt;87&gt;&lt;89&gt;&lt;98&gt;&lt;8e&gt;&lt;8c&gt;&lt;85&gt;&lt;8d&gt;&lt;9b&gt;&lt;91&gt;&lt;83&gt;&lt;85&gt;&lt;9d&gt;&lt;88&gt;&lt;8c&gt;&lt;93&gt; &lt;8e&gt;&lt;8c&gt;&lt;8f&gt;&lt;97&gt;&lt;88&gt;&lt;98&gt;&lt;99&gt;\n\n\n\n\nCurrent Information\n\nreviewed articles\n\n\nCarroll et al., 2007: barrier for screening (https://pubmed.ncbi.nlm.nih.gov/17454183)\nGhebre RG et al., 2015 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4312274/)\nCervical cancer in Somaliland (literature review): https://texchi2.github.io/2024MSC/2024Project_HPV.html\n&lt;88&gt;&lt;86&gt;HPV center&lt;9b&gt;&lt;97&gt;&lt;9c&gt;&lt;96&gt;&lt;87&gt;&lt;8d&gt;,&lt;9c&gt;&lt;82&gt;&lt;8e&gt;&lt;8b&gt;&lt;95&gt;&lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;98&gt;&lt;9a&gt;&lt;84&gt;&lt;8f&gt;&lt;83&gt;&lt;80&gt;&lt;83&gt;(https://hpvcentre.net/statistics/reports/SOM_FS.pdf)\n\n\n&lt;9f&gt;HGH&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;8a&gt;&lt;8f&gt;&lt;81&gt;:\n\n\n&lt;86&gt;&lt;84&gt;&lt;94&gt;&lt;88&gt;&lt;87&gt;&lt;89&gt;&lt;87&gt;&lt;9f&gt;(biopsy)&lt;8c&gt;,&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;8a&gt;&lt;9a&gt;&lt;84&gt;&lt;8c&gt;&lt;95&gt;&lt;80&gt;&lt;80&gt;&lt;82&gt;\n&lt;9f&gt;&lt;98&gt;&lt;90&gt;&lt;9c&gt;&lt;89&gt;&lt;87&gt;&lt;85&gt;&lt;91&gt;&lt;8a&gt;&lt;80&gt;&lt;81&gt;&lt;88&gt;&lt;80&gt;&lt;90&gt;&lt;9e&gt;&lt;9c&gt;&lt;80&gt;&lt;81&gt;&lt;88&gt;&lt;96&gt;&lt;91&gt;&lt;8a&gt;&lt;81&gt;&lt;89&gt;&lt;83&gt;&lt;85&gt;&lt;80&gt;&lt;82&gt;\n&lt;85&gt;&lt;88&gt;&lt;94&gt;&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;99&gt;&lt;8c&gt;&lt;88&gt;&lt;87&gt;Dr. Omar &lt;8b&gt;&lt;81&gt;&lt;9d&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;8e&gt;&lt;96&gt;(tele-pathology)&lt;8c&gt;&lt;8b&gt;&lt;90&gt;&lt;88&gt;&lt;9c&gt;&lt;97&gt;&lt;9c&gt;&lt;82&gt;&lt;88&gt;&lt;87&gt;&lt;92&gt;\n&lt;95&gt;&lt;98&gt;&lt;90&gt;&lt;8f&gt;&lt;8c&gt;&lt;95&gt;&lt;94&gt;&lt;9b&gt;&lt;86&gt;&lt;97&gt;&lt;9c&gt;&lt;89&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;8a&gt;,&lt;88&gt;&lt;8c&gt;&lt;8c&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;80&gt;&lt;82&gt;\n&lt;94&gt;&lt;90&gt;&lt;9c&gt;&lt;90&gt;&lt;86&gt;&lt;8d&gt;&lt;94&gt;&lt;8a&gt;&lt;95&gt;&lt;90&gt;&lt;86&gt;&lt;8f&gt;&lt;8a&gt;&lt;99&gt;&lt;95&gt;&lt;9b&gt;&lt;97&gt;&lt;9c&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;80&gt;&lt;82&gt;\n\n\n&lt;89&gt;&lt;8e&gt;&lt;92&gt;&lt;88&gt;&lt;87&gt;&lt;88&gt;&lt;98&gt;&lt;90&gt;&lt;9c&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;96&gt;&lt;8a&gt;&lt;9c&gt;&lt;83&gt;(tele-pathology conference):\n\n\n&lt;82&gt;&lt;80&gt;&lt;8b&gt;&lt;87&gt;&lt;8c&gt;&lt;97&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;99&gt;&lt;81&gt;&lt;87&gt;,&lt;88&gt;&lt;87&gt;&lt;88&gt;&lt;98&gt;&lt;90&gt;&lt;9c&gt;&lt;9c&gt;&lt;98&gt;&lt;9a&gt;&lt;8a&gt;&lt;80&gt;&lt;8c&gt;&lt;96&gt;&lt;8a&gt;&lt;8e&gt;&lt;96&gt;&lt;80&gt;&lt;82&gt;\nHGH &lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;8f&gt;&lt;9c&gt;&lt;89&gt; digital slide scanner&lt;80&gt;&lt;82&gt;\nHGH &lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;83&gt;&lt;85&gt;&lt;9c&gt;&lt;89&gt; H&E and cytology stain (Pap stain)&lt;9c&gt;&lt;8d&gt;&lt;8b&gt;&lt;99&gt;&lt;8c&gt;&lt;84&gt;IHC staining&lt;80&gt;&lt;82&gt;\n&lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;98&gt;&lt;80&gt;&lt;81&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;96&gt;&lt;89&gt;&lt;8c&gt;&lt;8f&gt;&lt;9b&gt;&lt;84&gt;&lt;8f&gt;&lt;8b&gt;,&lt;8f&gt;&lt;90&gt;&lt;9b&gt;&lt;88&gt;&lt;80&gt;&lt;82&gt;\nDr. Omar&lt;88&gt;&lt;87&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;8a&gt;&lt;80&gt;&lt;93&gt;&lt;93&gt; Mr. Mustafe&lt;9c&gt;2024&lt;80&gt;&lt;81&gt;&lt;93&gt;&lt;87&gt;&lt;8c&gt;&lt;97&gt;&lt;9a&gt;&lt;84&gt;&lt;93&gt;&lt;90&gt;&lt;8d&gt;&lt;96&gt;&lt;80&gt;&lt;82&gt;\n\n\n&lt;9f&gt;&lt;88&gt;&lt;98&gt;HGH&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;88&gt;&lt;91&gt;&lt;86&gt;Dr. Omar&lt;88&gt;&lt;8c&gt;(2023/02),&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;94&gt;&lt;82&gt;&lt;81&gt;:\n\n\n\n&lt;88&gt;Dr. Omar&lt;88&gt;&lt;8c&gt;,&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;88&gt;&lt;87&gt;&lt;89&gt;&lt;87&gt;&lt;9a&gt;&lt;84&gt;&lt;95&gt;&lt;87&gt;&lt;8f&gt;&lt;80&gt;&lt;81&gt;&lt;94&gt;&lt;9e&gt;&lt;80&gt;&lt;81&gt;&lt;83&gt;&lt;8d&gt;&lt;80&gt;&lt;81&gt;&lt;9e&gt;&lt;9e&gt;&lt;8b&gt;&lt;89&gt;&lt;87&gt;&lt;8a&gt;&lt;80&gt;&lt;82&gt;\n&lt;9e&gt;&lt;9b&gt;&lt;89&gt;&lt;8d&gt;HGH&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;9a&gt;&lt;84&gt;&lt;97&gt;&lt;87&gt;&lt;8f&gt;&lt;83&gt;&lt;88&gt;&lt;87&gt;&lt;96&gt;&lt;9c&gt;&lt;80&gt;&lt;82&gt;&lt;80&gt;&lt;82&gt;\n&lt;99&gt;&lt;95&gt;&lt;9f&gt;&lt;90&gt;&lt;9e&gt;&lt;9c&gt;,&lt;88&gt;&lt;87&gt;&lt;87&gt;&lt;8c&gt;&lt;97&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;99&gt;&lt;8e&gt;&lt;96&gt;,&lt;94&gt;&lt;93&gt;&lt;90&gt;&lt;88&gt;&lt;9c&gt;&lt;96&gt;&lt;95&gt;&lt;80&gt;&lt;82&gt;\nDr. Shih-Han Hung &lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;ENT&lt;8c&gt;&lt;87&gt;2023/08 &lt;88&gt;&lt;8b&gt;&lt;8c&gt;&lt;8c&gt;&lt;88&gt;&lt;87&gt;Dr. Omar &lt;8c&gt;&lt;81&gt;&lt;8c&gt;&lt;80&gt;&lt;8c&gt;&lt;88&gt;&lt;96&gt;&lt;9c&gt;&lt;89&gt;&lt;9b&gt;&lt;97&gt;&lt;9c&gt;&lt;9a&gt;&lt;84&gt;&lt;88&gt;&lt;88&gt;&lt;90&gt;&lt;9e&gt;&lt;9c&gt;&lt;8c&gt;&lt;88&gt;&lt;87&gt;&lt;99&gt;&lt;96&gt;&lt;87&gt;&lt;80&gt;&lt;82&gt;&lt;8b&gt;&lt;89&gt;&lt;99&gt;&lt;95&gt;&lt;95&gt;&lt;8f&gt;&lt;80&gt;&lt;8b&gt;&lt;80&gt;&lt;82&gt;\n\n\n&lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;98&gt;&lt;88&gt;&lt;95&gt;&lt;8e&gt;&lt;8b&gt;&lt;95&gt;&lt;96&gt;&lt;8f&gt;:\n\n\nPap smear/Pap stain (ready)\nHPV DNA\nHPV vaccine\n&lt;94&gt;OBGYN director Dr. Fatima&lt;86&gt;&lt;8b&gt;&lt;95&gt;&lt;95&gt;&lt;9f&gt;&lt;8b&gt;&lt;95&gt;,&lt;80&gt;&lt;8f&gt;&lt;81&gt;&lt;8e&gt;&lt;8e&gt;&lt;8f&gt;&lt;8a&gt;&lt;8f&gt;&lt;90&gt;&lt;98&gt;&lt;86&gt;&lt;93&gt;&lt;8b&gt;&lt;8e&gt;&lt;87&gt;&lt;80&gt;&lt;82&gt;\n&lt;90&gt;&lt;9c&gt;&lt;90&gt;&lt;86&gt;&lt;8d&gt;&lt;94&gt;&lt;8a&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;95&gt;&lt;90&gt;&lt;86&gt;&lt;80&gt;&lt;81&gt;&lt;8f&gt;&lt;8a&gt;&lt;9b&gt;&lt;95&gt;&lt;99&gt;&lt;89&gt;&lt;9c&gt;&lt;80&gt;&lt;82&gt;\n\n&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;&lt;8c&gt;&lt;81&gt;&lt;8c&gt;&lt;8f&gt;&lt;90&gt;&lt;9b&gt;&lt;8a&gt;&lt;80&gt;&lt;93&gt;&lt;8c&gt;&lt;87&gt;&lt;8e&gt;&lt;8f&gt;&lt;8a&gt;&lt;89&gt;&lt;80&gt;&lt;9c&gt;&lt;80&gt;&lt;87&gt;&lt;90&gt;(reagents),&lt;9d&gt;&lt;88&gt;&lt;95&gt;&lt;86&gt;&lt;88&gt;&lt;80&gt;&lt;8c&gt;&lt;80&gt;&lt;82&gt;\n\n\n\n\n&lt;90&gt;&lt;8e&gt;&lt;80&gt;&lt;81&gt;&lt;9f&gt;&lt;9b&gt;&lt;88&gt;&lt;87&gt;&lt;83&gt;&lt;9e&gt;&lt;8a&gt;&lt;89&gt;&lt;87&gt;&lt;9f&gt;:\n\n\nHPV DNA test (HGH&lt;99&gt;&lt;85&gt;&lt;97&gt;&lt;91&gt;&lt;8c&gt;&lt;8f&gt;&lt;9c&gt;&lt;89&gt;Qiagen Rotor-Gene Q real-time PCR &lt;84&gt;&lt;80&gt;&lt;99&gt;): &lt;88&gt;&lt;81&gt;&lt;8f&gt;&lt;96&gt;&lt;8e&gt; HPV DNA PCR reagents&lt;80&gt;&lt;82&gt;\n&lt;94&gt;HGH&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;Dr. Omar&lt;88&gt;&lt;80&gt;&lt;90&gt;&lt;8a&gt;&lt;89&gt;&lt;87&gt; Pap stain and cytology&lt;80&gt;&lt;82&gt;\n&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;8f&gt;&lt;90&gt;&lt;9b&gt;&lt;9b&gt;&lt;97&gt;&lt;9c&gt;&lt;95&gt;&lt;99&gt;&lt;8f&gt;&lt;8a&gt;&lt;8a&gt;&lt;80&gt;&lt;93&gt;&lt;94&gt;&lt;8f&gt;&lt;80&gt;&lt;82&gt;\n&lt;9a&gt;&lt;9c&gt;&lt;9f&gt;&lt;9b&gt;&lt;9e&gt;&lt;9f&gt;&lt;93&gt;&lt;89&gt;&lt;8a&gt;&lt;91&gt;&lt;98&gt;&lt;87&gt;&lt;8f&gt;,&lt;81&gt;&lt;99&gt;&lt;82&gt;&lt;8f&gt;&lt;90&gt;&lt;87&gt;&lt;94&gt;&lt;8b&gt;,&lt;81&gt;&lt;85&gt;&lt;8d&gt;&lt;96&gt;&lt;80&gt;&lt;82&gt;&lt;8c&gt;&lt;81&gt;&lt;8c&gt;&lt;9f&gt;&lt;93&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;9f&gt;&lt;93&gt;&lt;89&gt;&lt;8f&gt;&lt;8a&gt;&lt;88&gt;&lt;80&gt;&lt;93&gt;&lt;80&gt;&lt;82&gt;\n&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;9a&gt;&lt;9c&gt;&lt;9f&gt;&lt;9b&gt;&lt;9d&gt;&lt;93&gt;&lt;81&gt;,&lt;9d&gt;&lt;88&gt;&lt;80&gt;&lt;90&gt;&lt;9e&gt;&lt;9c&gt;&lt;9a&gt;&lt;84&gt;&lt;8f&gt;&lt;9d&gt;&lt;80&gt;&lt;80&gt;&lt;82&gt;\n\n\n\nAction Points(who/when):\n\n\n&lt;88&gt;&lt;86&gt;&lt;8b&gt;&lt;86&gt;&lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;92&gt;&lt;8c&gt;&lt;99&gt;&lt;8c&gt;&lt;90&gt;&lt;98&gt;&lt;8f&gt;&lt;8a&gt;&lt;97&gt;&lt;9c&gt;&lt;9f&gt;&lt;96&gt;&lt;88&gt;&lt;95&gt; (Dr. Huang / 2024/07/13)\n&lt;8f&gt;&lt;90&gt;&lt;8d&gt;&lt;87&gt;&lt;81&gt;&lt;8c&gt;&lt;83&gt;&lt;80&gt;&lt;80&gt;&lt;88&gt;&lt;89&gt;:\n\n&lt;88&gt;&lt;8d&gt;&lt;80&gt;&lt;81&gt;&lt;9c&gt;&lt;80&gt;&lt;85&gt;&lt;88&gt;Community Health Workers&lt;89&gt;&lt;92&gt;&lt;8c&gt;&lt;97&gt;&lt;88&gt;Volunteers&lt;89&gt;&lt;9f&gt;&lt;93&gt;&lt;88&gt;&lt;95&gt; (RN Penny / 2024/08/15)\n&lt;9c&gt; Reproductive Cancer &lt;81&gt;&lt;95&gt;&lt;99&gt;&lt;82&gt;&lt;9d&gt;&lt;90&gt;&lt;96&gt;&lt;99&gt; (RN Penny / 2024/08/31)\n&lt;88&gt;&lt;87&gt; WHO &lt;8e&gt;&lt;96&gt; HPV &lt;81&gt;&lt;8b&gt; (Dr. Huang / 2024/08/15)\n&lt;88&gt;&lt;8c&gt;&lt;95&gt;&lt;9a&gt;&lt;84&gt;&lt;97&gt;&lt;85&gt;&lt;82&gt;&lt;89&gt;&lt;81&gt;&lt;8b&gt; (Dr. Wang / 2024/08/31)\n&lt;88&gt;&lt;87&gt;&lt;81&gt;&lt;8b&gt;&lt;86&gt;&lt;99&gt;&lt;8e&gt;&lt;96&gt; mammography &lt;92&gt;&lt;8c&gt; chemotherapy &lt;9c&gt;&lt;8d&gt;&lt;8b&gt;&lt;99&gt;&lt;90&gt;&lt;88&gt;&lt;9c&gt; (Dr. Huang / 2024/09/15)\n&lt;8b&gt; IDEM &lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;88&gt;&lt;95&gt; (TMM / 2024/09/30)\n\n&lt;9d&gt;&lt;88&gt;&lt;95&gt;&lt;8c&gt;&lt;81&gt;&lt;8c&gt;&lt;80&gt;:\n\n&lt;9c&gt;Dr. Huang &lt;9b&gt;&lt;96&gt;&lt;8b&gt;&lt;89&gt;&lt;8d&gt;&lt;8f&gt;&lt;81&gt;&lt;9a&gt;&lt;93&gt;&lt;9b&gt;; &lt;9b&gt;&lt;96&gt;&lt;8b&gt;&lt;8b&gt;&lt;8c&gt;&lt;8f&gt;&lt;81&gt;&lt;9a&gt;&lt;80&gt; (2024/11)\n&lt;88&gt;&lt;87&gt;&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;94&gt;&lt;91&gt;&lt;8f&gt;&lt;8a&gt;&lt;86&gt;&lt;91&gt;&lt;8e&gt;&lt;96&gt;&lt;8c&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;94&gt;&lt;8f&gt;&lt;8f&gt;&lt;83&gt;&lt;80&gt; (Dr. Huang / 2024/07/11)\n&lt;93&gt;&lt;9a&gt;&lt;95&gt;&lt;9c&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt;&lt;93&gt;&lt;90&gt;&lt;86&gt;&lt;81&gt;&lt;98&gt;&lt;94&gt;&lt;88&gt;&lt;95&gt; (Dr. Huang / 2024/08/15)\n&lt;88&gt;&lt;95&gt;&lt;9c&gt;&lt;97&gt;&lt;85&gt;&lt;90&gt;&lt;86&gt;&lt;91&gt;&lt;86&gt;&lt;9f&gt;&lt;93&gt;&lt;88&gt;&lt;95&gt; (TMWH / 2024/07/31)\n\n&lt;90&gt;&lt;97&gt;&lt;92&gt;&lt;8c&gt;&lt;82&gt;&lt;99&gt;:\n\n&lt;94&gt;&lt;90&gt;&lt;97&gt;&lt;8c&gt;&lt;88&gt;&lt;86&gt;&lt;88&gt;&lt;88&gt;&lt;97&gt;&lt;87&gt;&lt;90&gt;&lt;99&gt;&lt;8c&gt;&lt;92&gt;&lt;8c&gt;&lt;99&gt;&lt;8c&gt;&lt;85&gt;&lt;9b&gt; (Dr. Huang / 2024/07/12)\n&lt;8a&gt;&lt;85&gt;&lt;81&gt;&lt;82&gt;&lt;99&gt;&lt;8e&gt;&lt;81&gt;&lt;8b&gt;&lt;8c&gt;&lt;8c&gt;&lt;85&gt;&lt;8b&gt; HPV DNA kits (TMWH / 2024/08/01)\n&lt;8c&gt;&lt;88&gt;&lt;90&gt; 2024  Phase 1 &lt;90&gt;&lt;97&gt; (Dr. Huang / 2024/08/31)\n 2025  Phase 2 &lt;88&gt;&lt;8a&gt;&lt;83&gt;&lt;88&gt;&lt;87&gt;&lt;90&gt;&lt;97&gt;&lt;9b&gt; (Dr. Huang / 2024/11/20)\n\n&lt;94&gt;&lt;92&gt;&lt;8c&gt;&lt;91&gt;&lt;8a&gt;:\n\n&lt;88&gt;&lt;9a&gt;&lt;94&gt;&lt;88&gt;&lt;95&gt;&lt;8c&gt;&lt;96&gt;&lt;82&gt;&lt;99&gt;SCI&lt;9c&gt;&lt;8b&gt;&lt;9a&gt;&lt;9b&gt;&lt;9c&gt;&lt;9f&gt;&lt;88&gt;&lt;8a&gt;&lt;99&gt; (Dr. Huang / 2024/10/31)\n&lt;8c&gt;&lt;88&gt;&lt;90&gt; 2024 &lt;9c&gt;&lt;9f&gt;&lt;91&gt;&lt;8a&gt; (Dr. Huang / 2024/11/20)\n\n\n\n\n\n\nB. &lt;88&gt;&lt;98&gt;&lt;97&gt;&lt;85&gt;&lt;92&gt;&lt;80&gt;&lt;82&gt;&lt;9d&gt;&lt;82&gt;&lt;8e&gt;(Viral Hepatitis)&lt;88&gt;&lt;87&gt;&lt;90&gt;&lt;98&gt;&lt;8e&gt;&lt;88&gt;&lt;88&gt;&lt;95&gt;\n\n&lt;93&gt;WHO Dr. Deq &lt;8b&gt;&lt;95&gt;&lt;8f&gt;&lt;90&gt;&lt;87&gt;&lt;90&gt;&lt;88&gt;&lt;9c&gt;&lt;84&gt;&lt;8f&gt;&lt;98&gt;&lt;8c&gt;TMM&lt;8f&gt;&lt;82&gt;&lt;80&gt;&lt;8b&gt; NGO SAHA &lt;90&gt;&lt;88&gt;&lt;9c&gt;\n&lt;8d&gt;&lt;94&gt;&lt;8a&gt;&lt;88&gt;&lt;98&gt;&lt;88&gt;&lt;9a&gt; HBV &lt;92&gt;&lt;8c&gt; HCV &lt;88&gt;&lt;87&gt;&lt;90&gt;&lt;98&gt;&lt;8e&gt;&lt;88&gt;&lt;9a&gt;&lt;84&gt; national policy\nHGH&lt;9c&gt;&lt;80&gt;&lt;91&gt;&lt;88&gt;&lt;90&gt;&lt;8b&gt;&lt;86&gt;HBV&lt;96&gt;&lt;80&gt;\n&lt;8b&gt;&lt;93&gt;&lt;88&gt;&lt;88&gt;&lt;96&gt;&lt;86&gt;&lt;99&gt;(HGH)&lt;82&gt;&lt;83&gt;&lt;9a&gt;&lt;84&gt; HBV &lt;92&gt;&lt;8c&gt; HCV &lt;90&gt;&lt;86&gt;&lt;8f&gt; + MoHD IDSR\n&lt;8f&gt;&lt;90&gt;&lt;98&gt;&lt;86&gt;&lt;93&gt;&lt;88&gt;&lt;87&gt;&lt;91&gt;&lt;9c&gt;&lt;8d&gt; HBV &lt;92&gt;&lt;8c&gt; HCV &lt;9a&gt;&lt;84&gt;&lt;8d&gt;&lt;98&gt;&lt;92&gt;&lt;8c&gt;&lt;87&gt;&lt;8d&gt;&lt;96&gt;(&lt;81&gt;&lt;9f&gt;&lt;80&gt;&lt;81&gt;&lt;8d&gt;&lt;90&gt;&lt;8f&gt;&lt;80&gt;&lt;81&gt;&lt;8d&gt;&lt;9a&gt;&lt;9f&gt;khat&lt;91&gt;&lt;89&gt;&lt;88&gt;&lt;87&gt;&lt;8f&gt;&lt;8d&gt;&lt;89&gt;&lt;89&gt;&lt;8c&gt;&lt;90&gt;&lt;98&gt;&lt;84&gt;&lt;82&gt;&lt;82&gt;&lt;82&gt;&lt;9d&gt;&lt;80&gt;&lt;81&gt;&lt;9c&gt;&lt;89&gt;&lt;95&gt;&lt;88&gt;&lt;90&gt;&lt;98&gt;&lt;82&gt;&lt;9d&gt;&lt;87&gt;&lt;9f&gt;&lt;99&gt;&lt;82&gt;&lt;8e&gt;&lt;8c&gt;&lt;98&gt;&lt;82&gt;&lt;9d&gt;&lt;82&gt;&lt;8e&gt; &lt;80&gt;&lt;81&gt;&lt;82&gt;&lt;9d&gt;&lt;8c&gt;&lt;96&gt;&lt;80&gt;&lt;81&gt;&lt;82&gt;&lt;9d&gt;&lt;99&gt;&lt;8c&gt;&lt;89&gt;&lt;83&gt;&lt;9b&gt;&lt;9a&gt;&lt;84&gt;&lt;8d&gt;&lt;9f&gt;&lt;80&gt;&lt;82&gt;)\n&lt;9c&gt;&lt;88&gt;&lt;98&gt;&lt;9e&gt;&lt;9a&gt;&lt;84&gt;&lt;82&gt;&lt;89&gt;&lt;8b&gt;&lt;86&gt;&lt;8a&gt; (Booklet)\n&lt;8b&gt; HBV &lt;8e&gt;&lt;9f&gt;&lt;80&gt;&lt;85&gt;&lt;9a&gt;&lt;84&gt;&lt;92&gt;&lt;8c&gt; HCV&lt;97&gt;&lt;85&gt;&lt;92&gt;&lt;99&gt;&lt;99&gt;&lt;82&gt;\n&lt;88&gt;&lt;95&gt;&lt;88&gt;&lt;90&gt;&lt;9e&gt;&lt;9c&gt;&lt;8c&gt;&lt;87&gt;&lt;99&gt;&lt;9a&gt;\n\n&lt;8c&gt;&lt;88&gt;&lt;90&gt; HBV &lt;92&gt;&lt;8c&gt; HCV &lt;9c&gt;&lt;8b&gt;&lt;96&gt;&lt;95&gt;&lt;96&gt;&lt;87&gt;&lt;9a&gt;&lt;84&gt;&lt;88&gt;&lt;9a&gt;(WHO )\nHGH (&lt;84&gt;500-700&lt;90&gt;&lt;8d&gt;&lt;86&gt;&lt;93&gt;)&lt;99&gt;&lt;85&gt;&lt;8c&gt;&lt;88&gt;&lt;90&gt; HBV/HCV &lt;92&gt;&lt;8c&gt; HBV &lt;96&gt;&lt;8b&gt;&lt;97&gt;&lt;8e&gt;\n&lt;8a&gt; HGH HBV/HCV &lt;96&gt;&lt;80&gt;&lt;81&gt;&lt;8b&gt;&lt;9c&gt;(2024/04 &lt;96&gt;&lt;88&gt;&lt;90&gt;&lt;8b&gt;)&lt;8c&gt;&lt;93&gt;&lt;95&gt;&lt;87&gt;&lt;85&gt;&lt;96&gt;&lt;85&gt;&lt;8b&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9f&gt;&lt;8b&gt;&lt;8c&gt;&lt;8f&gt;&lt;8a&gt;&lt;88&gt;&lt;96&gt;&lt;86&gt;&lt;94&gt;&lt;9f&gt;&lt;92&gt;&lt;8c&gt;&lt;90&gt;&lt;86&gt;&lt;94&gt;&lt;9f&gt;(&lt;9c&gt;&lt;86&gt;&lt;9a&gt;&lt;84&gt;&lt;80&gt;&lt;9a&gt;&lt;86&gt;&lt;8b&gt;&lt;93&gt;)\n&lt;9c&gt;&lt;99&gt;&lt;94&gt;&lt;88&gt;&lt;98&gt;&lt;9e&gt;&lt;9a&gt;&lt;84&gt;&lt;81&gt;&lt;95&gt;&lt;99&gt;&lt;82&gt;&lt;89&gt;&lt;8b&gt;&lt;86&gt;&lt;8a&gt;\nIDSR &lt;8b&gt; HBV &lt;8e&gt;&lt;9f&gt;&lt;80&gt;&lt;85&gt;&lt;8c&gt;&lt;96&gt;&lt;8b&gt;&lt;8b&gt; HCV&lt;97&gt;&lt;85&gt;&lt;92&gt;&lt;99&gt;&lt;99&gt;&lt;82&gt;\n\nAction Points (who/when)&lt;9a&gt;\n\nHBV/HCV mini review: (Somalia, 2018)\n&lt;90&gt;&lt;91&gt; MoHD &lt;94&gt;&lt;8b&gt;: HGH &lt;96&gt;&lt;80&gt;(HIS) &lt;88&gt;&lt;87&gt;&lt;96&gt;&lt;99&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt; (TMM / 20247&lt;9c&gt;&lt;88&gt;)\n&lt;9e&gt;&lt;9c&gt;&lt;8b&gt;&lt;85&gt;&lt;85&gt;&lt;9b&gt;&lt;94&gt;&lt;9f&gt;&lt;83&gt;&lt;96&gt;&lt;80&gt;&lt;80&gt;&lt;81&gt;&lt;86&gt;&lt;99&gt;&lt;97&gt;&lt;92&gt;&lt;8c&gt;&lt;8f&gt;&lt;9c&gt;&lt;89&gt;&lt;9a&gt;&lt;84&gt;HBV&lt;96&gt;&lt;80&gt;&lt;94&gt;&lt;9b&gt;&lt;86&gt;HBV/HCV&lt;9b&gt;&lt;9b&gt;&lt;8c&gt;&lt;8e&gt;&lt;87&gt;&lt;89&gt;&lt;95&gt;&lt;93&gt;&lt;9a&gt;\n&lt;88&gt;&lt;87&gt; WHO&lt;80&gt;&lt;81&gt;NGO SAHA &lt;92&gt;&lt;8c&gt; MoHD &lt;85&gt;&lt;90&gt;&lt;8c&gt;&lt;88&gt;&lt;9a&gt; HBV &lt;92&gt;&lt;8c&gt; HCV &lt;9c&gt;&lt;8b&gt;&lt;96&gt;&lt;95&gt;&lt;86&gt;&lt;9e&gt; (TMM&lt;80&gt;&lt;81&gt;WHO Dr. Deq&lt;80&gt;&lt;81&gt;SAHA Dr. Max&lt;80&gt;&lt;81&gt;MoHD &lt;85&gt;&lt;9b&gt; / 20248&lt;9c&gt;&lt;88&gt;)\n&lt;86&gt; HGH HBV/HCV &lt;96&gt;&lt;80&gt;&lt;9a&gt;&lt;84&gt;&lt;81&gt;&lt;8b&gt;&lt;9c&gt;&lt;96&gt;&lt;8f&gt; (TMM&lt;80&gt;&lt;81&gt;HGH HBV/HCV &lt;96&gt;&lt;80&gt; / 20247&lt;9c&gt;&lt;88&gt;)\n&lt;9f&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;2024&lt;90&gt;&lt;97&gt;&lt;8c&gt;&lt;9c&gt;&lt;8b&gt;&lt;98&gt;&lt;90&gt;&lt;8f&gt;&lt;83&gt;&lt;87&gt;&lt;8d&gt;&lt;96&gt;&lt;88&gt;&lt;86&gt;&lt;85&gt;&lt;8d&gt;&lt;87&gt;&lt;87&gt;&lt;91&gt;&lt;94&gt;&lt;8c&gt;&lt;81&gt;HBV/HCV&lt;92&gt;&lt;8c&gt;&lt;96&gt;&lt;8b&gt;&lt;97&gt;&lt;8e&gt;&lt;80&gt;&lt;82&gt;\n&lt;82&gt; HGH &lt;86&gt;&lt;93&gt;&lt;80&gt;&lt;8c&gt; HBV/HCV &lt;92&gt;&lt;8c&gt; HBV &lt;96&gt;&lt;8b&gt;&lt;97&gt;&lt;8e&gt;\n\n&lt;88&gt;&lt;9a&gt;&lt;92&gt;&lt;8c&gt;&lt;8e&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt; (TMM&lt;80&gt;&lt;81&gt;HGH &lt;8a&gt;&lt;9b&gt;&lt;87&gt;&lt;90&gt;&lt;83&gt; / 20248&lt;9c&gt;&lt;88&gt;)\n&lt;9f&gt;&lt;8c&gt;&lt;92&gt;&lt;8c&gt;&lt;8e&gt; (HGH &lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;&lt;9a&gt;&lt;8a&gt;&lt;80&gt;&lt;81&gt;TMM / 20249&lt;9c&gt;&lt;88&gt;1&lt;97&gt;&lt;87&gt;202411&lt;9c&gt;&lt;88&gt;30&lt;97&gt;)\n\n&lt;88&gt;&lt;9a&gt; HBV &lt;8e&gt;&lt;9f&gt;&lt;80&gt;&lt;85&gt;&lt;9a&gt;&lt;9c&gt;&lt;9f&gt;&lt;92&gt;&lt;8c&gt;&lt;99&gt;&lt;82&gt;&lt;96&gt;&lt;88&gt; (TMM + SAHA&lt;80&gt;&lt;81&gt;HGH HBV &lt;96&gt;&lt;80&gt; / 202410&lt;9c&gt;&lt;88&gt;)\n&lt;96&gt;&lt;8b&gt;&lt;99&gt;&lt;88&gt;&lt;98&gt;&lt;9e&gt;&lt;81&gt;&lt;95&gt;&lt;99&gt;&lt;82&gt;&lt;89&gt;&lt;8b&gt;&lt;86&gt;&lt;8a&gt;\n\n&lt;85&gt;&lt;92&gt; (TMM &lt;80&gt;&lt;81&gt;&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9d&gt;&lt;82&gt;&lt;8e&gt;&lt;88&gt; / 202411&lt;9c&gt;&lt;88&gt;)\n&lt;92&gt;&lt;8c&gt;&lt;88&gt; (&lt;95&gt;&lt;9c&gt;&lt;93&gt;&lt;80&gt;&lt;81&gt;&lt;88&gt; / 202412&lt;9c&gt;&lt;88&gt;)\n&lt;8d&gt;&lt;88&gt;&lt;92&gt;&lt;8c&gt;&lt;99&gt;&lt;94&gt; (TMM&lt;80&gt;&lt;81&gt;HGH &lt;8c&gt;&lt;94&gt;&lt;83&gt;&lt;96&gt;&lt;80&gt; / 202412&lt;9c&gt;&lt;88&gt;)\n\n&lt;88&gt;&lt;9a&gt;&lt;86&gt;&lt;93&gt; HBV &lt;92&gt;&lt;8c&gt; HCV &lt;90&gt;&lt;86&gt;&lt;9f&gt;&lt;93&gt;&lt;8b&gt;\n\n&lt;8b&gt;&lt;88&gt; (&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9d&gt;&lt;82&gt;&lt;8e&gt;&lt;88&gt;&lt;80&gt;&lt;81&gt;SAHA Dr. Max, HGH Dr. Ahmed / 20249&lt;9c&gt;&lt;88&gt;)\n&lt;9f&gt;&lt;93&gt;&lt;9f&gt;&lt;8c&gt; (&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9d&gt;&lt;82&gt;&lt;8e&gt;&lt;88&gt;&lt;80&gt;&lt;81&gt;HGH &lt;86&gt;&lt;93&gt; / 202410&lt;9c&gt;&lt;88&gt;1&lt;97&gt;&lt;87&gt;202412&lt;9c&gt;&lt;88&gt;31&lt;97&gt;)\n\n&lt;8d&gt;&lt;94&gt; HBV &lt;96&gt;&lt;8b&gt;&lt;97&gt;&lt;92&gt;&lt;8c&gt; HCV &lt;99&gt;&lt;82&gt;&lt;97&gt;&lt;89&gt;&lt;9a&gt;&lt;84&gt;&lt;8e&gt;&lt;92&gt;&lt;8c&gt;&lt;9b&gt;&lt;87&gt;&lt;89&gt; (TMM&lt;80&gt;&lt;81&gt;MoHD national cold chain / 202410&lt;9c&gt;&lt;88&gt;1&lt;97&gt;&lt;87&gt;202412&lt;9c&gt;&lt;88&gt;31&lt;97&gt;&lt;8c&gt;&lt;81&gt;&lt;8c&gt;&lt;80&gt;&lt;8c&gt;)\n&lt;8b&gt; HBV &lt;92&gt;&lt;8c&gt; HCV &lt;9b&gt;&lt;92&gt;&lt;8c&gt;&lt;95&gt;&lt;86&gt;&lt;9e&gt; (TMM&lt;80&gt;&lt;81&gt;MoHD IDSR/ 202411&lt;9c&gt;&lt;88&gt;)\n&lt;9a&gt;&lt;9c&gt;&lt;9f&gt;&lt;88&gt;&lt;87&gt; WHO&lt;80&gt;&lt;81&gt;SAHA&lt;80&gt;&lt;81&gt;MoHD&lt;80&gt;&lt;81&gt;HGH &lt;92&gt;&lt;8c&gt;&lt;85&gt;&lt;96&gt;&lt;9b&gt;&lt;97&gt;&lt;9c&gt;&lt;80&gt;&lt;85&gt;&lt;80&gt;&lt;8c&gt;&lt;96&gt;&lt;95&gt;&lt;8d&gt;&lt;94&gt;&lt;9c&gt;&lt;83&gt; (TMM, Dr. Deq, Dr. Max, Mr. Mahdi Dahir Bahdoon. / &lt;8f&gt;&lt;80&gt;&lt;8c&gt;&lt;9e&gt;20249&lt;9c&gt;&lt;88&gt;&lt;96&gt;&lt;8b&gt;&lt;8b&gt;)\n\n\n\n*&lt;84&gt;\n\n\n\n4. &lt;81&gt;&lt;88&gt;&lt;8a&gt;&lt;83&gt;\nA. &lt;94&gt;&lt;90&gt;&lt;8a&gt;&lt;86&gt;&lt;99&gt;&lt;91&gt;&lt;83&gt;&lt;9c&gt;&lt;94&gt;&lt;86&gt;/&lt;99&gt;&lt;98&gt;&lt;96&gt;&lt;8c&gt;&lt;86&gt;&lt;8c&gt;&lt;87&gt;&lt;8e&gt;HGH&lt;91&gt;&lt;9c&gt;&lt;98&gt;&lt;9a&gt;&lt;8a&gt;\n- &lt;88&gt;&lt;95&gt;&lt;85&gt;:&lt;97&gt;&lt;9c&gt;&lt;80&gt;&lt;8f&gt;&lt;86&gt;&lt;9d&gt;&lt;97&gt;&lt;9c&gt;&lt;80&gt;&lt;89&gt;&lt;8b&gt;&lt;93&gt;\n- &lt;89&gt;&lt;80&gt;&lt;9c&gt;&lt;80&gt;&lt;82&gt;&lt;99&gt;: &lt;86&gt;&lt;9d&gt;&lt;97&gt;&lt;9c&gt;&lt;80&gt;&lt;8f&gt;&lt;89&gt;&lt;8b&gt;&lt;93&gt;&lt;99&gt;(ready)\n- &lt;9b&gt;&lt;89&gt;&lt;8d&gt;&lt;80&gt;:202310&lt;9c&gt;&lt;88&gt;&lt;83&gt;&lt;86&gt;&lt;87&gt;&lt;84&gt;&lt;89&gt;&lt;8b&gt;&lt;93&gt;&lt;8a&gt;&lt;80&gt;,&lt;9f&gt;&lt;93&gt;&lt;90&gt;&lt;86&gt;;20248&lt;9c&gt;&lt;88&gt;&lt;91&gt;&lt;88&gt;&lt;87&gt;&lt;86&gt;&lt;8d&gt;&lt;92&gt;&lt;9e&gt;&lt;87&gt;&lt;8c&gt;&lt;87&gt;&lt;8e&gt;&lt;80&gt;&lt;9a&gt;&lt;8e&gt;&lt;89&gt;&lt;8b&gt;&lt;93&gt;\n- &lt;93&gt;: - &lt;86&gt;&lt;92&gt;&lt;9b&gt;&lt;9a&gt;&lt;83&gt;&lt;95&gt;,&lt;9c&gt;&lt;80&gt;&lt;8f&gt;&lt;8d&gt;&lt;86&gt;&lt;92&gt;; - &lt;97&gt;&lt;9c&gt;&lt;80&gt;&lt;8f&gt;&lt;82&gt;&lt;99&gt;&lt;9d&gt;&lt;8a&gt;&lt;9c&gt;&lt;80&gt;OT&lt;9a&gt;&lt;84&gt;&lt;86&gt;&lt;8b&gt;&lt;8a&gt;&lt;80&gt;&lt;93&gt;&lt;93&gt;&lt;80&gt;&lt;81&gt;&lt;8f&gt;&lt;8a&gt;&lt;96&gt;&lt;8b&gt;&lt;88&gt;&lt;80&gt;&lt;88&gt;&lt;88&gt;&lt;90&gt;&lt;86&gt;)\nB. TOM &lt;96&gt;&lt;8f&gt;&lt;86&gt;&lt;90&gt;&lt;98&gt;&lt;9d&gt;&lt;81&gt;&lt;88&gt;&lt;95&gt;\n- &lt;88&gt;&lt;95&gt;&lt;90&gt;&lt;8d&gt;:&lt;80&gt;&lt;8c&gt;TOM&lt;96&gt;&lt;8f&gt;&lt;86&gt;&lt;80&gt;&lt;8d&gt;&lt;88&gt;&lt;87&gt;&lt;90&gt;&lt;98&gt;&lt;9d&gt;&lt;81&gt;\n- &lt;85&gt;:&lt;88&gt;&lt;94&gt;&lt;82&gt;X&lt;85&gt;&lt;89&gt;&lt;89&gt;&lt;87&gt;,&lt;80&gt;&lt;8f&gt;&lt;81&gt;&lt;8e&gt;AI&lt;99&gt;&lt;85&gt;&lt;88&gt;&lt;97&gt;T-score/Z-score,&lt;95&gt;&lt;86&gt;\n- &lt;9b&gt;&lt;89&gt;&lt;8d&gt;&lt;80&gt;:&lt;95&gt;&lt;80&gt;Taiwan Osteoporosis Master (TOM),&lt;8f&gt;&lt;8a&gt;&lt;83&gt;&lt;88&gt;&lt;89&gt;&lt;8e&gt;&lt;8b&gt;&lt;95&gt;\n- &lt;93&gt;:&lt;91&gt;&lt;9c&gt;&lt;8d&gt;&lt;96&gt;&lt;8f&gt;&lt;86&gt;&lt;8d&gt;&lt;9f&gt;&lt;8d&gt;,&lt;94&gt;&lt;91&gt;&lt;88&gt;&lt;87&gt;&lt;94&gt;&lt;84&gt;&lt;91&gt;&lt;86&gt;&lt;94&gt;&lt;8f&gt;&lt;8c&gt;&lt;96&gt;&lt;99&gt;&lt;85&gt;&lt;91&gt;&lt;96&gt;&lt;80&gt;&lt;80&gt;&lt;81&gt;&lt;91&gt;&lt;8f&gt;&lt;99&gt;&lt;97&gt;&lt;85&gt;&lt;82&gt;&lt;9b&gt;&lt;95&gt;&lt;99&gt;&lt;8e&gt;&lt;81&gt;&lt;9a&gt;&lt;8c&gt;&lt;9e&gt;&lt;88&gt;&lt;87&gt;&lt;93&gt; TOM&lt;8a&gt;&lt;9a&gt;\n\ncase control study in hip fracture (retrospective)\n\n&lt;85&gt;&lt;88&gt;&lt;8c&gt;&lt;8b&gt;&lt;96&gt;&lt;8f&gt;&lt;86&gt;(TOM: pelvic x-ray &lt;8b&gt;&lt;8d&gt;&lt;94&gt;&lt;9d&gt;&lt;8f&gt;&lt;83&gt;&lt;95&gt; kVp:85, mAs:30, SID:100cm),&lt;8c&gt;&lt;88&gt;&lt;90&gt;&lt;82&gt;&lt;99&gt;&lt;88&gt;&lt;87&gt;&lt;9e&gt;(intranet)&lt;80&gt;&lt;82&gt;\n&lt;96&gt;&lt;9c&gt;&lt;88&gt;&lt;9f&gt;&lt;8c&gt;&lt;9c&gt;&lt;8d&gt;&lt;8b&gt;&lt;99&gt;&lt;8c&gt;&lt;94&gt;&lt;86&gt;&lt;99&gt;&lt;82&gt;&lt;9c&gt;&lt;98&gt;&lt;9c&gt;&lt;94&gt;&lt;84&gt;&lt;91&gt;&lt;82&gt;X&lt;85&gt;&lt;89&gt;&lt;89&gt;&lt;87&gt;&lt;8f&gt;&lt;8a&gt;&lt;94&gt;&lt;84&gt;&lt;91&gt;&lt;86&gt;&lt;9a&gt;&lt;84&gt;&lt;96&gt;&lt;94&gt;&lt;80&gt;&lt;82&gt;\n&lt;80&gt;&lt;8c&gt;&lt;96&gt;&lt;83&gt;&lt;8a&gt;&lt;98&gt;&lt;97&gt;&lt;85&gt;&lt;8b&gt;&lt;8d&gt;&lt;85&gt;&lt;94&gt;(Hip fracture Case control study),&lt;9f&gt;&lt;88&gt;&lt;86&gt;&lt;9e&gt;&lt;90&gt;&lt;95&gt;&lt;9c&gt;&lt;96&gt;&lt;8f&gt;&lt;86&gt;&lt;9b&gt;&lt;9b&gt;&lt;8c&gt;&lt;8f&gt;&lt;81&gt;&lt;80&gt;&lt;82&gt;\n&lt;93&gt;&lt;9a&gt;&lt;94&gt;&lt;90&gt;&lt;9e&gt;&lt;9c&gt;,&lt;88&gt;&lt;87&gt;&lt;91&gt;&lt;9c&gt;&lt;98&gt;&lt;9a&gt;&lt;8a&gt;&lt;8e&gt;&lt;96&gt;&lt;8c&gt;&lt;8c&gt;&lt;9f&gt;&lt;8c&gt;&lt;96&gt;&lt;90&gt;&lt;91&gt;,&lt;93&gt;&lt;9a&gt;&lt;90&gt;&lt;88&gt;&lt;9c&gt;&lt;9c&gt;&lt;9c&gt;&lt;80&gt;&lt;82&gt;&lt;9a&gt;&lt;84&gt;&lt;86&gt;&lt;98&gt;&lt;96&gt;&lt;95&gt;&lt;80&gt;&lt;82&gt;\n\nAction points(who/when): TMM / 2024/08"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html",
    "href": "2024TMM_12scholars_apply.html",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "",
    "text": "The Visiting Scholarship program, launched in 2024, aims to encourage outstanding health professionals from Somaliland to pursue focused training in Taiwan. This deepens understanding of Taiwan&lt;80&gt;&lt;99&gt;s healthcare environment and enhances future exchanges and partnerships."
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#programs",
    "href": "2024TMM_12scholars_apply.html#programs",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Programs",
    "text": "Programs\n1. Fellowship Program\nSpecialized professional training in medical, nursing, or allied health fields at Taipei Municipal Wanfang Hospital (TMWH) for up to 3 months.\n2. Observership Program\nShadowing opportunities across clinical and non-clinical departments at Taipei Municipal Wanfang Hospital for up to 2 weeks."
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#timeline",
    "href": "2024TMM_12scholars_apply.html#timeline",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Timeline",
    "text": "Timeline\nObservership Program: Up to 2 weeks; for hospital administration\nFellowship Program: Up to 3 months; the training curriculum will cover aspects mentioned below Participants will serve as conduits for knowledge transfer to build capacity at Hargeisa Hospital upon return."
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#scholars",
    "href": "2024TMM_12scholars_apply.html#scholars",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "12 Scholars",
    "text": "12 Scholars\nThe Taiwan Medical Mission Visiting Scholar Program to Taipei is slated to host up to 15 medical staff over 2024 through three cohorts of 5 persons each.\nThis is an opportunity for focused training at Taipei Municipal Wanfang Hospital in your specialty areas like:\n\nHospital Administration\nOperation theatre (OT) management\nOrthopedics\nNeurosurgery\nPathology\nNCD clinic and case management\nICU and CCU"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#eligibility",
    "href": "2024TMM_12scholars_apply.html#eligibility",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Eligibility",
    "text": "Eligibility\nPracticing professionals at Hargeisa Group Hospital with:\n\nCurrently employed at Hargeisa Group Hospital\nMinimum 1 year of experience post-qualification\nGood professional standing\nEnglish language proficiency\nEndorsement from department head and hospital director"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#how-to-apply",
    "href": "2024TMM_12scholars_apply.html#how-to-apply",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "How To Apply",
    "text": "How To Apply\nStep 1: Visit [https://texchi2.github.io/2024MSC/2024TMM_12scholars_apply.html] and download application form: Download This File\nStep 2 Please fill [2024 SCHOLARSHIP APPLICATION FORM] (refer our “an example” below); print and sign your signature (and signature of your department head) =&gt; total two signatures\nStep 3: Submit completed application and supporting documents (Passport copy, Degree/Diploma Certificate, NHPC license, CV with your wish list of courses in Taiwan, and one recommend letter) to TMM offiska in HGH by 26 February 2024 (deadline)\nStep 4: Shortlisted candidates will be notified for interviews\nStep 5: Final selections announced and placement confirmations\nContact: Dr. Tex Li-Hsing Chi, TMM chief\nEmail: [tmm2022sln@gmail.com]\nSubmit inquiries and complete the streamlined application process to unlock this invaluable Taiwan training opportunity!\nStep 6: confirmed scholars could submit\n\nproof of work from HGH administration, and\nhealth check report (within 3 months) with the following specific tests and screenings:\n\nChest X-ray\nTuberculosis (TB) Sputum Test\nSyphilis/VDRL/RPR/TPHA Serology Tests (antibody)\nMeasles and Rubella Serology (antibody)\n(please  Download  this health certificate form)"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#scholarship-application-form-an-example",
    "href": "2024TMM_12scholars_apply.html#scholarship-application-form-an-example",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "2024 SCHOLARSHIP APPLICATION FORM (an example)",
    "text": "2024 SCHOLARSHIP APPLICATION FORM (an example)"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#education",
    "href": "2024TMM_12scholars_apply.html#education",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Education",
    "text": "Education\nInstitution: University of Hargeisa\nDates Attended: 08-2015 to 09-2022\nDegree/Certificate: Bachelor’s Degree\nField of Study: Medicine"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#work-experience",
    "href": "2024TMM_12scholars_apply.html#work-experience",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Work Experience",
    "text": "Work Experience\nEmployer: Hargeisa Group Hospital\nTitle: Doctor\nDuration: 10-2022 to 02-2024"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#personal-statement",
    "href": "2024TMM_12scholars_apply.html#personal-statement",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Personal Statement",
    "text": "Personal Statement\n\nA brief summary of yourself:\nWhat’s the motivation for your visiting to TMWH? Discuss how receiving the TMM visiting scholarship to train in your specialty area in Taipei would benefit your professional development and enable you to better serve your home country upon return. (1000 words max):"
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#reference-from-the-department-head-of-hgh",
    "href": "2024TMM_12scholars_apply.html#reference-from-the-department-head-of-hgh",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Reference from the Department Head of HGH",
    "text": "Reference from the Department Head of HGH\nName: Abdi Mohamed\nPosition/Title: Director of Orthopedic Department\nRelation: Colleague\nContact: amoxamed@ortho.hgh\nSignature: ____________________________\nDate: ____________\nI certify that the information provided in this application is accurate to the best of my knowledge. I understand that any misrepresentations may warrant disqualification if discovered even after acceptance."
  },
  {
    "objectID": "2024TMM_12scholars_apply.html#contract-of-applicant-and-hgh",
    "href": "2024TMM_12scholars_apply.html#contract-of-applicant-and-hgh",
    "title": "2024 Announcement of Visiting Scholarship",
    "section": "Contract of Applicant and HGH",
    "text": "Contract of Applicant and HGH\nAs part of the scholarship application process, I hereby commit to returning to Hargeisa Group Hospital (HGH) after completing my studies abroad and contributing my knowledge and skills to improve patient care in Somaliland. During my time at HGH (at least one year upon return), I will prioritize effective knowledge transfer by sharing my experiences and insights with colleagues, participating in training programs, and engaging in continuous learning opportunities. Upon returning to my home country, I pledge to continue serving the healthcare community with dedication and professionalism, utilizing the skills and expertise gained during my scholarship program for the betterment of our nation’s health outcomes.\nApplicant Signature: __________________________\nDate: ____________\n\nThis website is hosted and maintained by Taiwan Medical Mission, a humanitarian non-profit organization. We are dedicated to providing medical aid and empowering healthcare professionals internationally.\nCopyright Taiwan Medical Mission in the Republic of Somaliland 2022-2024. All rights reserved."
  },
  {
    "objectID": "x2024TMM_health-certificate-quarto.html",
    "href": "x2024TMM_health-certificate-quarto.html",
    "title": "Health Certificate for Medical Practice Application",
    "section": "",
    "text": "(Hospital’s Name, Address, Tel, Fax)"
  },
  {
    "objectID": "x2024TMM_health-certificate-quarto.html#a.-chest-x-ray-for-tuberculosis",
    "href": "x2024TMM_health-certificate-quarto.html#a.-chest-x-ray-for-tuberculosis",
    "title": "Health Certificate for Medical Practice Application",
    "section": "A. Chest X-ray for Tuberculosis:",
    "text": "A. Chest X-ray for Tuberculosis:\nFindings:\nResult: Passed TB suspect Pending Failed\nNot required for pregnant women or children under 12 years of age"
  },
  {
    "objectID": "x2024TMM_health-certificate-quarto.html#b.-stool-examination-for-parasites",
    "href": "x2024TMM_health-certificate-quarto.html#b.-stool-examination-for-parasites",
    "title": "Health Certificate for Medical Practice Application",
    "section": "B. Stool Examination for Parasites:",
    "text": "B. Stool Examination for Parasites:\nPositive, Species: _________________ Negative\nOther parasites that do not require treatment: _________________\nNot required for applicants from countries/areas listed in Appendix 3"
  },
  {
    "objectID": "x2024TMM_health-certificate-quarto.html#c.-serological-tests-for-syphilis",
    "href": "x2024TMM_health-certificate-quarto.html#c.-serological-tests-for-syphilis",
    "title": "Health Certificate for Medical Practice Application",
    "section": "C. Serological Tests for Syphilis:",
    "text": "C. Serological Tests for Syphilis:\nTests: a. RPR VDRL Positive, Titers _______ Negative, Titers _______ b. TPHA TPPA FTA-abs TPLA EIA CIA Positive, Titers _______ Negative, Titers _______ c. Other ___________________ Positive, Titers _______ Negative, Titers _______\nResult: Passed Failed\nNot required for children under 15 years of age"
  },
  {
    "objectID": "x2024TMM_health-certificate-quarto.html#d.-proof-of-positive-measles-and-rubella-antibody-or-measles-and-rubella-vaccination-certificates",
    "href": "x2024TMM_health-certificate-quarto.html#d.-proof-of-positive-measles-and-rubella-antibody-or-measles-and-rubella-vaccination-certificates",
    "title": "Health Certificate for Medical Practice Application",
    "section": "D. Proof of Positive Measles and Rubella Antibody or Measles and Rubella Vaccination Certificates:",
    "text": "D. Proof of Positive Measles and Rubella Antibody or Measles and Rubella Vaccination Certificates:\n\nAntibody Tests Measles Antibody Positive Negative Equivocal Rubella Antibody Positive Negative Equivocal\nVaccination Certificates Measles Vaccination Certificate Rubella Vaccination Certificate\nHaving contraindications, not suitable for vaccination"
  },
  {
    "objectID": "RequestForm_MoHD_DHIS2_database.html",
    "href": "RequestForm_MoHD_DHIS2_database.html",
    "title": "DHIS2 DATA REQUEST APPLICATION FORM",
    "section": "",
    "text": "Requester Information:\nName: ________________________\nOrganization: __________________\nPosition: ______________________\nEmail: ________________________\nPhone: ________________________\nData Requested:\n[ ] Dengue fever weekly aggregate reports\n[ ] HBV/HCV monthly aggregate reports\n[ ] Other (please specify): ___________________\nTime Period: From (dd/mm/yyyy): //______ To (dd/mm/yyyy): //______\nGeographical Area:\n[ ] Nationwide\n[ ] Specific region(s): [ ] Hargeisa Group Hospital, [ ] Burco General Hospital, [ ] Boroma General Hospital, [ ] Berbera General Hospital\nData Format Requested: [ ] Excel spreadsheet, or [ ] CSV file\nPurpose of Data Request:\n[ ] Disease Surveillance\n[ ] Research\n[ ] Program planning\n[ ] Policy development\n[ ] Other (please specify): ___________________\nBrief description of how the data will be used:\nData Security Measures: [ ] Data will be stored on encrypted, password-protected devices accessible only to authorized personnel. All data will be de-identified before analysis. No individual-level data will be shared or published.\nData Destruction:\nProposed date for data destruction: //______\nAgreement:\n[ ] I agree to use the data only for the purpose stated above.\n[ ] I agree not to share the data with any third parties without explicit permission from MoHD.\n[ ] I agree to acknowledge MoHD as the data source in any publications or presentations.\nSignature: ____________________ Date: //______\nFor Official Use Only:\nDate Received: //______ Request ID: __________________\nApproved by: MoHD Director General _________________\nDate Approved: //______"
  },
  {
    "objectID": "20240729_MoHD_TMM_agenda_eIDSR.html",
    "href": "20240729_MoHD_TMM_agenda_eIDSR.html",
    "title": "Meeting Agenda",
    "section": "",
    "text": "eIDSR Implementation, Dengue Surveillance, and Data Access in Somaliland\nDate: Monday, 29 July, 2024\nTime: 09:00–10:00\nAttendees: MoHD DG Dr. Hergeye, Public Health director Mr. Mahdi Dahir, TMM chief Dr. Tex Chi\n\nIDSR Implementation and Data Management (from community to MoHD)\n\nOverview of IDSR roll-out plan in Somaliland for 2024\n\n\nWeekly/monthly aggregate reporting\nMoHD DHIS2 database and dashboard implementation\n\n\neIDSR: Integration of DHIS2 and ICDF HIS in 4 public general hospitals (Hargeisa, Boroma, Berbera, and Burco)\n\n\nCurrent status and challenges\nStrategies for real-time data sharing and analysis\n\n\neIDSR: mHealth initiatives\n\n\nMobile technologies for data collection and reporting in regional hospitals, health centers, and communities\nCase-based immediate reporting using DHIS2 tracker module app (e.g., dengue fever surveillance)\nE-learning programs for training of healthcare workers\n\n\n\n\nDengue RDT Quality Concerns and Surveillance\n\nReports of false negative results in severe dengue cases\n\n\nProposed quality control measures for diagnostic tools\n\n\n\n\nData Access and Request Workflow\n\nTMM’s request for specific data:\n\n\nDengue fever data (IDSR) from HGH (epi-week 1, 2023 to June 2024)\nHBV/HCV case data\n\n\nData sharing protocols and necessary approvals\n\n\nWorkflow for data requests\nApplication form template review: https://texchi2.github.io/2024MSC/RequestForm_MoHD_DHIS2_database.html"
  }
]